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Abstract
Members of the Arenaviridae family are able to cause severe disease in
humans. The members of this family which induce haemorrhagic fever (HF)
are responsible for over 300,000 reported cases per annum, making
arenaviruses the largest cause of HF worldwide. Complications from
arenavirus induced disease vary from cerebral and developmental
complications in infants and the immunocompromised, to HF with cases
ultimately fatal in up to 80% of cases. HF causing arenaviruses can induce
high grade fever; diarrhoea; vomiting and general malaise, leading to loss of
vascular permeability; internal haemorrhaging; disseminated intravascular
coagulation and coma. Fundamental mechanisms of the viral replication
strategies are currently unknown, it is therefore of paramount importance to
increase knowledge in this area in order to identify potential therapeutic
strategies. The nucleoprotein (NP) of arenaviruses is essential for viral
replication, and is thus a good candidate for further investigation. This study
presents the analysis of the host-cell interactome of the HF causing Lujo virus
(LUJV) NP, an arenaviral infection associated with 80% mortality. The NP of
LUJV was found to associate with members of the translation initiation and
elongation complexes by immunoprecipitation and immunofluorescence
microscopy. In addition, the NP of the congenital pathogen lymphocytic
choriomeningitis virus was found to co-localise with translation associated
proteins, with such proteins also identified within viral particles. Finally, it is
demonstrated here that the translation of arenaviral-like mRNAs is enhanced
in the presence of NP, through a mechanism predicted to be driven by the
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Chapter 1 – Introduction
1. Introduction
1.1. General Introduction
Arenaviruses represent an important global public health concern, with limited
to no therapeutics available to combat them. As neglected tropical diseases,
knowledge regarding certain fundamental aspects of their replication cycle
requires greater clarity. In particular, it is becoming increasingly clear that the
nucleoprotein (NP) of arenaviruses is crucial to multiple stages of the virus
replication cycle, outside of the more established roles of RNA genome
encapsidation. Lujo virus (LUJV), the most recently emerged human pathogen
within the Arenaviridae family induces disease associated with haemorrhagic
fever and an 80% mortality rate. Better understanding the functions of an
arenaviral protein, such as NP, could allow for the identification of targets for
future therapeutic attack. Utilising LUJV NP as a model NP for arenavirus NPs
in general could allow for the identification of such a therapeutic target, which
can then be investigated for other arenavirus NPs, with the aim to identify a
key interaction with potential implications across the Arenaviridae family.
1.1.1. Discovery of the Arenaviridae Family, Lujo virus and Lymphocytic
choriomeningitis virus
The Arenaviridae family of ambisense RNA viruses consists of over 30
members, with 7 discovered in 2015 alone. Currently 9 arenaviruses are
known to cause severe disease, including haemorrhagic fever and cerebral
complications in humans and are collectively the largest cause of
haemorrhagic fever (HF) in humans per annum (Gryseels et al., 2015; Bisordi
et al., 2015; Aqrawi et al., 2015; Lavergne et al., 2015; Li et al., 2015;
Hellebuyck et al., 2015; Witkowski et al., 2015; IUMS, 2015; CDC, 2015).
The first arenavirus discovered was lymphocytic choriomeningitis virus
(LCMV) after an outbreak of infectious encephalitis in St. Louis, USA in 1933
– discussed in greater detail in section 1.1.4 (Muckenfuss et al., 1934).
2
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Following this discovery, the detection of further novel infections, combined
with morphological studies, led to the establishment of a novel taxonomic
group initially coined as Arenoviruses (Rowe et al., 1970). The appearance of
these viruses under electron microscopy showed prominent, dense granule-
like structures within particles, giving the family its name – Arenaviridae –
‘arena’ being the Latin for sand. The most prominent member of the family is
Lassa virus (LASV), the causative agent of Lassa fever, which is reported to
infect upwards of 300,000 individuals per year, with a high proportion of cases
remaining undetected (Monath et al., 1974; Kernéis et al., 2009; Sogoba et
al., 2012). The disease severity of Lassa fever varies between outbreaks, but
taken together the case fatality rate (CFR) of hospitalised patients is
approximately 15-30% in acute outbreaks (Yun & Walker, 2012), with the
overall CFR, once asymptomatic infections are included, roughly 1-2%.
Annually, LASV is the single largest cause of HF complications, far
outstripping the total number of cases during the 2013-16 Ebola virus
outbreak (Peterson et al., 2014; World Health Organisation, 2015). All
infectious arenaviruses exhibit a very broad tissue tropism, with evidence of
viral infection in nearly all organs and tissues (Bird et al., 2012, Schafer et al.,
2014).
Table 1 Arenaviruses known to induce severe disease in humans
Species Serogroup Distribution
LCMV OW Worldwide
LASV OW Guinean Africa
LUJV OW Zambia








Sau Paulo District -
Brazil
3
Chapter 1 – Introduction
Each member of the Arenaviridae family replicates within a specific resevoir
host. These hosts are almost exclusively rodents – with exceptions being the
South American Tacaribe virus (TACV), which resides in Caribbean fruit bats
(Cogswell-Hawkinson et al., 2012), and a small subset of recently identified
arenaviruses that can cause infections within snakes (Aqrawi et al., 2015).
This close and sometimes exclusive association between virus and host
species often confines each arenavirus within specific geographical regions,
meaning that the infections are often endemic within these locations. This
geographical restriction potentially curbs their lethality due to the behavioural
changes of hosts after interacting with human populations. As human
populations grow and expand, the availability of food alters, enabling host
rodents to come in closer contact with humans. Mass migration of human
populations has been shown to directly drive LASV evolution thorough host
selection pressures, discussed in greater detail in section 1.1.3 (Lalis et al.,
2012). This viral-rodent co-evolution has been shown to restrict disease in
rodents and could explain the far lower CFR of LASV at present, compared to
when it first became prominent in the expanding regions of West Africa
(Sogoba et al., 2012; Monath et al., 1974; Rowe et al., 1970; Bannister, 2010;
Peterson et al., 2014; Zapata & Salvato, 2013). The emergence of new
arenaviruses into naïve human populations has caused outbreaks with far
higher CFR than is now present in LASV endemic regions, such as Guanarito
virus (GTOV) in Venezuela, with CFRs of approximately 15% (Salas et al.,
1991; Weaver et al., 2000).
Arenaviruses are certainly neglected tropical diseases, with many aspects of
their replication cycle incompletely understood. With increased focus on HF
causing infections following the 2013-16 EBOV outbreak, there is a need for
an increase in knowledge regarding fundamental aspects of the arenaviral
replication cycle. The most recently emerged HF causing arenavirus infection
is Lujo virus (LUJV), which was first detected in 2008 in Zambia, following an
outbreak of severe febrile illness with associated haemorrhagic shock
complications (Sewlall et al., 2014; Briese et al., 2009). The resulting
nosocomial outbreak in Johannesburg was associated with a CFR of 80%,
4
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and highlighted the concerns over newly emerging arenaviruses into naïve
populations.
1.1.2. Classification
The Arenaviridae family, along with the Orthomyxoviridae, Bunyavirdae and
Ophioviridae families together form a collection of segmented negative-strand
RNA viruses, with the Bunyaviridae being the most closely related family. The
Arenaviridae family constitutes the family with the highest number of HF
causing pathogens, with 7 known to cause HF, and LCMV being able to
manifest clinically as a cerebral infection involving aseptic meningitis and its
associated symptoms.
Figure 1. Illustration of virion structure
Arenaviruses exhibit a cytoplasmic replication strategy. Virions are on
average approximately 100nm in diameter, although virion diameter varies
Diagram illustrating a visual representation of an arenaviral particle. Viral ss RNA genome
(blue) is encapsidated with NP (red) forming an RNP. At the 3’ and 5’ ends of this ssRNA
strand is the L polymerase (orange). A host-derived lipid bilayer (light green and orange)
embedded with GP spikes (maroon) bound to the matrix protein Z (green) on the matrix
side of the membrane. Host-derived ribosomes have been described to populate the
virion, shown in purple.
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between 80 and 130nm (Murphy & Whitfield, 1975). The “sand” particles
which give their name to the family are known to be host-derived ribosomes,
represented in figure 1, although these packaged ribosomes are not thought
to be essential for viral replication (Rowe et al., 1970; Leung & Rawls, 1977).
The four encoded proteins consist of the polymerase (L); matrix protein (Z);
glycoprotein – expressed as a precursor protein (GPC) and post
translationally modified into a tripartite complex known as GP; and the
nucleoprotein (NP).
A defining characteristic of all arenaviruses is their bi-segmented genome.
While arenaviruses are classified as negative sense viruses, their coding
strategy is in fact ambisense, whereby both the single stranded RNA genome
segments consist of both positive and negative sense open reading frames
(ORFs), as illustrated in figure 2.
Figure 2. Illustration of genome structure
In total, there are over 30 arenavirus species, subdivided into two genera;
Mammarenavirus and Reptarenavirus. The Mammarenavirus genus
comprises the mammalian host-infecting viruses, whereas the recently
described Reptarenavirus genus represents reptilian pathogens (IUMS,
2015). The mammarenaviruses are zoonoses, with several known to infect
humans. In addition other mammals such as mountain gorillas and a variety
of other non-human primates are known to become infected with LASV,
Diagram illustrating the genome structure of the Arenaviridae. Ambisence genome
segments are shown linearised for diagrammatical purposes. The L segment
encodes the polymerase protein L (orange), and the matrix protein Z (green). The S
segment encodes the NP (red) and GP (maroon). Inverted letters indicate negative
polarity.
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potentially conferring a transmission route through the bushmeat trade (Ogbu
et al., 2007). Transmission from the reservoir host is through exposure to
infected tissue or excreta, with virions stable in dried rodent urine and faeces
for prolonged periods (CDC, 2015). Human-to-human transmission is again
through coincidental ingestion or exposure of infected bodily fluids with LASV
known to persist in semen for up to 6 weeks (Mary Milazzo et al., 2011;
Kernéis et al., 2009).
The mammarenaviruses are subdivided into two geographically limited clades
– the Old World arenaviruses (OW) originating from Africa, Europe and Asia;
and the New World arenaviruses (NW), or Tacaribe Complex viruses found in
the Americas. LCMV is the exception, an OW virus that exhibits a worldwide
distribution through association with its natural reservoir, the common house
mouse. The essentially asymptomatic, persistent infections observed in host
reservoir species are evident of a long-term association with their respective
hosts (Zapata & Salvato, 2013). Given the ancient geographical isolation that
the OW and NW clades exhibit, these infections are generally unable to infect
other rodent species, and show a degree of co-evolution with their hosts
(Zapata & Salvato, 2013).
The relatively recently discovered reptarenaviruses cause a condition known
as Inclusion Body Disease in snakes. The first member of this genus was
discovered in 2012, with three more species isolated since (Stenglein et al.,
2012). The isolation of these viruses from snakes, which are known predators
of multiple rodent species, is further evidence of long-term association with
hosts given that distinct viruses, some significantly diverse (Bodewes et al.,
2014), have evolved to establish stable infections in predatory reptiles.
1.1.3. Rodent and human life cycle
The host tropism of arenaviruses means that they are held stably within one,
or a small number, of specific reservoir host species, limited to specific
ecosystems and habitats within that ecosystem. Stable host infection results
in persistent, sub-clinical manifestation of infection, which presents with
7
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rodents appearing marginally smaller in size than non-infected counterparts
(Fichet-Calvet et al., 2014; Fichet-Calvet et al., 2007).
The predominant identifying features of arenavirus-infected rodents – smaller
size – does not appear to inhibit the ability of those infected to thrive in a non-
stressed environment. However, recent studies have identified mutations in
LASV genomes after the Biafra war in Nigeria, and the Sierra Leonean and
Guinean civil wars. The mass migration of human populations stressed the
local rodent populations, altering the availability of food. This competition
favoured non-infected rodents, creating a selection pressure to generate viral
clones which would not inhibit the host’s ability to compete for food and mates
(Lalis et al., 2012; Shaffer et al., 2014). This competition-driven evolution
could allow virally-infected rodents to be likely to interact with humans due to
increased ability to compete with their non-infected counterparts. Indeed, in
the aftermath of the conflicts, LASV infection rates increased noticeably. (Lalis
et al., 2012).
The infectious cycle in rodents is one of persistence; permissive rodents
exhibit minimal clinical signs and can possess high titres in blood and excreta
(Chiller & Oldstone, 1984). Strains which cannot block interferon signalling are
cleared by the immune system. The specific residues controlling acute vs
chronic infection in rodents have been identified for LCMV, with a mutation in
GP, F260L, and the polymerase K1079Q responsible for the persistent form
(Teijaro et al., 2013; Wilson et al., 2013; Matloubian et al., 1990). This
persistence contributes to the ability of rodents to thrive, and therefore infect
humans through their behaviour and exploitation of human dwellings.
Virus transmission between rodent hosts is predominantly horizontal,
although vertical transmission is also common, and is often virus species
specific. For example, LCMV is known to able to cross the placenta in humans
and cause complications in infants as a result (Zapata & Salvato, 2013; Fichet-
Calvet et al., 2014; Milazzo et al., 2011; Barton et al., 2002). Arenavirus
infections in humans occur following close interaction with a virus-infected
rodent host resulting in exposure to infected bodily fluids, most commonly
8
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through inhalation of virus-contaminated urine or faeces via airborne droplets
(Centers for Disease & Prevention, 2006; Emond et al., 1982; Dylla et al.,
2008). Ingestion and preparation of virus-contaminated food, such as bush
meat, is also a possible infection route (Dylla et al., 2008). In addition, in
incidents of HF outbreaks, nosocomial transmission is common, thus the
exposure risk of healthcare workers must be taken into account during HF
outbreaks (Paweska et al., 2009). A final transmission route that is both
extremely rare and often fatal is via organ transplantation; cases of LCMV
infection after transplantation have been reported, with the harvesting of
organs common after trauma rather than illness. Individuals who are sub-
clinically infected with LCMV are able to pass on this infection to recipients of
their harvested organs. The immunosuppression medication allows the
transplanted infection to take hold, with infection by this route often exhibiting
a CFR of 100% (Wright & Fishman, 2014; Palacios et al., 2008; Macneil et al.,
2012; Fischer et al., 2006).
There are not thought to be other stable hosts within mammals outside of the
specific limited host species. Given the constitutively expressed receptor
utilised by many arenaviruses of the OW, -dystroglycan, it is conceivable that
predatory mammals could become infected in the wild upon hunting of
infected rodents. Macaques and other primates are utilised experimentally to
study disease progression, and thus could become infected in the wild
(Hensley et al., 2011).
1.1.4. Geographical distribution and epidemiology
Arenaviruses exhibit worldwide, pocketed, distribution through their
association with rodents. The extent to which each disease is geographically
restricted corresponds exactly to the natural habitat of its host species. The
geographical isolation of the ancestral host of most rodent species and
subsequent divergent evolution is evidence of co-evolution between virus and
host (Zapata & Salvato, 2013). The first recognised arenavirus outbreak in
humans was the St. Louis encephalitis outbreak of 1933, but as these
infections are thought to enjoy a long-term association within their natural
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hosts it is likely these infections have been causing disease for many centuries
(Muckenfuss et al., 1934; Charrel et al., 2011).
The most widespread arenavirus is LCMV, with the distribution pattern of its
host, the common house mouse (Mus muluscus) near-global, as illustrated in
figure 3 (IUCN, 2015). The life cycle of the common house mouse is one of
direct reliance on human dwellings. This association carried the rodent
globally, likely through colonial-era naval trade. In certain areas, up to 60% of
rodents show sero-prevalence of LCMV.
Members of OW clade, with the exception being LCMV, show geographical
isolation in isolated regions of Africa and Asia; correspondingly, NW species
are found throughout the Americas. This distribution pattern suggests that
wherever there are local geographically isolated rodent populations, there
could be an associated arenavirus species. For example, Whitewater Arroyo
virus localised in central USA, Catarina virus found in Texas and the Amapari
virus found in Northern Mexico were all isolated from specific areas from
closely related rodent species, and are all able to induce cerebral illness in
humans (Lele et al., 2003; Milazzo et al., 2010; Cajimat et al., 2007; Mary
Milazzo et al., 2011). Recent identification of rodent-borne arenaviral
infections in South East Asia are also evidence that arenaviruses have a far
wider distribution pattern than originally thought, and absence of obvious
infection in rodents is not indicative of an absence of infection (Lele et al.,
2003; Van Cuong et al., 2015).
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Figure 3. Map illustrating the geographical distribution of selected arenaviruses
The arenavirus that is associated with the largest burden of human disease is
LASV, which is hosted within the Mastomys natalensis species prominent
across much of sub-Saharan Africa (IUCN, 2015). LASV itself is limited to the
Guinea region of West Africa, extending from Guinea to Nigeria. However,
recent analysis of habitats and social changes has expanded the risk areas of
LASV infection further East and South, from Cameroon, Democratic Republic
of Congo and south towards Angola (Fichet-Calvet & Rogers, 2009; Peterson
et al., 2014). The reason for the lack of LASV within rodents in other areas of
Africa is unknown. The Guinea region of West Africa, from Cameroon west
towards Senegal, is where LASV is prevalent and is the most populous region
Map illustrating the relative geographical distribution of selected members of the
Arenaviridae. Data based on clinical reporting, host species distribution and historical
reports. LCMV – Lymphocytic choriomeningitis virus; GTOV – Guanarito Virus; LASV
– Lassa Virus; LUJV – Lujo virus; JUNV Junin Virus; MACV – Machupo Virus; CCHF
– Chapare virus; WWAV – Whitewater Arroyo Virus; BzHF – Brazillian Haemorrhagic
Fever Virus; EBOV – Ebola virus, 2013-16 outbreak. (Weaver et al., 2000; Mary
Louise Milazzo et al., 2011; Shao et al., 2015; Charrel & de Lamballerie, 2010;
Maiztegui, 1975; Childs et al., 1992; Briese et al., 2009; Ogbu et al., 2007)
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of Africa, with Nigeria predicted to become the world’s third most populous
country by 2050 (United Nations Populations Division, 2015). The potential for
more devastating outbreaks of LASV within this region to occur following
behavioural changes in the local rodent population is clear (Shaffer JG; Grant
DS; Schieffelin, 2014; Olugasa & Dogba, 2015).
M. natalensis is also the rodent host species for a number of other
arenaviruses in geographically distinct locations (Gryseels et al., 2015)
including: the non-pathogenic Mopeia virus in Mozambique and Zimbabwe;
Morogoro virus in Tanzania; Luna virus in Zambia; and finally Gairo virus in
central Tanzania. This divergent distribution of separate viral infections within
the same host species could indicate divergent evolution, with the virus
adapting to its host differently in different geographical locations. Gairo virus
itself is more closely related to an Ethiopian arenavirus not hosted within M.
natalensis – Mobala virus – whilst still exhibiting features similar to other M.
natalensis infecting species (Gryseels et al., 2015).
NW arenaviruses share this distribution trend, with localised pockets of human
infections due to interaction with the resident rodent species in their habitats.
Junin virus (JUNV) is the predominant human NW pathogen, responsible for
Argentinian haemorrhagic fever. JUNV is localised to the rural, agricultural
regions of Northern Argentina, with few cases as a result. In untreated and
un-vaccinated individuals, the CFR can reach 15-30%, with this brought down
to 1-2% when patients are treated with convalescent plasma (Yun et al., 2008;
Gomez et al., 2011). JUNV is carried within a number of host rodent species,
the accepted host reservoir being Colomys musculinus, and several small
field mouse species that have similar habitats to the reservoir species. In
addition, the predatory Galictis cuja rat is known to be infected by JUNV in the
wild (Gomez et al., 2011; Yun et al., 2008; Garcia et al., 2000).
The pathogen responsible for Bolivian haemorrhagic fever (BHF) – Machupo
virus (MACV) – is hosted within large cane mice of the Calomys callosus
species in the northern rainforest region of Bolivia. They are known to invade
towns and villages at times of environmental stress such as low food
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availability, and thus cause urban case outbreaks of BHF with CFRs of up to
40%, with an average CFR of approximately 20% (Shao et al., 2015). Rodent
control measures in Bolivia have proven effective in limiting the outbreaks of
BHF; however, the ability for rodents to persist in urban environments and
adapt is well documented (Barnett & Dickson, 1989), and thus control
measures may not prove adequate in combatting arenaviral diseases.
Another arenavirus-mediated haemorrhagic fever is Venezuelan
haemorrhagic fever (VHF), the causative agent being Guanarito virus
(GTOV). It is responsible for several cases of VHF per year and is associated
with a CFR of approximately 30% (Milazzo et al., 2011; Salas et al., 1991).
The host species of GTOV is the cane mouse Zygontontomys brevicuda,
which is prevalent in the far northern regions of South America, from northern
Brazil to Panama. Cases of GTOV in humans are isolated to the rapidly
expanding western regions of Venezuela’s Orinoco oil belt. This provides
further evidence that human population expansion has the potential to force
otherwise endemic but isolated diseases into human populations (Talwani,
2002; Weaver et al., 2000).
Finally, the newly described Lujo virus (LUJV) of the OW clade of arenaviruses
emerged in Zambia in 2008, causing an index case and a further 4 cases of
nosocomial transmission under patient containment conditions (Briese et al.,
2009; Sewlall et al., 2014). To date, this is the only known outbreak and while
the initial outbreak was small, the ease with which it was transmitted
nosocomially despite standard infection control procedures indicates that
LUJV could have the potential to be a devastating human pathogen. To date,
the host species of LUJV is unknown, despite efforts to trap multiple rodent
species in efforts to detect the host species (Ishii et al., 2012).
1.1.5. Genetic diversity and evolution
The two distinct genera of the Arenaviridae family – the mammarenaviruses
and the reptarenaviruses – are further subdivided into clades. The
mammarenaviruses are subdivided into two serogroups with GP antibody
cross-reactivity throughout the two serogroups. These two groups generally
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correspond to their relative geographical distributions; the Old World (OW)
group of agents originating from the African and Eurasian continents and the
New World (NW) serogroup, which is further subdivided into clades A, B and
C based on overall amino acid sequence analysis, of agents originating from
the Americas (Charrel et al., 2008; Radoshitzky et al., 2015). The specific
separation between species can be defined as a 12% overall amino acid
sequence (Radoshitzky et al., 2015). Within the NW group the majority of
human pathogens are found in clade B, with a few, such as Whitewater Arroyo
virus, found in clade A. The amino acid and nucleotide differences between
different arenavirus species within a serogroup is generally over 30%, with
some exhibiting as much as a 50% difference (figure 4) (Briese et al., 2009).
The geographical separation of arenavirus species results in distinct
differences in viral evolution. Despite being one of the more closely related
arenaviruses, LASV and Mopeia virus (MOPV), exhibit an approximately 26%
amino acid difference and are both found in the same reservoir host. Despite
this, MOPV is not known to infect humans, indicating a different evolutionary
path perhaps due to less interaction between its host and humans in the much
less densely populated Central and Southern Africa compared to West Africa
(Georges et al., 1985; Briese et al., 2009).
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Figure 4. Neighbour-joining phylogenetic tree depicting LUJV L and S segment
relationships with other members of the Arenaviridae family members
In 2008 LUJV emerged in Lusaka, Zambia followed by nosocomial secondary
and tertiary transmission at a clinic in Johannesburg, South Africa – giving the
virus its name. Sequence analysis of the virus isolated from two of the infected
patients confirmed the presence of a novel arenavirus. Phylogenetic analysis
showed that LUJV was significantly distinct from other OW arenaviruses
(Briese et al., 2009). This analysis placed LUJV at the very root of the
phylogenetic analysis; whilst being most closely related to other OW
arenaviruses, the LUJV GP sequences are more closely related to its NW
cousins than other OW viruses, shown in figure 4 (Briese et al., 2009). The
discovery of such a diverse arenavirus is evidence that there could be several
more highly divergent arenaviruses yet to have emerged into human
populations.
1.1.6. Arenaviral infectious syndromes in humans and disease
pathogenesis
1.1.6.1. HF complications of Arenaviral infections
Humans, and other secondary hosts – i.e. organisms in which infections
become clinically observable – can become infected with arenaviruses.
Individuals who encounter infectious material through exposure to infected
urine; faeces; blood; ingestion of contaminated meat; direct human-human
contact; airborne liquid droplets and sexual contact transmission can become
infected. Less common routes of infection include vertical transmission and
through breast feeding (Peterson et al., 2014; Dobec et al., 2006; Kernéis et
al., 2009; Charrel et al., 2011; Lalis et al., 2012). LASV exhibits an incubation
period varying from 3-21 days. The usual HF clinical manifestations begin with
Phylogenetic relationships of LUJV inferred on full L (panel A) and S segment
nucleotide sequence (panel B) Phylogenies were reconstructed by neighbour-joining
analysis applying a Jukes-Cantor model; the scale bar indicates substitutions per site;
robust boostrap support for the positioning of LUJV was obtained in all cases (>98%
of 1000 pseudoreplicates). GenBank Accession numbers for reference sequences
are provided in appendix I (Briese et al., 2009).
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mild febrile illness progressing to severe ‘flu-like’ symptoms including high-
grade fever, weakness and malaise in the majority of cases. Coughing,
pharyngitis and severe headaches are common, with gastrointestinal
manifestations including diarrhoea, vomiting and general nausea also
common complications (Yun & Walker, 2012). In HF-causing infections, such
as LUJV, GTOV, JUNV and, in certain cases, LASV, it is the disturbance of
vascular function and subsequent increase in vascular permeability which
manifests as haemorrhagic complications, oedema and pleural and
pericardial effusions (Yun & Walker, 2012). Disseminated intravascular
coagulation (DIC) is also a life-threatening complication of HF infections, such
as LUJV, and indicates a poor prognosis (Sewlall et al., 2014; Ogbu et al.,
2007).
In patients who are unlikely to recover, deterioration manifests as severe
oedema, respiratory distress, seizures, encephalopathy and can result in
coma, DIC and fatal haemorrhagic shock (Yun & Walker, 2012). Primary
bleeding in most cases of LASV is not sufficient to induce life-threatening
shock. However other infections such as those caused by LUJV may be
severe enough to induce life-threatening haemorrhagic shock,as bleeding
starts at an earlier stage of disease (Bird et al., 2012; Sewlall et al., 2014).
After symptom onset, recovery will usually begin between 8 and 10 days, and
in cases of severe disease, deterioration will occur between days 6 and 10
(Yun & Walker, 2012). Sensorineural deafness is common amongst those
who recover from arenaviral disease, a complication also commonly observed
in EBOV survivors (Okokhere et al., 2009 ).
In the majority of locations where human disease-causing arenaviral
infections are endemic, other febrile illnesses are common. This can cause a
high proportion of mis-diagnoses as large proportions of populations are sub-
clinically infected with malaria, or other more common tropical diseases such
as Dengue fever. Mis-diagnosis can lead to increased risk of nosocomial
transmission and the prolonging of outbreaks as a result.
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Viraemia is a good clinical indicator for prognosis. LASV infected patients
found to have a lower viral titre, corresponding to approximately a TCID50/mL
of <103, being indicative of a better prognosis (Faye et al., 2015; Asogun et
al., 2012; Yun & Walker, 2012). Viraemia peaks between 4 and 9 days post
symptom onset. Patients will generally clear virus from their blood within three
weeks post symptom relief. However, it has been noted to persist in mammary
glands and testes for months, conferring sexual transmission via semen for
several months after recovery (Asogun et al., 2012; Bausch et al., 2000; Mate
et al., 2015).
The precise cellular pathogenesis that gives rise to the symptoms of
arenavirus infection is poorly understood. In particular the cellular processes
which induce or facilitate the systemic symptoms and terminal syndromes.
The lack of T-cell immune responses to LASV is indicative of poor prognosis,
but the underlying mechanisms are unknown (Yun & Walker, 2012). The lack
of an adaptive immune response means that neutralising antibodies are not
present in the blood and can lead to fatal disease.
The clinical manifestations of LUJV mimic those of LASV but to a more severe
extent clinically, rivalling EBOV in terms of severity. The 2008 LUJV outbreak
was associated with rapid onset of fever and rapid deterioration to HF
symptoms (Sewlall et al., 2014). Out of the 5 patients, only one survived long
enough to receive high dose broad spectrum anti-viral ribavirin, in addition to
clotting factor VIIa to combat DIC, with this patient ultimately surviving. Mild
immunosuppressants were also administered in order to prevent induction of
a cytokine storm (Sewlall et al., 2014). The availability of many of these agents
in rural outbreaks would be low, and any larger-scale outbreaks of this newly
emerged pathogen would require swift responses from aid agencies and
governments (Sewlall et al., 2014).
Histological observations and changes in human tissue infected with LUJV is
unknown, with analysis of representative the animal model – LUJV-infected
13/N Guinea pigs – indicating histological changes within all organs,
especially kidneys, liver, spleen and lungs (Bird et al., 2012). Clinical
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observations in humans matched this systemic distribution. This results in
rapid deterioration from the relatively benign initial onset followed by rapid and
severe multi-organ failure. The risk of nosocomial infection is increased if
primary differential diagnoses do not include haemorrhagic fever, due to lack
of protective measures (Sewlall et al., 2014).
Healthcare professionals should be aware of this disease progression when
dealing with severe febrile illnesses in patients from rural locations in
developing nations, and arenaviral HF should be considered as an important
differential diagnosis.
1.1.6.2. Cerebral complications of LCMV infection
LCMV is generally asymptomatic and rapidly cleared in otherwise healthy
adults (Bonthius, 2012). However, LCMV is still a major public health concern
due to its high CFR in immunocompromised patients. LCMV is, as discussed
above (1.1.3), able to cross the placenta, conferring severe developmental
abnormalities in infected infants or prenates. Additionally, LCMV is an agent
known to be transmitted through tissue and solid organ transplantation; as it
is generally asymptomatic the infection in the organ donor is missed (Schafer
et al., 2014; Palacios et al., 2008; Macneil et al., 2012). The majority of
transplants occur after either brain or cardiac death, where a clear cause of
death has been confirmed (Manara et al., 2012; Souter & Van Norman, 2010).
The required use of immunosuppressant medication after receiving donated
organs allows LCMV to thrive unchecked in an immunosuppressed patient,
which can cause CFRs of up to 100% through transplantation transmission
(Palacios et al., 2008; Fischer et al., 2006).
LCMV is the most widely researched arenavirus, and thus more is known
about its immuno-regulatory mechanisms. In mice, LCMV is able to establish
persistent infections through modulating the host interferon response.
Interfering with these processes prevent the activation of cytotoxic T-
lymphocytes (CTLs), thus allowing infected cells to persist (Chiller & Oldstone,
1984; Teijaro et al., 2013). In humans, LCMV is unable to overcome the
intracellular type I interferon signalling, thus allowing the immune system to
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clear the virus. In immunosuppressed individuals the activation of CTLs is
impaired, thus allowing the infection to continue unperturbed. In mice, it is the
NP which is responsible for interfering with interferon signalling by preventing
the activation of IB Kinase (IK) and interferon regulatory factor-3 (IRF3)
(Pythoud et al., 2012; Rodrigo et al., 2012). While cells infected with LCMV
are able to signal appropriately in humans, this signal is not acted upon in
immunocompromised patients.
1.1.7. Small animal models of LUJV and LCMV
The reservoir species of LUJV is unknown despite efforts to capture infected
rodents in the region of Zambia from where the outbreak occurred (Ishii et al.,
2012). The disease progression of LUJV within its reservoir species is
therefore unknown, and in the absence of an effective infectious model,
details of its disease progression is limited to the case reports of the patients
from the 2008 outbreak (Sewlall et al., 2014; Paweska et al., 2009).
LUJV was found to infect clone 13/N Guinea pigs, presenting with similar
clinical features as patients infected in the 2008 outbreak (Bird et al., 2012).
The disease, as is common for all arenaviral infections, was able to infect
multiple host tissues, indicating the use of a ubiquitous entry receptor. This
may be -dystroglycan, as is utilised by LASV and LCMV and other OW and
NW clade C arenaviral infections (Moraz et al., 2013; Shah et al., 2006).
Disease onset was approximately 5 days post exposure – as opposed to
between 7 and 13 days in humans – with fever, loss in weight, ocular
discharge, dehydration, haematuria, genitourinary haemorrhage and eventual
moribundity and death (Bird et al., 2012; Sewlall et al., 2014). All infected
animals had either died or had been euthanised within 17 days of infection.
Autopsy of deceased animals identified significant internal frank haemorrhage
in multiple organs; most notably within the large and small bowel, liver, bladder
and in the surrounding lymphatic tissue. Evidence of DIC was found in the
heart and liver, with secondary necrosis of the liver and cardiomyopathy (from
~12 days post infection (PI).) also observable (Bird et al., 2012).
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13/N guinea pigs provide an effective clinical model of LUJV infection.
However, the severe limitations presented by working with a Bio-safety level
4 (BSL4) pathogen within experimental animals restricts their use significantly.
The identification of an effective BSL2 model for LUJV infection would greatly
assist in evaluating therapeutic procedures or testing novel therapeutics prior
to assessment in LUJV infected animals.
LCMV has for some time been used in studies involving experimental animals,
most notably mice, for research regarding general immune responses to viral
infections (Teijaro et al., 2013; Wilson et al., 2013). The clinical presentation
of LCMV is also well established, and divergent from the majority of arenaviral
infections, exhibiting cerebral tropism, causing encephalitis rather than any
haemorrhagic complications. Utilising LCMV as a model for HF causing
infections must take into account effects that are known to be common
between the LCMV and the HF infection of interest. Finally, in cases of infant
and pre-/post-natal exposure LCMV has been indicated in severe
developmental abnormalities and any animal model must thus produce similar
developmental impairments in infected animal infants. In this instance, LCMV
itself is of research interest in the prevention of developmental abnormalities
in children, and infections of the immunocompromised.
1.1.8. Diagnosis
Diagnosis of viral HF is notoriously challenging, with many alternative and
more common causes of acute and severe febrile illness endemic in most
areas where pathogenic arenaviruses are present. In addition, malaria can be
endemic, with persistent and asymptomatic infections in swathes of the
population in Africa, with a positive test resulting in improper treatment. For
LASV, dedicated facilities in Nigeria utilise PCR and ELISA-based techniques
(Asogun et al., 2012). After the 2013-16 EBOV outbreak new laboratories
were established in Sierra Leone, and other West African nations, in order to
diagnose acute febrile illnesses more quickly as a direct result of the
international effort to combat the outbreak (Asogun et al., 2012; Crowe et al.,
2015; Personal Experience, 2015).
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1.1.9. Treatments
The number of effective therapies for arenaviral infections is limited, with high-
dose intravenous (IV) ribavirin indicated in treatment of LASV, and
convalescent serum useful in treatment of NW infections (Hadi et al., 2010;
Ruggiero et al., 1986). Ribavirin is often used as post-exposure prophylaxis,
given to close contacts and healthcare workers after a case of LASV is
confirmed. However, post-exposure prophylaxis has its limitations, for
example, the efficacy of ribavirin is only observed if administered early, and
does not appear to be capable of reversing the course of a well-established
infection (Hadi et al., 2010). Commonly, disease in the index case will have
progressed too far for successful treatment after diagnosis is confirmed,
meaning the infection could have spread to other individuals necessitating
rapid post-exposure therapy.
The side-effects of ribavirin, including severe ‘flu-like’ symptoms and suicidal
depression, make it a less than ideal choice as a post-exposure prophylactic,
and thus new therapies are required. Ribavirin is contraindicated in a number
of circumstances, most prominently in patients with anaemia, sickle cell
anaemia (SCA), pregnancy or bleeding disorders making its use as a
therapeutic in HF patients more complicated. With SCA also highly prevalent
in areas endemic for malaria, ribavirin is an undesirable therapeutic agent in
tropical regions. In addition, ribavirin is severely contraindicated in pregnancy,
causing severe congenital defects. Its use is not recommended in expectant
mothers, those wishing to become pregnant and males whose partner is
planning to become pregnant, and its use prohibits in either male or female
recipients pregnancy attempts for 6 months (US National Library of Medicine,
2015).
These defects and side-effects are due to ribavirin’s proposed mechanism of
anti-viral action. As a nucleoside antimetabolite, ribavirin is incorporated into
the viral genome during RNA replication, but without the canonical Watson-
Crick base pairing between purines and pyrimidines. Subsequent rounds of
template-directed RNA synthesis allow further mis-incorporation events to
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occur leading to exponential increase in the number of viral polymerase
mistakes. Eventually, the error rate reaches a point where the accumulated
viral genomes are no longer viable, known as ‘error catastrophe’. As ribavirin
can also be incorporated into host DNA and RNA, this lack of specificity
confers the observed side-effects and contraindication in humans, particularly
during pregnancy (McEvoy, 2005; MeSH, 2015; US National Library of
Medicine, 2015). Ribavirin is supplied as a prodrug, and it is the ribavirin-5’-
monophosphate, -diphosphate and -triphosphate forms metabolised and
phosphorylated in the liver, that are likely the agents behind its proposed
activity (McEvoy, 2005).
The use of convalescent serum has been shown to be efficacious in treating
those infected with JUNV, and could therefore be used in other cases of
arenaviral infectious outbreaks. Again, this comes with severe limitations; in
novel outbreaks, the availability of convalescent serum will be essentially non-
existent, with a reliance on stable healthcare networks to provide a continuous
cold storage chain to maintain efficacy. In the case of acute, novel outbreaks
both ribavirin and convalescent serum are less than ideal therapies. Novel
therapeutic approaches are therefore warranted, and thus identifying
mechanisms of viral replication strategies are essential.
In addition to limited therapeutics, there are no widely available vaccines for
arenaviral infections. The Candid #1 strain of JUNV has been licenced for use
in Argentina for decades, but is restricted to use only in Argentina. It is,
however, given to front-line healthcare workers and armed forces personnel
in the United States in the event of bioterrorism threats (Ambrosio et al., 2011;
Bausch et al., 2010; Centers for Disease et al., 2012; Murphy, 2008).
The vaccine was developed in 1979 by an international consortium of
Argentinian, US, Pan-American and UN public health organisations. It was
isolated after serial passages of the XJ44 strain of JUNV in FRhL-2 cells,
generating a protective and safe immunogenic response in Guinea pigs, mice
and Rhesus monkeys prior to human clinical trials (Ambrosio et al., 2011). As
is the case with many neglected, yet significant, human pathogens, the
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vaccine was not commercially viable to produce. The Argentinian government
financed the manufacture of the vaccine, with the final product providing 95%
efficacy (Ambrosio et al., 2011).
1.2. Arenaviral structures, genome and proteins
1.2.1. Structure and genome
Arenavirus particles are lipid soluble and are approximately 100nm in
diameter. They consist of a host-derived lipid membrane, forming an envelope
with embedded glycoprotein spikes. Particles are pleomorphic but generally
spherical, and are considerably larger than non-enveloped viruses such as
poliovirus, and comparable to certain herpesviruses (Chevaliez & Pawlotsky,
2006; Mocarski Jr, 2007; Murphy & Whitfield, 1975). Arenaviruses are
composed of four virus-encoded proteins. The Glycoproteins (GP) GP1, GP2
and SSP are predominantly responsible for cell entry, membrane fusion and
budding (Geisbert et al., 2005). On the inside of the viral envelope is the matrix
(Z) protein. Z is a multifunctional protein, with roles in viral assembly, viral and
cellular protein trafficking – such as ESCRT complex proteins and GP, NP
and RNP complexes – and immune-modulation (Fehling et al., 2012; Fan et
al., 2010). Within the interior of the virus particle the two circularised
ambisense genome segments, circularised through direct RNA-RNA
interaction (figure 5) are encapsidated with the viral nucleoprotein (NP),
forming a ribonucleoprotein (RNP) when associated with the polymerase (L)
(Pedersen & Konigshofer, 1976). Finally, the large polymerase (L) is thought
to interact with the 3’ and 5’ ends of the ambisense genomes, associated with
the RNP, in a similar manner to La Crosse Virus (LACV) of the closely related
Bunyaviridae (Pedersen & Konigshofer, 1976; Gerlach et al., 2015).
Diagram depicting the 3’ and 5’ ends of the LCMV S segment accession
#NC_004294, forming the proposed panhandle structure where L is thought to bind.
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Figure 5. Diragram depicting proposed panhandle structure of LCMV S segment
Figure 6. Electron micrograph showing LCMV morphology
As briefly discussed above, an early observation made from electron
micrograph images is that purified arenavirus particles contain large dense
structures within the virion interior, that give virus particles a ‘sandy’
appearance. These electron-dense sites are widely considered to represent
host cell ribosomes (Rowe et al., 1970), and their sandy appearance was
chosen to derive the family name – ‘arena’ being Latin for sand (shown in
figure 6 (Murphy & Whitfield, 1975)). Subsequent investigations have further
confirmed the presence of ribosomal subunits in virions (Pedersen &
Konigshofer, 1976; Leung & Rawls, 1977).
The presence of ribosomes within viral particles is an intriguing element of the
arenavirus life cycle. Their presence could indicate that other cellular
components are packaged within viral particles. The presence of such factors
– while not necessarily essential – could play a role in establishing an infection
more efficiently than without.
Electron micrograph of LCMV particles isolated from infected Vero cells (Murphy &
Whitfield, 1975)
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1.2.2. Ambisense strategy of gene expression
Arenaviruses employ an ambisense genome replication strategy. Each virion-
incorporated genomic RNA segment (vRNA) has the potential to encode two
open reading frames (ORF) (Zapata & Salvato, 2013); one from the vRNA
strand and another from its antigenomic, complementary copy (cRNA). The
sequences that encode these ORFs are separated by an intragenic region
(IGR), which has the potential to form a large hairpin secondary structure, and
is believed to mediate transcription termination during mRNA synthesis.
During transcription of the vRNA template, the virus-encoded RNA-dependent
RNA-polymerase (RdRp) complete with a 5’ capped oligonucleotide snatched
from cellular mRNAs, binds to the 3’ end of the template, thus priming mRNA
synthesis. The RdRp moves towards the template 5’ end, but upon reaching
the IGR, the polymerase is thought to respond to cis-acting signals and is
forced to terminate mRNA synthesis (Pinschewer et al., 2003; Morin et al.,
2010; Tortorici et al., 2001). A similar transcription reaction can also occur
following replication of this vRNA genome to yield a cRNA antigenome. As
described above, the viral RdRp complete with snatched capped RNA
oligonucleotide can also bind to the cRNA 3’ end, and similarly extend a
nascent RNA. When the IGR hairpin is reached, the RdRp again terminates
transcription and releases the nascent mRNA. In the case of the S segment,
the mRNA transcribed from the vRNA possesses an ORF that encodes NP,
whereas the mRNA transcribed from the cRNA encodes GPC (figure 7). In
the case of the L segment, the ORF of the polymerase protein L is transcribed
from the vRNA strand, with the ORF of the matrix protein Z transcribed into
mRNA from cRNA. GPC and Z can then be synthesised, with the switch
between primary mRNA and antigenome formation controlled by a feedback
system, proposed to be driven by NP abundance (Iapalucci et al., 1991; Burri
et al., 2012). Extension past the IGR will allow for the generation of GP and Z
and the following formation of virions.
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Figure 7. Arenavirus S segment transcription events
Present at the 3’ and 5’ ends of the vRNA and cRNA are conserved and
complementary sequences, (figure 5) which are proposed to form a
panhandle structure within virions, where the polymerase sits, in a similar
manner to bunyavirus polymerases (Gerlach et al., 2015). Within the 5’ and 3’
ends of both the S and L segment are the promoter sequences for the
arenavirus polymerase L (Perez & de La Torre, 2003). Alteration of these
promoter sequences results in the loss of reporter expression, suggesting that
initiation of RNA synthesis by L is sequence dependent and is sensitive to
mutation (Perez & de La Torre, 2003).
Diagram illustrating the ambisense strategy of arenaviruses, demonstrated by the S
segment here. 1) Transcriptional copying of the vRNA genome by L results in the
generation of NP mRNA. 2) Generation of complementary RNA (cRNA) to from an
anti-genome. 3) Generation of GPC mRNA from the anti-genome cRNA template.
The same applies between L/Z in the L segment of RNA. Sequences in the ‘negative’
sense within the ambisense vRNA and cRNA are shown with upside-down
annotation.
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None of the arenavirus mRNAs possess 3’ poly(A) tails, but instead are
thought to possess an extended hairpin secondary structure, copied from the
conserved untranslated region (UTR) within the vRNA and cRNA templates
(Meyer & Southern, 1994). How the poly(A) tail-less arenavirus mRNAs are
efficiently translated is unknown. The established role of the cellular mRNA 3’
poly(A) tail in translation is to both protect the mRNA 3’ end from endo- and
exonuclease attack (Weill et al., 2012) and to bind poly(A) binding protein
(PABP). PABP subsequently associates with components of the eIF4F cap
binding complex, leading to mRNA circularisation. Circularisation is essential
to confer efficient primary scanning of ribosome complexes to find the initiator
codon (Jackson et al., 2010).
One possibility is that the predicted arenaviral 3’ secondary structure encoded
by the IGR is able to functionally replace the conventional poly(A) tail. This
may be through limiting RNA endonuclease degradation, and possibly
interacting with other cellular or virus-encoded proteins to mediate eIF4F
interactions. However, these possibilities remain to be tested. Other viruses,
such as vaccinia virus and human respiratory syncytial virus (hRSV), are
known to generate poly(A) tails through a virus encoded activity in order to
ensure that their mRNAs are translated efficiently (Mohamed et al., 2001;
Grosfeld et al., 1995), and thus it is likely that arenaviruses will have evolved
a strategy to ensure efficient translation.
This proposed 3’ hairpin structure would be predicted to trigger a significant
immune response due to double stranded (ds) RNA being a pathogen-
associated molecular pattern (PAMP) detected by multiple internal
surveillance proteins, such as PKR, RIG-I and TLR3 (Saito & Gale Jr., 2008;
K M Hastie et al., 2012; Akira et al., 2006). Therefore, it seems unlikely that
such a significant immune trigger would be so well-conserved amongst all
arenaviruses, suggestive of an important conserved role. Identifying a function
for this predicted structure could help establish a novel therapeutic target.
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1.2.2.1. Replication
At a certain time point post infection, the overall activity of the viral polymerase
shifts from transcription to replication, and the switch for this fundamental
change in polymerase activity is poorly understood (Burri et al., 2012;
Iapalucci et al., 1991). During replication, which requires the synthesis of a
complementary full-length copy of the vRNA or cRNA templates, with the
presence of multiple copies of NP believed to be responsible for allowing L to
pass over the IGR.
As depicted in figure 7, after the abundance of NP has reached sufficient
levels, L is proposed to be able to pass over the IGR, generating a complete
cRNA sequence or, in the reverse, new vRNA copies. The promoter regions
held within the 3’ and 5’ vRNA & cRNAs allow for L to initiate this replication,
in conjunction with NP conferring genome replication as opposed to
transcription of mRNAs, during the extension both the template and nascent
genomic/anti-genomic strands are encapsidated to form either genomic or
anti-genomic, uncapped RNPs. Comparatively, the replication stage of
bunyavirus RNAs has been proposed whereby the template strand is
unwound from the RNP, and threaded through the polymerase, before re-
associating with NP to re-form the original RNP (Gerlach et al., 2015).
Simultaneously, the nascent strand would then be encapsidated by free NP,
possibly by a second polymerase (Gerlach et al., 2015). This proposal has yet
to be tested extensively, and how the process occurs during arenaviral
replication is not fully understood. Nascent RNPs can subsequently act as a
template for further genomic, antigenomic or messenger RNA strands. Each
step in the replication cycle is explained in greater detail in 1.2.3.
1.2.3. Viral Proteins
The four arenaviral proteins, NP, GP, L and Z contribute to the viral life cycle
in four specific areas: L is responsible for the transcription and replication of
the viral genome (Salvato et al., 1989); GP is responsible for membrane
attachment and subsequent fusion within endosomes (York et al., 2008); Z
has roles in virion organisation and intracellular transport, in addition to
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intracellular reorganisation and immune ablation (Fehling et al., 2012); with
NP finally responsible for the formation of RNPs – and therefore RNA stability
– and immune regulation (Martinez-Sobrido et al., 2006; Pedersen &
Konigshofer, 1976). In addition to these defined roles, there is significant
multifunctionality and overlap of function, where viral proteins work in
combination. This includes the association of Z and GP while embedded
within the viral envelope (Fehling et al., 2012) or NP and L working in
conjunction to ensure efficient RNA replication and translation. In addition,
there is a degree of overlap in functions of NP and Z, with both proteins
implicated in innate immune regulation (Fan et al., 2010; Martinez-Sobrido et
al., 2006); and regulation of L and, in turn, transcription and replication
(Kranzusch & Whelan, 2011; Tortorici et al., 2001; Pinschewer et al., 2003).
Overall, each arenaviral protein can be considered multifunctional, and
important in many stages of the replication cycle within an infected cell.
1.2.3.1. Glycoprotein
The glycoprotein of arenaviruses is responsible for cell entry, membrane
fusion and budding, along with conferring the assembly and budding sites of
newly formed virions. GP is initially translated as a glycoprotein precursor
protein (GPC) of approximately 75 kDa. This is then cleaved within the
endoplasmic reticulum (ER), initially by signal pepsidases to remove the 58
residue stable signal peptide (SSP), with GPC cleaved at conserved sites
between the GP1 and GP2 domains, corresponding to RX(hydrophobicX)X
by pepsidases and subtisin kexin isosyme-1 (SKI-1) and Site-1 protease
(S1P) to form three constituent subunits of mature GP; GP1, GP2 and SSP
(Burri et al., 2012). In the case of LASV and LCMV respectively, these sites
are RRLL and RRLA. GP1, GP2 and SSP are then processed, with GP1 &
GP2 glycosylated within the endoplasmic reticulum (ER), enabling the
formation of mature GP trimers.
Through GP, arenaviruses utilise ubiquitous receptors for cell entry, with the
exact mechanisms regarding co- and secondary receptors unknown. The
primary receptor usage for the OW viruses LASV and LCMV was first
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identified in 1998 as -dystroglycan, and later, in 2007 transferrin-1 (TfR1)
was established as the primary receptor for NW human infections (Cao et al.,
1998; Radoshitzky et al., 2007). In both instances, neutralising antibodies
against the surface receptor were utilised to identify the receptor responsible
for viral entry. In the case of NW clade C arenaviruses – non-pathogenic in
humans – these utilise -dystroglycan similar to their closely related OW
counterparts.
The interaction between the receptor binding domain of GP (GP1) and the
primary receptor for NW infections is known to be distinct from the usual
transferrin binding domain, at the very apical tip of the receptor (Nunberg &
York, 2012; Abraham et al., 2010). As there is not a major conformational
change in the structure of the receptor it appears that – while crucial – the
primary receptor binding is passive, rather than actively stimulating
endocytosis (Abraham et al., 2010).
The evolution of viral sequences is evident in those species that can infect
humans. The predominant clade B pathogens – JUNV, GTOV and MACV –
all utilise TfR1, with others, such as TACV also using TfR1 but are not able to
infect humans. Single nucleotide changes in GP1 are sufficient to allow
human infection by non-pathogenic arenaviruses and it is possible that this
mutation occurs naturally after increased exposure to humans, conferring
infection (Martin et al., 2010; Abraham et al., 2010).
Upon binding, the virion is endocytosed, with GP-mediated fusion of viral and
endosome membranes occurring as the endosome matures, and the pH
drops (York et al., 2008). TfR1 is constantly recycled via clathrin-mediated
endocytosis, and thus it is likely that TfR1-mediated endocytosis will confer
efficient entry. Indeed, the passive nature of the initial binding with TfR1 could
mean that the cell internalisation mechanisms are not alerted of virions that
are bound to the receptor, with the internalisation of TfR1 simply part of the
routine recycling of surface receptors. The body of work related to arenaviral
entry has encompassed NW infections, with the broad basis of internalisation
mechanisms theorised to be similar between NW and OW infections.
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SSP is responsible for targeting GPC polypeptides into the endoplasmic
reticulum (ER) for processing and glycosylation. SSP contains two
hydrophobic membrane spanning regions, with a constitutively conserved
lysine (K33) present on the extracellular/lumen side of membranes and known
to be essential for membrane fusion (York & Nunberg, 2006). Both C and N
termini of SSP are present on the cytosolic/matrix side (Nunberg & York, 2012;
York et al., 2004). SSP is also essential in GP translocation from the ER,
masking the retention motif of GP2 (Burri et al., 2012). Upon initial ER
processing, N- glycosylation is the next essential step in GP maturation and
function, with both GP1 and GP2 containing sites of significant glycosylation
(Burri et al., 2012; Eichler et al., 2006). The stable and correct glycosylation
of GP1 and GP2 is essential for transport to the membrane and external
functions such as subsequent membrane fusion in newly infected cells.
In assembly, the matrix protein Z is the major modulator of the transport
machinery (Fehling et al., 2012), and it is especially important in transporting
GP to the plasma membrane (PM). Z interacts with the mature GP complex
of GP1, GP2 and SSP in a manner dependent on Z myristolisation and SSP
(Burri et al., 2012; Perez et al., 2004; Capul et al., 2007). Interaction between
Z and the GP complex is required for egress and, in addition, this GP/Z
complex must also interact with NP/RNP and L to form mature progeny
particles. Interfering with the process of this binding is, therefore, an important
target for therapeutic development.
1.2.3.2. L
As its name suggests, the arenavirus polymerase protein L is large, being the
largest arenaviral protein, with a molecular weight of approximately 250kDa.
It is responsible for several activities that all result in viral RNA synthesis;
these include recognition and binding of promoter RNA sequences, cellular
cap binding, endonuclease cleavage, nucleotide polymerization as well as
likely mediating NP dissociation and re-association of the RNP template
(Morin et al., 2010; Tortorici et al., 2001).
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After membrane fusion, the process of viral replication can begin with L
transcribing the vRNA genome into mRNA (Wilda et al., 2008). L recognises
promoter sequences that by analogy with other negative-stranded RNA
viruses likely include the 3’ end of genomic and anti-genomic RNAs, and
possibly the 5’ end also. During both mRNA transcription and RNA replication,
the L protein moves along the RNP template and synthesises the nascent
RNA strand in a template-dependant manner. Also, by analogy with other
RdRps, the arenavirus L protein is thought to mediate the transient
dissociation of individual NP monomers from the RNA strand, followed by their
subsequent re-addition, and reformation of the RNP. The naked RNA that is
exposed during NP removal enters the RdRp active site and is copied into
nascent RNA. This emerges from L, presumably through a dedicated exit
channel. In the case of mRNA transcription, the nascent RNA is capped
through the NL1 domain of the polymerase, where the removal of the cap
structure of host capped mRNA takes place (Morin et al., 2010). The nascent
mRNA is then extended until the IGR, at which point the RdRp terminates
transcription and releases a mRNA, dependent on the abundance of NP (Burri
et al., 2012; Iwasaki et al., 2015). In the case of RNA replication, the nascent
RNA strand emerges from the exit channel and must be encapsidated to
generate a new RNP. The exact mechanism is not fully understood, but
evidence is emerging from the bunyavirus and orthomyxovirus fields that this
involves a second RdRp, first reported by Gerlach et al. in 2015 through the
structure of LaCrosse virus polymerase. MACV L EM images (figure 8)
indicated a similar overall structure to the LaCrosse virus polymerase, with
recent findings implicating that arenavirus L proteins could act in a similar
manner to those of the Bunyaviridae family members (Gerlach et al., 2015;
Kranzusch et al., 2010; Lehmann et al., 2014).
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Figure 8. EM observation of MACV L
1.2.3.3. Z
The smallest arenavirus protein is the matrix protein known as Z. It is known
to have multiple roles in the viral life cycle, with its most well established
functions being internal transport of GP and RNP/L complexes and the
facilitation of assembly and budding (Perez et al., 2004; Fehling et al., 2012).
Beyond these functions, Z has a role in immune modulation and internal
modulation of the cellular environment.
Z is between 90 and 103 residues in length for all the mammarenaviruses,
making it all the more remarkable that it performs such a plethora of functions
(Fehling et al., 2012). Z sequences across the Arenaviridae family share
similar features: a myristoylation signal; a really interesting new gene (RING)
zinc binding domain and tetra-peptide late domains (Fehling et al., 2012).
These structural similarities underpin the basis of their multifunctional nature.
The myristoylation site aids in the trafficking and membrane anchoring of
mature GP complexes, as well as the incorporation of RNP and L into the
budding virion (Perez et al., 2004). This anchoring can also facilitate Z in its
other functions and self-assembly. By allowing the internal transport of
proteins and interactions with other cellular and viral proteins through
EM negative stain images of the MACV polymerase. Class averages of L after
visualisation, observed by negative stain with each containing ≈100 particles. 
(Kranzusch et al., 2010).
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myristoylation, arenaviral replication and release is enhanced (Strecker et al.,
2006; Loureiro et al., 2011).
The Z protein RING domain is thought to act as a platform for interactions with
cellular and viral proteins (Volpon et al., 2010). The interaction between LASV
Z and eIF4E identified a novel RING domain sequence, which provided
evidence that Z inhibits the cap-binding function of eIF4E. This interaction has
been implicated in the inhibition of arenaviral translation. This function is
thought to coincide with growing abundance of Z within a cell, whereby a
feedback system stimulates – not dissimilar to NP’s stimulation of the switch
between transcription and replication – termination of translation and confers
the recruitment of viral proteins and RNPs to viral assembly areas. The RING
domain of Z is also essential for Z self-assembly, in conjunction with the
myristoylation of the N terminus of the polypeptide (Fehling et al., 2012).
The recently described structure, shown in figure 10, of LASV Z in a
dodecomeric orientation, was found to be comprised from 6 dimers (Hastie et
al., 2016). The monomeric form of Z is known to be responsible for the
interaction of LASV Z with eIF4E, however LCMV Z is known to interact with
eIF4E through a multimeric form of Z (Volpon et al., 2010; Kentsis et al., 2002).
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Figure 9. Crystal structure of LASV Z
Z is also known to regulate transcription and replication during infection,
dependent on the relative abundance of L and NP within the cell, in
combination with the relative abundance of Z (Garcin et al., 1993; Jácamo et
al., 2003). Indeed, this regulatory mechanism is so strong, that cells
transiently expressing Z exhibit a degree of protection against LCMV infection
through polymerase inhibition (Cornu & de La Torre, 2001). The mechanism
behind this is not fully understood, but could indicate that Z acts in a feedback
cycle; when the abundance is reaching high levels, Z would be able to direct
components for assembly and budding, rather than continuing with strand
elongation. Two Z binding sites on L indicate that Z directly binds L through
the RING finger domains, inhibiting the polymerase’s function (Kranzusch &
Whelan, 2011; Wilda et al., 2008).
In assembly, Z is responsible for the anchoring and trafficking of proteins to
the PM prior to release. Its association with the mature GP complex stabilises
it in the membrane, with the association not dependent on other viral proteins,
and the interaction appears to be in the embedded SSP of the mature GP
X-Ray crystal structure of the dodecomeric structure of LASV Z at a resolution of 2.9Å
(Hastie et al., 2016)
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complex (Capul et al., 2007). Z appears to be able to generate ‘assembly
areas’ in cells, forming vesicle-like structures of GP-Z near the nuclei – most
likely derived from the ER where GP is processed (Schlie et al., 2010; Burri et
al., 2013). This indicates an internal trafficking mechanism, again most likely
facilitated by Z.
The assembly of arenaviruses occurs at the PM of infected cells, with viral
egress from polarised lung epithelial cells generally limited to the basolateral
face of cells, rather than the apical face (Dylla et al., 2008). The utilisation of
the basolateral face of lung tissue indicates that the virus is not expelled from
the lungs in high volumes, and thus not a predominantly aerosolised virus –
supporting the established transmission mechanisms (Kernéis et al., 2009).
While infection through the lung is known to occur, and aerosolised
transmission possible (Stephenson et al., 1984; Sewlall et al., 2014), it is not
the accepted human-human transmission route. A more common
transmission route is the transfer of contaminated liquid droplets between
patient and carer (Paweska et al., 2009; Sewlall et al., 2014).
Given that arenaviruses are theorised to replicate within replication-
transcription complexes (RTCs) distributed throughout the cytoplasm, RNPs
and proteins need to be trafficked to the PM. Z is known to traffic GP to the
PM, and association between NP and Z has been shown within infectious
particles, indicating that Z anchors RNPs into the membrane through
association with NP. Indeed, several arenaviruses, most notably LASV,
JUNV, LCMV and TCRV all exhibit this conserved interaction, through the C
terminus of NP (Fehling et al., 2012; Schlie et al., 2010; Shtanko et al., 2010).
It is theorised that Z aids in trafficking RNPs to assembly sites at the PM.
1.2.3.4. NP
The arenaviral NP is a highly abundant structural protein with a role in
encapsidation of the viral genome to form RNPs, which is responsible for
protecting the genome segments and providing structural integrity. It is also
known to act as an anti-terminator during genome replication, which is
proposed to allow for the synthesis of full-length vRNA and cRNAs
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(Pinschewer et al., 2003; Tortorici et al., 2001; Pedersen & Konigshofer,
1976). In addition, NP is known to have roles that relate to inhibiting the
induction of innate immune responses within the infected host cell. The
arenaviral NPs are all of approximately 60-65 kDa, with their functions
predominantly conserved between NW and OW clades.
The role of NP in RNP formation has been known since the 1970s, with LCMV
NP subsequently identified as capable of modulating cellular interferon
responses. This is shown through the ability of certain strains of LCMV to
prevent the activation of CTLs to LCMV-infected cells (Matloubian et al.,
1990). Since then, NP has been shown to modulate specific pathways in
interferon signalling, most notably inhibiting the passage of signalling after
detection through blocking the phosphorylation of I and IRF3/7 (Russier et
al., 2012; Rodrigo et al., 2012; Pythoud et al., 2012), shown in figure 10. This
blockade of signalling indicates that arenaviral NPs are able to counteract
direct activation of interferon stimulated genes (ISGs) by preventing the
activation signals reaching the nucleus. By doing so, detection of any PAMP
within the cytosol will not result in the generation of an antiviral state within
infected cells, allowing infection to persist (Saito & Gale Jr., 2008; Levy &
Garcia-Sastre, 2001). An outline of some of the known innate immune
regulatory functions of NP is shown in figure 10.
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Figure 10. Diagram previously described roles of NP in the regulation cellular
immune signalling cascades
NP is required to generate RNPs by encapsidating all nascent vRNAs and
cRNAs within an infected cell. The association between NP and L is thought
to be important to allow the appropriate removal of NP from the template and
simultaneous addition of NP to nascent RNA. In the case of LACV, NP may
remain in association with neighbouring NP molecules preserving the NP
chain as an extended NP multimer (Gerlach et al., 2015). The RNA is thought
to be transiently disassociated from the NP multimers and this exposes RNA
bases to the active site of the polymerase for copying. Once replicated, the
template emerges from the polymerase and is simultaneously threaded within
the intact NP multimeric chain. Whether the process of arenavirus
encapsidation is similar is unknown, but the LACV model is currently the most
Diagram illustrating the ability of NP to disrupt interferon signalling. NP is known to
inhibit RIG-I functionality and signalling to NF-B, blocking its nuclear translocation.
NP is also shown to inhibit I phosphorylation (red to green star), which in turn
blocks IRF3 and IRF7 phosphorylation and their subsequent nuclear translocation.
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plausible explanation proposed given the current knowledge of arenavirus
RNA synthesis.
This simultaneous addition of NP to nascent RNAs will allow for the immediate
generation of RNPs and thus maintain stability through disguising RNAs from
the immune system (Hastie et al., 2011; Fehling et al., 2012; Iwasaki et al.,
2015). Corresponding with this mechanism, the ability of NP to coat RNA
means that as the genome/antigenome pool increases, the abundance of NP
must increase exponentially to match it. The interaction with L is also mediated
through the RNP, and thus the anti-termination effects of NP would not be
present without a functional NP (Tortorici et al., 2001; Iwasaki et al., 2015).
This method implies that the majority of the initial internal recruitment following
viral infection of the cell will be performed by NP, as the abundance of Z and
GPC will not increase significantly until the infection has been established
within a cell. The elongation of nascent RNAs is dependent on NP abundance,
allowing for the formation of cRNA templates for GPC and Z mRNA synthesis
(Fehling et al., 2012; Tortorici et al., 2001).
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Figure 11. Crystal structure of LASV NP and comparison with other DEDD
exonucleases
The crystal structure of LASV NP, shown in figure 11, was first solved in 2011.
It revealed a dsRNA specific exonuclease domain, proposed to remove
dsRNAs that could otherwise serve as an immune trigger (Hastie et al., 2011;
Jiang et al., 2013; Hastie et al., 2012). The LASV NP exonuclease domain
showed remarkable structural homology with other known DEDD exonuclease
proteins ISG-20 and DNA Pol III. The presence of dsRNA regions within
arenaviral mRNAs is well established, with LCMV NP and GP mRNA known
to contain conserved 3’ mRNA hairpins (Meyer & Southern, 1994). These
Superimposition of LASV NP and known DEDD exonucleases. (A) Structural comparison
of NPΔ340 and two known DEDDh exonucleases. NPΔ340 is coloured green, ISG-20
(PDB ID 1WLJ) is coloured cyan, and the E. coli DNA pol IIIε (PDB ID 2GUI) is coloured 
yellow. Inset shows a close-up view of the superimposed DEDDh residues of the active
site. Numbered residues reflect those of LASV NP. (B) Electrostatic surface potential
calculated with APBS (the Adaptive Poisson-Boltzmann Solver) software shows that
each exonuclease has an acidic active site and highlights the basic arm of LASV NP.
Positive surface is coloured blue; negative surface is coloured red with limits ± 10 kT/e.
(Hastie et al., 2012)
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dsRNA sequences, if detected by the innate immune system, would ultimately
lead to the stimulation of an interferon response and the activation of ISGs. In
order to combat the initial detection of dsRNA, it was proposed that NP
digested the dsRNA intermediary, preventing surveillance molecules ever
encountering their dsRNA PAMP, illustrated in figure 12 (Hastie et al., 2012;
Reynard et al., 2014). The possibility that these 3’ hairpin structures would
only be present for NP to then digest in order to prevent detection is puzzling,
and raises the possibility that the 3’ mRNA hairpins may serve yet
undetermined roles, possibly in viral translation.
Figure 12. Proposed function of NP in dsRNA digestion
Another intriguing aspect of the participation of NP in the viral life cycle is its
involvement within so-called RTCs as diagrammatically shown in figure 13.
JUNV NP was shown to co-localise with translation associated proteins inside
distinct cytoplasmic puncta, present throughout the cytoplasm (Baird et al.,
2012). The re-distribution of these factors was not attributed directly to NP,
although cytoplasmic puncta were observed during NP expression, shown
Diagram illustrating the proposed role of NP in digestion of dsRNA from 3’ mRNA. In
NP+, NP is shown to digest the dsRNA PAMP, preventing RIG-I (or similar
surveillance proteins) detection and activation of ISG signaling. NP- shows RIG-I’s
normal pathway, through which dsRNA would induce ISG expression.
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schematically in figure 13. NP may play a role in establishing such structures
or may simply be present due to high concentrations of viral RNAs.
Sequestration of cellular factors – and the ‘hiding’ of viral replication – is not
without precedent. Both HCV and DENV stimulate the formation of new sub-
cellular structures as virus factories for the synthesis of viral components and
RNA replication in order to isolate PAMPs from immune surveillance proteins
such as PKR and RIG-I (Welsch et al., 2009; Gosert et al., 2003). RNA
replication, transcription and translation are theorised to take place within
these structures, yet their precise sub-cellular origin is still unknown.
NP has been shown to interact with a sequence of translation initiation factors,
most notably the eukaryotic initiation factors (eIF) 4A and eIF4G, with a
proposed model whereby NP substitutes the function of eIF4E in translation
initiation through 5’ cap binding (Linero et al., 2013). This association provides
evidence that NP could have an active role in facilitating the translation of
arenaviral mRNAs at the expense of cellular mRNAs, although this is yet to
be assessed.
Diagram illustrating the proposed use of RTCs by arenaviruses – notably JUNV –
shown as the yellow oval in the lower left. These structures were shown to contain
ribosomal subunits – with a ribosome depicted by the purple dodecahedron within
the RTC. Other elements of life cycle such as viral assembly (top), GP maturation
(right), and NF-B/I inhibition (lower right) are also shown.
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Figure 13. Diagram illustrating proposed formation of cytosolic puncta for
arenaviral replication
Potential involvement in translation would indicate a novel role for NP in the
direct propagation of infection. The 3’ hairpin structures on mRNA could play
a role in translation. The role of this structure is unknown, but, given the lack
of poly(A) tails present on viral mRNAs, the structure could facilitate the
circularisation of mRNA through interaction with PABP, eIF4G or another host
or viral protein. One possibility is that NP substitutes for one of these eIF4F
complex components. A model proposing a similar substitution of the entire
eIF4F complex has been proposed for other negative-stranded RNA viruses
in the Hantavirus genus of the Bunyaviridae family (Mir & Panganiban, 2008).
The NSP3 of rotavirus is known to substitute the function of PABP in 3’ mRNA
and eIF4G binding. The active sequestration of PABP into the nucleus during
bunyamwera virus (BUNV) infection by NSs is similarly intriguing, with cellular
mRNAs left un-circularised, however, no cellular or viral protein has yet been
identified to circularise BUNV mRNAs, but it is possible that a cellular protein
– such as stem loop binding protein (SLBP) – is responsible for BUNV mRNA
circularisation. From a cellular mRNA perspective, poly(A)-less histone
mRNAs possess a stable stem-loop structure, bound by SLBP, with SLBP
binding to eIF4G to confer circularisation.
Diagram showing proposed arenaviral mRNA-protein interactions in the absence of
circularisation. Circularisation could be achieved via PABP, direct interaction between
eIF4G, or an intermediary such as NP binding with the proposed 3’ stem loop.
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Figure 14. Diagram illustrating an arenaviral mRNA in the absence of
circularisation
Without circularisation, translational efficiency would be reduced, impacting
on the virus’ ability to propagate. It is therefore possible that arenaviruses
possess the ability to circularise their mRNAs, in order to maximise
translational output and limit mRNA degradation, with such an organisation
depicted in figure 14 (Kahvejian et al., 2012; Wells et al., 2012; Jackson et al.,
2010). In addition, many viruses initiate a host cell translation shut-off to
increase viral translation output, such as for influenza and herpes viruses
(Covarrubias et al., 2009; Yanguez et al., 2011). Maximising the availability of
translation factors through the sequestration of host translation factors by a
viral protein would also lower cellular translational efficiency while
simultaneously increase viral translational output.
NP, given its wide role in immune regulation, is an excellent target for antiviral
therapy, as perturbing its ability to shut-down the immune response could
allow the host to clear the virus, rather than relying on virocidal therapies. Most
viral therapeutics aim to target viral proteins and pathways specifically, and it
is therefore necessary to identify crucial elements of the viral life cycle in
developing antivirals. One of the most successful anti-viral compounds is
acyclovir, which is a modified nucleotide derivative, for the effective treatment
of herpes simplex and varicella virus infections through specific targeting of
the viral polymerase. However, unlike other nucleoside analogues such as
ribavirin, it cannot be incorporated into human DNA, as it requires initial
metabolism by a viral thymidine kinase prior to cellular processing. The final
acyclovir tri-phosphate is then incorporated by viral DNA polymerase,
inhibiting strand elongation (Gnann et al., 1983).
Most other antiviral agents confer a degree of an effect on host processes,
with ribavirin’s side-effects during LASV and HRSV treatment well
documented, as discussed above (US National Library of Medicine, 2015).
Novel therapeutics targeting viral processes such as sofosbuvir’s targeting of
HCV RNA polymerase enable greater specificity for the treatment of certain
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RNA viruses, without the severe adverse effects observed during ribavirin
therapy (Fung et al., 2014). The drawback for targeting viral processes is the
possibility of resistance emergence. However, identifying a host process, not
necessary for human life, which the virus must utilise could also allow for
potent antiviral identification (Sayce et al., 2010). This strategy could also limit
the potential for resistance development.
1.3. Studied viruses in detail
1.3.1. LUJV and NP
Lujo virus was first isolated from five patients from southern Africa in 2008,
with the index case presenting to a clinic in the Zambian capital Lusaka with
acute febrile illness. This patient was subsequently flown for treatment to
Johannesburg in South Africa, with an attending paramedic (patient 2) on the
flight becoming exposed before returning to Zambia. Three more people were
exposed and subsequently became infected, one nurse (patient 3) attending
to patient 1, a cleaner (patient 4) attending to patient 1’s room and a nurse
attending to patient 2 (patient 5). Patients 1-4 all died within 26 days of
exposure. Patient 5 survived after high dose IV ribavirin – although the role of
ribavirin in this recovery is unknown – as well as immunosuppressants and
clotting factor administration in a specialist clinic in Johannesburg (Sewlall et
al., 2014). Patient 5 was finally discharged after 42 days, with symptoms
persisting for several months post-clearance. The severity of illnesses
described in the doctors’ reports indicated a rapid onset febrile infection,
generating haemorrhagic complications. Initial diagnoses of alternative,
endemic agents such as malaria or dengue virus may have contributed to the
nosocomial transmission.
LUJV is a disease of acute research interest. The human population in areas
of southern Africa, such as Zambia, is rapidly expanding, with increasing
tourism and resources-trade stimulating growth and expansion into rural
areas. Patient 1 was thought to have become exposed to LUJV at home, with
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evidence of rodents on their property, although no rodent carrying LUJV has
yet been identified (Ishii et al., 2012; Sewlall et al., 2014).
Since 2009, work has been performed to learn more about LUJV, with the
establishment of a stable animal model for human infection in clone 13/N
Guinea Pigs. LUJV was able to infect multiple organs, generating histological
changes in the kidneys, liver and lungs. Persistent weight loss of between 3-
5% per day, with all animals succumbing to the infection in between 11-16
days (Bird et al., 2012). The disseminated nature of infection mimicked the
progression observed in humans, with similar clinical manifestations such as
leukopenia, lymphopenia and coagulopathy (Bird et al., 2012). Individual
tissue investigations showed a large degree of internal haemorrhaging and
necrosis.
The individual differences of the functions of LUJV proteins to those of related
arenaviruses is incompletely understood, with limited knowledge of several
aspects of the LUJV life-cycle. Classified as an ACDP BSL4 pathogen there
are significant restrictions on working with infectious LUJV, and identification
of protein functionality is challenging in the context of a viral infection.
The roles of LUJV NP are likely to be similar to the NPs of other arenaviruses
- predominantly involved in RNP formation, RNA stability and transcriptional
anti-termination. However, other arenaviral NPs have roles, as discussed,
outside these functions. LUJV NP is likely to possess similar functions, such
as interferon induction ablation, as other arenaviruses are known possess.
The nucleotide variation between LUJV and LASV NP is up to 38%, with LUJV
an apparent outlier of the OW clade of viruses (Sewlall et al., 2014; Briese et
al., 2009). This diversity could confer significant differences between LUJV
and other members of the OW clade such as LASV and LCMV.
As NP is known to be crucial in the replication of other arenaviruses, this study
will focus predominantly on the identification, and characterisation, of
important interactions between LUJV NP and cellular proteins. The lack of
knowledge regarding aspects of the arenaviral replication cycle such as
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translation and RNA replication suggests that more functions for each
arenavirus protein are likely to be established.
1.3.2. LCMV
LCMV is the most geographically widespread arenaviral infection, with an
almost worldwide distribution through its association with the Mus musculus
common house mouse. The life cycle of this host has become reliant on
human dwellings, through millennial association with humans, with this
association even instrumental in the domestication of the cat (Boursot et al.,
1996; Cucchi et al., 2005). This reliance on humans has drawn them into co-
habitation with humans, and thus exposes individuals to diseases carried by
them.
LCMV infection generates a predominantly mild or asymptomatic illness in
humans, and is thus generally undiagnosed. Squalid habitation most likely
increases potential exposure to LCMV and, through the mouse, it was most
likely transported worldwide through colonial era naval trade.
LCMV is a neglected pathogen with potential to cause human disease, chiefly
among the immunocompromised and pre- and postnates. LCMV is capable of
generating severe infections within immunocompromised patients and
expectant mothers, and with the increase in the immunocompromised
population, the risk that more patients will become terminally infected is
growing. Developmental abnormalities in children infected with LCMV in a pre-
or perinatal setting are also of distinct interest, with LCMV being a significantly
undiagnosed pathogen of new-borns and young children (Barton et al., 2002;
Jamieson et al., 2006; Bonthius, 2012). The recent and ongoing Zika virus
outbreak (2015-16) gives evidence that a predominantly low-level, generally
asymptomatic, infection can have devastating consequences on health in
specific circumstances (Attar, 2016; World Health Organisation, 2016).
The NP of LCMV is perhaps the most well researched protein of all of the
arenaviruses and it has been identified as a significant modulator of cellular
interferon signalling, especially through I and IRF3 ablation, as shown in
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figure 8 (Martinez-Sobrido et al., 2009; Pythoud et al., 2012). Characterising
common strategies between LCMV NP and LUJV NP is key to identifying
potential therapeutic strategies to combat arenaviral infections.
Identifying a common trait between two OW arenaviral species could lead to
the identification of a pathway to target via a broad spectrum antiviral agent.
There is a significant need to improve therapeutics beyond the contraindicated
use of IV ribavirin, especially pre and during pregnancy (US National Library
of Medicine, 2015). Vaccination is the ultimate aim in all infectious diseases,
but given the huge diversity in arenaviral distribution – geographical, socio-
economic factors and religious belief – the realities of a vaccination
programme currently make it impractical. Thus, for emerging infectious
diseases, effective therapeutics are vital.
1.4. Nucleoprotein as a target for research and therapeutics
The NP of arenaviruses is a crucial component of the viral replication cycle. It
possesses the ability to modulate the immune response; assist in cap-
snatching; act as an anti-terminator; stimulate transcription-replication
switching; and maintain stable RNA species as part of an RNP.
These functions are evidence that NP’s effective functionality is essential to
the replication-cycle of arenaviral infections. Many of these abilities are shared
between species – even between the two OW and NW serotypes. Given the
lack of effective, targeted therapeutics and the need to identify novel, pan-
tropic functions of NP, more research is needed in order to identify a pathway
which could be targeted for therapy.
Several aspects of the arenaviral replication cycle are still poorly understood,
including translation of viral mRNAs and where the replication centres, or
RTCs, are derived from. Direct protein interacting partners for all arenavirus
proteins are only known to a limited extent, with incompletely understood
mechanisms of cell entry; how GP is translocated to the ER; which
cytoskeletal network Z and NP exploit; translational enhancement and factor
recruitment.
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It is therefore necessary to identify novel and fundamental elements regarding
the involvement of NP in viral replication cycle, and host cell manipulation. As
discussed, interactions between NP and cellular proteins have been
previously identified. In addition, the nucleocapsid proteins (N) of the related
CCHFV and HAZV are known to interact with protein folding machinery
(Surtees, 2014). The involvement of NP in this pathway could indicate that NP
assists in the folding or glycosylation of arenaviral proteins. As the NP of LASV
and CCHFV N are known to be structurally similar (Carter et al., 2012), there
is the possibility that features of their functionality are also conserved.
One possible target for therapeutic development is the potential role of the 3’
hairpins on arenaviral mRNA transcripts. These structures are, for a freely
expressed RNA rather than one encapsidated within an RNP, illogical. dsRNA
is a well known PAMP, recognised by a number of cellular surveillance
proteins. IRES structures and other dsRNA elements present on may positive
sense RNA viruses might similarly act as immune triggers for internal
surveillance mechanisms, but the overall genome-ordered RNA structure
(GORS) is thought to provide protection from such detection (Simmonds et
al., 2004). The presence of a singular structured hairpin present on arenaviral
mRNAs is unlikely to provide similar protection. The evolutionary selection
pressures on expressing such a feature would indicate that, if unnecessary
for replication, it should have been removed through selection. The knowledge
of a dsRNA specific exonuclease, potentially digesting such a structure, would
seemingly move to solve this problem. However, the dsRNA specificity of the
exonuclease has been questioned (Hastie et al., 2012; Qi et al., 2010), and it
is possible that the digestion of dsRNA occurs after the mRNA has served its
purpose in the context of replication. As discussed, there is limited knowledge
regarding the efficient translation of arenaviral mRNAs, excluding the known
interactions between JUNV NP and eIF4A and eIF4G (Linero et al., 2013).
How mRNA can be circularised without a poly(A) tail is an unanswered
question regarding efficient translation of mRNA, and the 3’ tail could have a
role in facilitating this. Encoding a key feature of a highly multifunctional
protein to simply degrade an encoded immune marker would be a convoluted
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mechanism, and thus the 3’ mRNA hairpin likely has another role in the
arenavirus replication cycle.
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Project Aims
The arenavirus NP is indispensable to virus multiplication. While its roles in
RNP formation, RNA synthesis, segment packaging and innate immune
regulation have been described, it is likely that additional roles exist. It is likely
that these established and additional roles include important functional
interactions with cellular factors.
The aim of this project was to elucidate the cellular interaction partners of the
arenavirus NP. The two arenaviruses chosen were the HF-causing Lujo virus
along with the congenital pathogen LCMV The aim of studying these two
distinct viral species from across the OW clade was to identify common
partners of NP that were potentially important across an entire clade. LUJV
NP was used to initially catalogue a cellular interactome through the use of
SILAC proteomics, in conjunction with immunoprecipitation (IP) and
immunofluorescence microscopy (IF). In addition, in order to better visualise
NP, a polyclonal antiserum against LUJV NP was generated. The use of
LCMV then also allowed for the experimental examination of the observed
interactions in the context of an infectious virus system. Finally, characterising
the relationship between LCMV NP and identified interacting partners led to
the final objective of the project which was to determine whether NP enhanced
arenavirus mRNA translation through a suggested novel mechanism.
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2. Materials and Methods
2.1. Biological Materials
2.1.1. Vectors
The LUJV NP cDNA corresponding to the LUJV NP ORF was synthesised by
Dundee Cell Products and was provided cloned into an Enhanced green
fluorescent protein (EGFP)-N1 expression vector, as a LUJV NP C terminal
fusion protein. Expression of this protein is driven via a CMV promoter,
generating strong and consistent expression upon entry into mammalian cell
types. The parent EGFP-N1 also contains an SV40 poly(A) signal, increasing
RNA stability, and enabling enhanced mRNA translation. The provided
sequence was confirmed to match the GenBank JX017360.1 sequence via
DNA sequencing.
The LUJV NP ORF from pEGFP-N1 vector was subcloned into a pET28a
vector, as a his-SUMO- N terminal fusion protein. pET28a enables good
expression levels of his-SUMO tagged proteins in Escherichia coli (E. coli),
enabling Ni affinity purification of fused proteins.
A plasmid designed to express an arenaviral-like mRNA was constructed by
GeneArt in a pMK parental vector. The plasmid was comprised of 5’
sequences of LCMV mRNA, from the 5’ nucleotide of the LCMV antigenome
up until the final nucleotide prior to the initiator AUG; the complete Gaussia
luciferase sequence as obtained from GenBank AY015993.1; followed by the
3’ mRNA sequences, as described by Meyer and Southern (1994). This
plasmid was termed NPEG (NP Ends Gaussia).
See Appendix I for both his-SUMO- and –EGFP fused LUJV NP sequences,
and NPEG plasmid sequences.
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2.1.2. Bacterial Strains
Plasmid DNA constructs were amplified through transformation of E. coli,
strain DH5 Competent Cells (Life technologies), using the Inoue method for
transformation. For protein expression, the E. coli BL21 Rosetta-2 strain was
used.
2.1.3. Continuous cell lines
Human embryonic kidney 293T (HEK293T), Baby Hamster Kidney fibroblast
clone 21 (BHK21), Vero E6 cells (Vero) and adenocarcinomic human alveolar
basal epithelial cells (A549 cells) were utilised to express recombinant
proteins or to permit viral replication. HEK293T cells constitutively express the
SV40 large T antigen allowing for continuous growth. Both BHK21 and Vero
cells show natural continuous growth with no external influence preventing
senescence (Ammerman et al., 2008; Hernandez & Brown, 2010). A549 cells
were originally explanted from an human adenocarcinoma (Giard et al., 1973).
2.1.4. LCMV strain.
LCMV strain Armstrong (LCMV Arm) was kindly provided by Prof. Roger
Hewson of Public Health England (PHE) as an infectious cell culture
supernatant from Vero cells. cRNA sequences for both S and L segments of
LCMV Arm are available via GenBank with accession numbers AY847350.1
and AY847341.1 respectively.
2.2. Methods
2.2.1. Manipulation of cDNA
2.2.1.1. Bacterial Transformations
For routine plasmid amplification, DH5 cells (as in 2.1.2) were transformed
according to the manufacturer’s recommendations. Briefly, 50ng of plasmid
DNA or 1l of ligation reaction product was mixed with competent cells for 30
minutes on ice; followed by a 45 second 42C heat shock and cooled on ice
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for 2 minutes. 1000 l of Luria-Bertani (LB) media (10g tryptone, 10g NaCl,
5g yeast extract, autoclaved in 1L ddH2O) was added to the transformation
mixture, and incubated, while shaking, at 37C for 1 hour. Cells that had
settled were then agitated by shaking, with 200l being spread onto
corresponding antibiotic LB agar plates and incubated at 37C for 16 hours.
2.2.1.2. Agarose gel electrophoresis
The integrity, purity and size of plasmid DNA, PCR products, restriction
digests and ligation reactions was determined using 1% agarose gels (0.5g
analytical grade agarose (Sigma Aldrich) in 50 ml 1x TAE (40mM Tris-Acetate,
1mM ethylene-diamine-tetraacetic acid (EDTA); with SYBR Safe DNA stain
(Life Technologies) at 1 1:10000 dilution). DNA samples were mixed to a
concentration of 1x Orange G DNA loading dye (20g sucrose and 100mg
Orange G dissolved in 50 ml ddH2O. Samples were loaded alongside
Hyperladder 1 (Bioline) for relative size comparison and subsequently run at
90V for 30-50 minutes in 1x TAE buffer. Blue light transillumination was used
for DNA visualisation.
2.2.1.3. Restriction enzyme digestion
Plasmid DNA and PCR products were subjected to restriction enzyme
digestion for cloning or diagnostic purposes. Reaction volumes of 50l were
used throughout, containing 1.2 g of DNA; 1x CutSmart reaction buffer (New
England Biolabs (NEB)) 2 units of appropriate enzymes (NEB), with nuclease
free H2O added to give a final volume of 50l. Reactions were incubated using
their appropriate reaction temperatures. Products were then purified by
agarose gel electrophoresis, followed by gel extraction utilising a Zymoclean
Gel DNA recovery kit (Zymo Research), following the manufacturer’s
recommendations.
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2.2.1.4. Polymerase chain reaction (PCR)
Subcloning of cDNA was necessary for the generation of his-SUMO-LUJV NP
within a pET28a vector for the purification of LUJV NP. The LUJV NP ORF
from the pEGFP-N1 expression plasmid was amplified by PCR to incorporate
terminal restriction endonuclease sites to facilitate subcloning into the pET28a
plasmid. PCR reactions were performed in 20l reaction volumes containing
50 ng Template DNA; 0.4M of both forward and reverse primers; 0.3mM of
dNTPs (Roche), 10x Termopol buffer – diluted to final concentration of 1x
(NEB) and 1 unit of Vent polymerase (NEB). Reaction cycles were performed
in a thermocycler (Eppendorf); 5min 95C denaturation; 35 cycles of 95C, 30
seconds – 50-65C (dependent on primer Tm), 30 seconds – and a 90 seconds
72C elongation. A final 5-minute extension at 72C was performed, before
being cooled to 4C. Products were then purified via agarose gel
electrophoresis and gel extraction.
2.2.1.5. Ligations
Ligation reactions were performed at three ratios of DNA (insert:vector) to
ensure maximum efficiency; at 3:1, 6:1 and 9:1. 1x Ligase reaction buffer
(Promega (30mM Tris-HCl (ph7.8); 10 mM MgCl2; 10mM DTT; 1mM ATP))
and 1 unit of T4 DNA Ligase (Promega), with nuclease free H2O added to give
a final volume of 20l. Reactions were incubated in a cooling water bath –
from 21C to 4C – overnight.
2.2.1.6. Plasmid DNA amplification
Overnight cultures, grown at 30C from either picked colonies, glycerol stocks
or an appropriate starter culture for larger scale amplification, were pelleted
by centrifugation at 4000 xg at 4C for 10 minutes. Plasmid DNA was isolated
and purified from bacterial cell pellets using appropriate Thermo Scientific
Plasmid DNA extraction kits according to the manufacturer’s instruction.
Briefly, plasmid DNA was isolated via alkaline lysis, isolation on silica
membranes under high salt concentrations and elution from the silica
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membrane after ethanol based washing. After purification, a NanoDrop 1000
(Thermo Scientific) was used to quantify DNA by spectrophotometry.
2.2.2. Protein expression and purification in E. coli
2.2.2.1. Culture media and induction.
Initially, 50ml starter cultures were grown from picked colonies of pET28a-his-
SUMO-LUJV NP transformed E. coli Rosetta-2 cells and used to inoculate 1L
of LB containing 100 g/ml kanamycin. This growth culture was then allowed
to reach an OD600 of 0.6-0.8 by growth at 37C. Cells were then induced with
100M IPTG for 16hrs at 18C.
Upon further experimental analysis, a shift to using auto-induction media was
taken. Auto-induction media (20g Tryptone, 10g NaCl, 5g Yeast, autoclaved
in 1L ddH2O, supplemented with sterilised sugars (25 ml 8% w/v Lactose; 10
ml 60% v/v Glycerol; 5ml 10% w/v Glucose) and 100 g/ml kanamycin) was
inoculated with stabs from pET28a-his-SUMO-LUJV NP transformed E. coli
Rosetta-2 glycerol stocks, grown at 18C for 60 hours.
2.2.2.2. Bacterial lysis for protein purification
Bacterial cells from 1.2.2.1 were recovered by centrifugation at 4000 xg at 4C
for 15 minutes. The supernatant discarded and cells resuspended in lysis
buffer (500mM NaCl; 20mM Tris-HCl pH 7.5; 0.5% v/v Triton X-100; 1mg/ml
chicken egg white lysozyme (Sigma Aldrich); 1-unit DNase; 1-unit RNase with
the addition of cOmplete Ultra protease inhibitor cocktail tablets, as per the
manufacturer’s instruction (Roche)). 15ml of lysis buffer was used per 1 L of
growth culture. Cells were incubated in lysis buffer with agitation at 4C for 30
minutes, followed by a sonication cycle of 10 cycles of 10 second 10m
amplitude bursts, followed by 10 seconds off – repeated three times. The
samples were kept on ice throughout, with 2 minute incubations between
cycles. Lysates were clarified at 40,000 xg at 4C for 20 minutes. The
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supernatant was retained for his-SUMO-LUJV NP purification via Ni affinity
chromatography. Based on work by (Tanner et al., 2014).
2.2.2.3. Ni affinity chromatography
Super-NiNTA100 resin (Generon) was clarified with 4 column volumes (CV)
of his-Binding Buffer (BB) (500mM NaCl; 20mM Tris-HCl pH 7.5; 20mM
imidazole), with 2ml of resin slurry clarified per 1L of growth culture (1CV).
Bacterial cell lysate was then allowed to flow through the resin at a flow rate
of 0.5 ml/min. Washing buffers were prepared, with the composition identical
to the BB, with increased imidazole concentrations. All buffers were prepared
and used at 4C. Each washing step utilised 5 CV of corresponding wash
buffer. Elution of affinity tagged protein was performed at 1M imidazole
concentration (2 CV), with eluted protein concentration determined by adding
1 l sample into a 1:5 dilution of Protein Assay Reagent (Bio-Rad) in ddH2O
and reading the absorbance at 595nm, verses an elution buffer control. Eluted
his-SUMO-LUJV NP was then incubated overnight at 4C under dialysing
conditions with SUMO-Protease (expressed and purified in-house). The
dialysis conditions were: (Gel Filtration Buffer (GFB)) 500mM NaCl; 20mM
Tris-HCl pH 7.5; 1mM EDTA; 1mM DTT – prepared at 4C. Based on work by
(Ariza et al., 2013)
In final purification stages, after size exclusion (2.2.2.4), samples were re-
clarified over a 5ml His-Trap column, utilising the same buffer conditions as
above. Elution was performed at 500mM imidazole.
2.2.2.4. Size exclusion chromatography
Size exclusion chromatography was used to further purify LUJV NP from both
the his-Sumo tag and the SUMO protease. A 320ml HiLoad 26/600 Superdex
S75 column (GE Healthcare) was used with and Akta Prime pump and
collection system at 4C, with a 280nm absorbance sensor to determine
protein concentration in eluted samples.
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Prepared GFB was de-gassed and filtered using a 0.2m sterile filter. The
S75 column was equilibrated with degassed GFB. Sample protein was
concentrated to a volume ≥5.1 ml using a 10 kDa MWCO Vivaspin column 
(Sartorius) and filtered using a 0.2m filter. Sample was loaded into a clarified
5ml injection loop. The pump and collection system was instructed to collect
3ml fractions after the void volume ~90ml had passed through, with a flow rate
of 0.3ml/min. Columns were routinely calibrated using a gel filtration buffer
standard kit (Bio-rad). Fractions were subsequently collected, with samples
analysed via SDS PAGE.
2.2.2.5. Immunochallenge
1.5 mg of purified NP was used to inoculate a sheep for the production of
polyclonal antibodies. Inoculations were performed by Alta Bioscience, with a
primary inoculation via intra-muscular injection followed by two booster doses.
Antigens were administered in the presence of Freund’s adjuvant. Pre-
immune sera was collected, and subsequent collections of immune sera after
primary, secondary and tertiary challenges by the antigen. It was clarified by
centrifugation, aliquoted and frozen at -20C.
2.2.3. Mammalian cell culture
2.2.3.1. Maintaining continuous cells in culture
All cells were maintained at 37C in a humid, 5% CO2 atmosphere. All cell
types listed in 2.1.3, in the absence of viral infection, were maintained in
“complete media”: Dulbecco’s modified Eagle’s medium (DMEM, Sigma
Aldrich), supplemented with 10% v/v foetal bovine serum (FBS, Sigma
Aldrich); 100 IU penicillin/ml and 100g streptomycin/ml (Life Technologies).
Cells were passaged using trypsin-EDTA (Sigma Aldrich) upon reaching 90-
95% confluency. Cells were seeded into specific culture flasks and plates at
appropriate densities after counting with a haemocytometer: 12 well plates
(1x105 cells/well); 6 well plate (2x105 cells/well); 10cm dish (1x106 cells/dish)
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and T175 flasks (5x106 cells/flask). For immunofluorescence experiments,
autoclaved glass coverslips (VWR) were placed into wells prior to seeding.
2.2.3.2. Cryogenic storing and thawing of cells
Long-term storage of cells required freezing in liquid nitrogen. Cells were
trypsinised and washed twice with cool, followed by ice-cold PBS, then
centrifuged at 500 xg at 4C for 10 minutes, followed by a further wash step
and centrifugation. Cells were counted, and resuspended in ice-cold FBS,
10% DMSO to a final concentration of 1x106 cells/ml. Cells were then
aliquoted into cryovials, cooled to -80C at a controlled rate of -1C/minute
(CoolCell, biocision). Cells were then transferred to liquid nitrogen storage.
Frozen cells selected for re-animation were rapidly thawed at 37C,
centrifuged at 500xg at 4C for 5 minutes, washed in complete media,
resuspended, and transferred to 25cm2 flask. Cells were subsequently
expanded when reaching 80-90% confluency.
2.2.3.3. Cellular transfection using Lipofectamine 2000
HEK293T, Vero and A549 cells were transfected for varying experimental
procedures, using Lipofectamine 2000 (Life Technologies). The utilisation of
the lipofectamine 2000 method ensures minimal toxicity and high efficiency of
DNA introduction. The cationic liposomes enable DNA to complex within
liposomes, and enable plasma membrane fusion and introduction of genetic
material into target cells (Dalby et al., 2004).
For the transfection of plasmid DNA, cells were allowed to reach 70%
confluency (60% in the case of experiments involving IF), with transfection
agent:DNA:Media ratio dependent on well size. For SILAC-based and
Interaction validation transfections, 10cm dishes were used. For experiments
involving IF, 12 well plates used. All volumes and ratios were as per the
manufacturer’s recommendation. Briefly – in the case of 10cm dish
transfections – 20g plasmid DNA was mixed 500l DMEM and incubated for
5 minutes (Tube A); 64l Lipofectamine 2000, mixed with 500l DMEM and
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incubated for 5 minutes (Tube B). Tube B was then added drop-wise into Tube
A, and incubated for 20 minutes. Cells were supplemented with fresh DMEM,
with 1ml of transfection mixture added per dish. After 4 hours, DMEM was
aspirated and replaced with complete media.
2.2.4. Mammalian cell protein expression analysis
2.2.4.1. Preparation of whole cell lysate
Cells were harvested via physical scraping whilst in culture media. Cells were
recovered via aspiration, and centrifuged at 1000xg for 10 minutes, washed
3x with ice-cold PBS, with centrifugation between each wash. Cells were then
resuspended in lysis buffer (10 mM Tris-HCl pH 7.5; 150 mM NaCl; 0.5 mM
EDTA; 0.5% NP40; 1x EDTA-free cOmplete protease inhibitor cocktail
(Roche)) for IP. Cells were incubated on ice, with pipette mixing every 10 min,
for 30 minutes. Lysates were then clarified at 20,000xg at 4C for 10 minutes.
2.2.4.2. BCA assay determination of protein concentration
Total protein concentration was determined from whole cell lysates using the
micro bicinchoninic acid protein assay system (BCA; Pierce), used as per the
manufacturer’s instruction. Bovine serum albumin (BSA) standards were
prepared from the provided stock in order to prepare a standard curve.
2.2.4.3. Immunoprecipitations involving GFP-Trap and RFP-Trap
Immunoprecipitations (IP) were used to ‘pull-down’ EGFP or LUJV NP-EGFP
for SILAC-based proteomics and subsequent validations. GFP-Trap IPs
involve the use of alpaca-anti GFP antibodies, conjugated to agarose beads.
The alpaca antibody, of the camelid family, consists of a single domain
specific to GFP and EGFP, with the RFP-Trap control specific to only RFP.
GFP/RFP-Trap beads were equilibrated in ice-cold dilution buffer (10 mM Tris-
HCl pH 7.5; 150 mM NaCl; 0.5 mM EDTA; 1x EDTA-free cOmplete protease
inhibitor cocktail (Roche)), via two washing and centrifugation steps (2000xg,
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4C). GFP-Trap and RFP-Trap beads were all obtained from Chromotek, and
handled according to the manufacturer’s recommendations.
In the case of SILAC IPs, only GFP-Trap beads were used. In the case of
validation experiments, both GFP- and RFP-Trap beads were used, with
lysates divided 50-50 and diluted as such.
Lysates from 2.2.4.1 were diluted to lower final NP40 concentration below
0.1% and a final volume of 1ml with dilution buffer and exposed onto 30l per
IP equilibrated GFP/RFP-Trap beads. Cell lysates were incubated with GFP-
Trap beads for 90 minutes at 4C, with rotation, to allow EGFP/LUJVNP EGFP
to bind to GFP-Trap beads. Following the incubation period, the beads were
sedimented at 2000xg and supernatant removed (known as flow through
(FT)), with the beads washed twice in ice-cold wash buffer (10 mM Tris-HCl
pH 7.5; 250 mM NaCl; 0.5 mM EDTA; 1x EDTA-free cOmplete protease
inhibitor cocktail (Roche)). Immunoprecipitated proteins were then eluted from
the beads via heating at 95C in 50l 2x NuPAGE LDS sample buffer (4x
NuPAGE LDS sample buffer (Thermo Fisher Scientific) – diluted to final, 2x
concentration in ddH2O; 10mM DTT). Beads were then sedimented at 2700xg
for 5 minutes, 4C.
In the case of SILAC IPs, equal volumes of eluted proteins were combined,
and sent to Dr Stuart Armstrong at the University of Liverpool for mass-
spectrometry (MS) analysis.
2.2.4.4. SDS polyacrylamide gel electrophoresis (SDS PAGE)
5 ml SDS PAGE mini-gels were made as 10, 12 or 15% resolving gels, and
5% Stacking gels, as shown in table 2.
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Table 2 SDS poly-acrylamide gel recipes
Standardised protein samples were mixed 1:4 with 5x Laemmeli Buffer (60mM
Tris-HCl pH 6.8; 10% (v/v) Glycerol; 2% (w/v) SDS; 5% (v/v) -
mercaptoethanol, 0.01% (w/v) bromophpenol blue), with samples
subsequently denatured at 95C for 5 minutes, prior to loading. Samples were
loaded into wells at appropriate volumes for well size. Samples were loaded
alongside ColourPlus Prestained protein ladder (10-230kDa) to assist in band
size identification. Electrophoresis was performed with 1x SDS running buffer
(25mM Tris; 192mM Glycine; 0.1% (w/v) SDS) at 200V for 45-60min.
2.2.4.5. Protein visualisation by Coomassie stain
Proteins resolved via SDS PAGE electrophoresis were visualised by
incubating gels in 1x Coomassie stain (0.25% (w/v) Coomassie R250; 50%
(v/v) CH3OH; 10% (v/v) glacial acetic acid (CH3COOH)) for one hour at RTP,
with agitation. Gels were de-stained in destain buffer (40% (v/v) CH3OH; 10%
(v/v CH3COOH) for two hours, with rehydration in ddH2O prior to imaging.
2.2.4.6. Silver stain visualisation of proteins.
Silver staining of gels was performed using a SilverQuest staining kit
(Invitrogen), as per the manufacturer’s recommendations.
2.2.4.7. Western blot analysis
Proteins resolved via SDS PAGE electrophoresis gels were transferred to
fluorescence compatible polyvinylindene fluoride membranes (PVDF;
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Immobilon-P Transfer membrane, Milipore) using a semi-dry Tans-Blot (Bio-
Rad) in Towbin buffer (25mM Tris, 192mM glycine, 20% methanol (v/v)) for 1
hour at 15V. PVDF membranes were subsequently blocked for 1 hour at room
temperature in 1:1 Odyssey blocking Buffer-TBS (OBB; LiCor): TBS (50mM
Tris pH 7.5, 150mM NaCl). Blocking buffer was then replaced with appropriate
primary antibody solution in 1:1 OBB:TBS for either 1 hour at room
temperature or overnight at 4C. Membranes were washed three times in TBS
and then incubated with appropriate fluorescently labelled secondary
antibodies for 1hr at room temperature, protected from light. Membranes were
then washed twice with PBS and finally once in water and dried, before
visualising using LiCor Odyssey Sa infrared imaging system. A table of
primary and secondary antibodies is provided in tables 3 and 4.
2.2.5. Stable isotope labelling of amino acids in cell culture (SILAC)
Frozen HEK293T cells were reanimated, as in 2.2.3.2, into isotopically distinct
SILAC-DMEM (Dundee Cell Products), supplemented with dialysed, SILAC
grade FBS (Dundee Cell Products), for a minimum of seven doublings to
ensure ≥95% labelled amino acid inclusion. SILAC culture media recipes used 
were: ‘light’ R0K0 media for control samples; ‘medium’ R6K4 13C labelled
arginine and 2D (2H) labelled lysine and ‘heavy’ R10K8 of 13C & 15N labelled
arginine with 13C & 15N labelled lysine – as depicted in figure 16. Cells were
maintained as in 2.2.3.1, with the substitution of a PBS-EDTA based cell
dissociation buffer (Life Technologies) trypsin for, to prevent introduction of
unlabelled amino acids.
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Figure 15. Diagram illustrating SILAC MS procedure
2.2.5.1. Immunofluorescence microscopy (IF)
IF experiments were performed to visualise various cellular and viral proteins
and to determine their sub-cellular localisation. Cells were grown on sterilised
19mm glass coverslips within 12-well plates, and where appropriate,
transfection or infection had already taken place prior to fixing. Cells were
fixed in 4% paraformaldehyde (4% PFA) for 20 minutes at room temperature.
Fixative was then removed, with fixed cells washed three times in PBS and
either utilised immediately or stored in PBS at 4C. Cells to be processed
immediately were permeabilised in 0.5% (v/v) Triton-X 100 in PBS for 10
minutes at room temperature. Permeabilised cells were washed 3 times in
PBS.
Primary and secondary antibody staining was performed separately with
appropriate antibodies diluted to the recommended concentrations, in 2%
Diagram showing the mix after precipitation (MAP) SILAC IP procedure.
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(v/v) FBS in PBS. Primary antibodies were then introduced onto coverslips,
and incubated at room temperature for 1 hour. Primary antibodies were
washed three times in PBS, before incubation with secondary antibodies at
room temperature for 1 hour. A table of primary and secondary antibodies are
provided in Tables 3 and 4. Cells were then washed three times in PBS.
Coverslips were then mounted onto microscope slides using an appropriate
anti-fade reagent. In experiments involving EGFP in addition to fluorescent
antibodies, cells were mounted onto slides with ProLong Diamond anti-fade
reagent with DAPI (Life Technologies). With experiments involving only
fluorescent antibodies, cells were mounted with ProLong Gold antifade
reagent with DAPI (Life Technologies). Mounted coverslips were cured at
room temperature for 24 hours in the dark, and then stored at 4C for long-
term storage prior to visualisation. Mounted cells were then visualised using
an inverted Laser Scanning Microscope (LSM) 700 with a 63x Plan-
Apochromat objective (Carl Zeiss).
2.2.6. Virological techniques
2.2.6.1. LCMV infection
For LCMV-Arm propagation, BHK21 cells were seeded into T175 culture
flasks and allowed to reach 50% confluency. Cells were then infected at a
multiplicity of infection (MOI) of 0.001, and incubated in LCMV propagation
media (DMEM; 50mM Glutamine; 10% heat inactivated FBS; 5% Tryptose
phosphate; 5ml Pen/Strep) for 96 hours. After the incubation period,
supernatant was aspirated and collected, centrifuged at 1000xg, 4C for 10
minutes, aliquoted, and stored at -70C.
2.2.6.2. Quantification of virus via plaque assay
Plaque assays were performed in duplicate in 6 well plates. 20 l of LCMV
Armstrong was diluted 10 fold into 200l of SFM (10-1) which was further
serially diluted to create 10-2 - 10-6 dilutions. Virus dilutions were then used to
infect BHK21 cells as in 2.2.6.1. BHK21 cells (1x105) BHK21 cells were
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seeded onto 12 well plates and allowed to reach 90-95% confluency prior to
infection. Dilutions were used to infect cells for 1 hour at 37C. After
adsorption, dilutions were removed and replaced with complete medium
mixed 1:1 with 1.6% (w/v) carboxy-methyl cellulose (CMC; Sigma). The CMC
overlay prevents virus from spreading throughout the well, only able to infect
the direct neighbour cell.
Cells were incubated for 6 days, then fixed in 20% (v/v) formaldehyde for 20
minutes. Cells were washed thoroughly with ddH2O and then stained with
crystal violet solution (0.1% (w/v) crystal violet, 20% ethanol) for 5 minutes.
The positively-charged chromophore within crystal violet binds the negatively
charged membrane, meaning violet staining indicates living cells, with no
staining an indication of cell death. Plaques of dead cells can then be counted,
and the viral titre calculated via the following calculation:
2.2.6.3. Purification of LCMV by iodixanol density gradient
centrifugation.
A continuous 5-30%, or 20-45% iodixanol gradient was prepared at least 24
hours prior to LCMV purification. Briefly, sequential layering of 1.9ml 30%-5%
iodixanol in TNE (100mM Tris-HCL pH 7.4; 100mM NaCl; 1mM EDTA) in 5%
increments were loaded into a PolyClear 14 x 95mm Open-top centrifuge tube
(Senton). In between layer additions, the gradient was frozen on dry-ice, with
final, long-term storage at -70C. An overnight thawing step was performed,
prior to loading, to allow for layers to diffuse, creating a continuous gradient.
Iodixanol was supplied as a 60% solution (OptiPrep, Sigma Aldrich).
LCMV was used to infect BHK21 cells, as in 2.2.3.5. However, after the
incubation period, supernatant was collected and then centrifuged at 1000xg,
4C for 10 minutes, to remove cellular contamination. Cell supernatant was
then mixed at 1:4 dilution with 50% (w/v) PEG6000 in TNE. LCMV was then
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precipitated overnight at 4C with continuous mixing. Supernatant/PEG mix
was then centrifuged at 3000xg for 40 minutes at 4C, to recover precipitated
virus. The pellet was then resuspended in 2ml TNE, and layered on-top of the
continuous iodixanol gradient. The gradient was then ultracentifuged at
200,000xg for 90 minutes at 4C in a SW40 swinging bucket rota (Beckman
Coulter). After cycle completion, 500 l fractions were recovered, from the top
(least dense) to the bottom (densest). Fractions were then mixed, samples
were taken for WB analysis and infectivity determination, and frozen at -70C.
Samples for WB analysis were inactivated at 65C for 15 minutes.
After identifying fractions containing infectious virus, the fraction was
inactivated at 65C for 15 minutes, and sent for MS analysis. Figure 16
illustrates gthe rationale behind comparative MS analysis of LUJV-NP-EGFP
vs LCMV NP interactome.
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Figure 16. Diagram showing the comparative analysis of NP interactome and
virion proteome
2.2.7. Mass-spectrometry analysis of virus
MS analysis of the isolated fraction containing LCMV was performed in order
to identify cellular proteins packaged within viral particles. MS analysis was
performed by Dr Stuart Armstrong at the University of Liverpool.
2.2.7.1. NanoLC MS ESI MS/MS analysis
Protein samples generated by EGFP-trap immunoprecipitations were
separated by 12% SDS-PAGE electrophoresis. The resulting separated
proteins were cut from the gel in 10 slices and subjected to in-gel digestion
with trypsin. Trypsin-digested peptides were separated using an Ultimate
U3000 nanoflow liquid chromatography (LC) system (Dionex Corporation)
Diagram illustrating the immunoprecipitation, and inclusion within viral
particles, of cellular proteins, and subsequent analysis via MS
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consisting of a solvent degasser, micro- and nanoflow pumps, a flow control
module, a UV detector, and a thermostated autosampler. A sample volume of
10 μl (comprising 2 μg) was loaded at a constant flow rate of 20 μl/min onto a 
PepMap C18 trap column (0.3 mm by 5 mm; Dionex Corporation). After trap
enrichment, peptides were eluted onto a PepMap C18 nanocolumn (75 μm by 
15 cm; Dionex Corporation) with a linear gradient of 5 to 35% solvent B (90%
acetonitrile with 0.1% formic acid) over 65 minutes at a constant flow rate of
300 nl/min. The high-pressure liquid chromatography system was coupled to
an LTQ Orbitrap XL instrument (Thermo Fisher Scientific Inc.) via a
nanoelectrospray ion source (Proxeon Biosystems). The spray voltage was
set to 1.2 kV, and the temperature of the heated capillary was set to 200°C.
Full-scan MS survey spectra (m/z 335 to 1,800) in profile mode were acquired
in the Orbitrap instrument with a resolution of 60,000 after accumulation of
500,000 ions. The five most intense peptide ions from the preview scan in the
Orbitrap instrument were fragmented by collision-induced dissociation
(normalized collision energy, 35%; activation Q, 0.250; activation time, 30 ms)
in the LTQ instrument after the accumulation of 10,000 ions. Maximal filling
times were 1,000 ms for the full scans and 150 ms for the MS/MS scans.
Precursor ion charge state screening was enabled, and all unassigned charge
states as well as singly charged species were rejected. The dynamic
exclusion list was restricted to a maximum of 500 entries with a maximum
retention period of 90 seconds and a relative mass window of 10 parts per
million (ppm). The lock mass option was enabled for survey scans to improve
mass accuracy. The data were acquired using Xcalibur software.
2.3. Role of Nucleoprotein in translation
2.3.1. Production of Arenavirus-like mRNA via in vitro transcription
mRNAs were synthesised from plasmid DNA by T7 promoter driven in vitro
transcription through the use of an mMESSAGE mMACHINE® T7 Ultra Kit
(Ambion) as per the manufacturer’s recommendation. NPEG and 3’NPEG
plasmid DNA was linearised by SfiI. DNA was then transcribed by T7 RNA
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polymerase for 1 hour at 37C, prior to incubation with TURBO DNase for 15
minutes at 37C to remove DNA templates from the synthesised RNA. RNA
was then purified via the use of RNeasy Mini Kit (QIAGEN) and eluted into
RNase free H2O. RNA was subsequently quantified using a NanoDrop 1000
(Thermo Scientific) by spectrophotometry.
2.3.2. Transfection
RNA transfections were performed using lipofectamine 2000 (Invitrogen)
reagent as per the manufacturer’s recommendation. Briefly, 500ng RNA/ well
(12-well plate) was incubated with appropriate volumes of lipofectamine 2000
and SF DMEM. Transfection mix was then added to A549 cells.
2.3.3. Luciferase assay
A 12-well plate was seeded with 1x105 A549 cells, whereupon at 80%
confluency they were infected/mock infected with LCMV-Arm at an MOI of
0.01, or MOI 1 for HRSV and subsequently incubated for 24 hours. A 0-hour
time point was then collected prior to the differential transfection/mock
transfection with appropriate mRNA, as shown in figure 17. Supernatants
were then collected every two hours for the duration of the study, with media
replaced with complete DMEM after each sample was collected.
The secreted luciferase was then detected using the Pierce Gaussia
Luciferase Glow Assay Kit (Thermoscientific) in which a solution of
coelenterazine in Gaussia Glow Assay Buffer is added to 20µl of each sample
in a 96-well plate. Samples were then incubated for 10 minutes at room
temperature to allow for signal stabilisation, with relative luciferase units (RLU)
recorded accordingly, detected using a luminometre with RLU signal
corresponding to the concentration of Gaussia luciferase in each sample.
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Figure 17. Diagram depicting procedure of arenaviral-like mRNA translation assay
Diagram showing the layout of Gaussia luciferase assays performed in chapter 6. A shows
NPEG and LCMV; B shows NPEG and HRSV; and C shows 3’ NPEG and LCMV.
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2.3.4. List of primary antibodies




WB Dilution IF Dilution
EGFP Santa Cruz sc-8334 1:2000 N/A
Actin Sigma Aldrich sc-966 1:2000 N/A
GAPDH Abcam ab8245 1:10000 N/A
LUJV NP In house N/A 1:5000 1:5000
LUJV NP - For use with
LCMV NP in House N/A 1:2500 1:1000
HSP/HSC70 Abcam ab2787 1:1000 1:100
eIF1A Abcam ab172623 1:1000 1:100
eIF2S1 Abcam ab26197 1:1000 1:100
eIF3E Abcam ab36766 1:1000 1:200
eIF4E-Phospo (S209) Abcam ab131513 N/A 1:150
eIF4E Abcam ab1126 1:1000 1:100
eIF4A1 Abcam ab31217 1:1000 1:100
eIF4G1 Abcam ab2609 1:2000 1:500
eEF1A Abcam ab37969 1:1000 N/A
PABP Abcam ab21060 1:500 1:200
RPS11 Abcam ab175213 1:2000 1:150
RPL10A Abcam ab174318 1:2000 1:200
RPL26L1 Abcam ab181110 1:2000 1:150
RPS19 Abcam ab57643 1:2000 N/A
PICV NP in house N/A 1:2000 N/A
LCMV NP Abcam ab31774 N/A 1:500
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2.3.5. Table of Secondary Antibodies
Table 4 Table of secondary antibodies
Mouse Alexa Fluor 594
Life
Technologies A21201 N/A 1:500
Rabbit IRDye 800CW LiCor 926-32213 1:10,000 N/A
Sheep IRDye 800CW LiCor 926-32214 1:10,000 N/A
Rabbit IRDye 680RD LiCor 926-32213 1:10,000 N/A
Mouse IRDye 680RD LiCor 926-68072 1:10,000 N/A
Mouse Alexa Fluor 488
Life
Technologies A11001 N/A 1:500
Rabbit Alexa Fluor 594
Life
Technologies A11061 N/A 1:500
Sheep Alexa Fluor 647
Life
Technologies A21448 N/A 1:500
Target- primary
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3. Expression and purification of LUJV NP and
Pichindé virus NP in BL21 Rosetta 2
3.1. Introduction
Lujo virus is a newly emerged haemorrhagic fever-causing infectious agent,
capable of significant morbidity and high mortality rates in humans (Sewlall et
al., 2014). In order to study the molecular and cellular biology of this pathogen,
we sought to develop immunological tools that would allow identification of
native LUJV NP in order to better understand its role in the virus lifecycle. The
provision of LUJV NP antibodies would allow us to perform several important
and revealing experimental procedures that would otherwise be problematic.
These include determination of NP localization within infected or transfected
cells, immunoprecipitation of NP from cell lysates, and identification of NP
within cell lysates by way of western blotting.
An alternative approach to detecting a viral structural protein such as LUJV
NP is to attach its ORF to that of EGFP or one of its derivatives, as described
in chapter 4. In this way the LUJV moiety is detected by virtue of its linkage to
the fluorescent EGFP molecule, for which many high affinity antibodies are
already available should immunological detection be necessary. However, the
use of EGFP, and other fusion proteins poses several issues.
Negative sense RNA viruses, such as those classified in the Arenaviridae
family, encode relatively few proteins compared to positive sense RNA viruses
such as HCV (Moradpour & Penin, 2013), or DNA viruses such as those in
the Herpesviridae family (Jackson et al., 2011). Negative sense virus proteins,
therefore, often perform multiple roles in the viral life cycle (Carter et al., 2012;
Fehling et al., 2012; Hale et al., 2008). The arenavirus NP is known to be
important in interferon modulation, transcriptional anti-termination, factor
recruitment alongside encapsidating viral genomes (Pythoud et al., 2012;
Tortorici et al., 2001; Baird et al., 2012; Pedersen & Konigshofer, 1976). The
introduction of a tag – such as EGFP – is likely to either disrupt protein
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structure, or interfere with assembly of multimeric complexes and therefore
impinge the protein function in vivo. Therefore, using a tagged protein for
research, while offering benefits in detection and purification, will likely limit
the conclusions that can be made due to possible alteration or disruption of
one or several functions of the native protein.
The tagging of proteins remains a useful method for tracking proteins and
identifying interacting partners, and this technique is exploited to initially
identify interacting partners of LUJV NP in chapter 4. However, the most
authentic and functionally accurate method for determining a protein’s location
in vivo remains the use of un-tagged native protein. However, there is a lack
of effective and commercially available antisera against NPs readily available
for members of the Arenaviridae family. This chapter describes the expression
and purification of LUJV NP and Pichindé virus (PICV) NP in Escherichia coli.
PICV is a NW arenavirus, classified as a hazard group 2 organism which
enables its use in BSL2 containment facilities. As it is asymptomatic in
humans, it could act as a good surrogate species for the NW group pathogens
in order to compare observations between NW and OW arenavirus. The
generation polyclonal antisera in this manner should provide a useful tool for
future research applications regarding the NW members of the Arenaviridae
family.
Figure 18. Representation of SUMO- fusion proteins
After the purification of the NPs validation of the subsequently generated
sheep polyclonal antibodies was also required. The strategy that was adopted
was to express LUJV NP as a fusion protein, with the LUJV NP ORF linked to
the ORF for his-SUMO within a pET28a expression vector. This attachment
allows for SUMO-protease structure based recognition and cleavage, allowing
Diagram illustrating the fusion protein comprising his-SUMO-LUJV NP. The 6xHis tag is
illustrated by: H. The unboxed region between SUMO and NP ORFS represents the
cleavage site of SUMO protease, after the C terminal of the SUMO ORF.
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the efficient removal of the SUMO and 6xHis affinity tags from native LUJV
NP (Figure 18) (Panavas et al., 2009).
In the pET system, expression of the protein of interest is driven by
bacteriophage T7 RNA polymerase, which binds to the specific promoter
region upstream of the target ORF for expression. pET systems can therefore
be introduced into various strains of E. coli BL21 cells, which express T7 RNA
polymerase. Inducing the expression of target protein is linked to the lac
operator upstream of the target protein, with IPTG binding to the lac repressor,
catalysing its removal from the operator, allowing for the synthesis of mRNA
from lac operator linked genes. The auto-induction procedure utilised is based
on providing growth cultures with low levels of glucose, enough to allow cells
to reach saturation (Studier, 2005). Alongside this glucose is lactose, the
metabolism of which is inhibited in the presence of glucose. The use of
glucose by the growing culture then allows the bacterial culture to reach high
concentrations, where the metabolism of lactose begins, inducing the
expression of lac operon linked proteins. Finally, glycerol can be utilised by
the saturated culture as a late stage energy source to prevent bacterial death
from resulting in a loss of protein (Studier, 2005).
Purification of viral nucleocapsid proteins in E. coli from plasmid cDNAs is well
documented, but it is has become apparent that each protein may behave
differently during expression and purification. For example, despite sharing
60% amino acid sequence homology and striking structural similarity, the N
proteins of HAZV and CCHFV require entirely different strategies for their
effective purification (Surtees, 2014).
The establishment of a successful purification procedure required iterative
testing of multiple different growth conditions, buffer preparations and the
incorporation of various chromatography techniques in order to generate the
required NP purity, whilst retaining a usable yield. The trialling of multiple
different conditions allowed for incremental improvements in yield and purity
of LUJV NP. The final, optimised, procedure is based on two separate
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purification procedures – Ni affinity chromatography (IMAC) followed by size
exclusion chromatography (SEC).
Ni affinity chromatography utilises polyhistidine tagged proteins – in this case
his-SUMO – binding to resin embedded with immobilised metal ions, such as
Ni2+. Histidine, through its side chain, binds to these immobilised ions due to
electron donor groups within the imidazole ring. The use of poly-histidine
allows for the protein to effectively bind the matrix, through interaction with the
Ni2+ ions. Sequential washing with buffers containing imidazole creates
competition for binding sites with weaker binding partners, removing them
from the resin matrix and facilitating the purification of target protein. This
method does allow the potential for contaminant proteins to be eluted with the
sample, as they may simply bind the matrix with equal efficiency as the poly-
histidine tagged protein. Alternatively, the target protein may interact and bind
with bacterial proteins, co-precipitating them when eluted from the matrix
(Bornhorst & Falke, 2000).
In order to minimize this, his-SUMO cleavage acts as a further purification
step. The cleavage of SUMO tag, comprising the 6xhis-SUMO portion of the
fusion protein (figure 18), from the target protein generates two separate
proteins – in the case of LUJV NP, one ~63kDa protein comprising LUJV NP,
and the his-SUMO tag of ~15kDa are generated, in addition to the ~25kDa
SUMO-protease. The SUMO tag is cleaved through a tertiary structure-driven
recognition site, rather than a sequence-based cleavage site, which allows for
increased specificity of the protease (Panavas et al., 2009). This allows the
various components to be separated from each other by size exclusion
chromatography on account of their relative size, increasing sample purity. As
the specificity of the SUMO-protease is for the tertiary protein structure, any
improperly folded proteins will not be cleaved, potentially allowing for un-
cleaved proteins to be eluted alongside cleaved fractions after size exclusion
(Panavas et al., 2009). By passing the SUMO-cleaved protein mixture through
a naïve nickel resin column, unwanted his-tag containing contaminants can
be removed from the sample (Panavas et al., 2009).
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Size exclusion chromatography (SEC), unlike Ni affinity, relies on the target
proteins not binding with the resin matrix. SEC utilises a bead matrix with
varying microscopic pores present within beads. This physical structure of the
matrix allows for proteins of different size to flow through the resin matrix at
different rates (Wang et al., 2010). Depending on the chosen column type,
this allows multimeric and large proteins to flow through without restriction,
whilst smaller proteins must flow through more and more pores, slowing their
progress. This procedure, alongside that of Ni affinity chromatography, has
the potential to generate protein fractions of high purity.
The generation of antisera was performed in sheep, which provide a large
yield of specific polyclonal antibody, enabling great flexibility in future
applications. The procedure requires the use of purified protein in order to
generate specific and reactive antibodies without undesired cross-reactivity
with other host proteins. The use of an initial priming challenge, followed by
boosters comprising secondary and tertiary immunisations allows for the
generation of large volumes of antibody, dependent on the organism used in
the immune-challenge procedure.
Finally, this chapter shows the application of the established purification
procedure in order to purify the NW model arenavirus PICV NP. PICV is a
well-established infectious model for several of the pathogenic NW arenaviral
infections. Much like LCMV, it does not cause infection in immunocompetent
adults, but serves as an effective model for arenaviral infection in animals and
cells (Kumar et al., 2012; Zhang et al., 2001).
This chapter demonstrates a method for the purification of two arenaviral
nucleoproteins – LUJV NP and PICV NP – and the subsequent specificity of
LUJV NP antisera reactivity, and its cross reactivity with another arenaviral
nucleoprotein. These antisera could prove to be an effective research tool
regarding the study of arenaviral NPs and their intracellular functions.
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3.2. Results
3.2.1. pET28a expression plasmid
A parental pET28a expression vector was digested and ligated with an LUJV
NP insert, in order to generate a his-SUMO-LUJV NP fusion protein. E. coli
DH5 were subsequently transformed with the pET28a his-SUMO-LUJV NP
plasmid, and grown on selective media in order to isolate successfully
transformed colonies. Plasmid DNA was extracted, purified and the construct
confirmed as correct via sequencing.
3.2.2. Identification of effective bacterial expression vector
In order to identify the most appropriate strain of E. coli BL21 for the
expression of LUJV NP, the expression properties of a panel of different E.
coli BL21 strains were tested. Bacterial strains were transformed with his-
SUMO-LUJV NP and single colonies individually selected for culturing.
Subsequently, these cultures were grown in volumes of 300ml until reaching
an OD600 of 0.6 and induced with IPTG. After growth, cells were pelleted, lysed
and purified via IMAC to harvest soluble protein. The comparative initial
purification profiles of both BL21 Rosetta 2 (R2) and BL21 Codon+ (C+)
strains is shown in figure 19, with the position of his-SUMO-LUJV NP marked.
The overall expression of LUJV NP was higher in R2, relative to C+, while also
exhibiting a more effective purification profile. The R2 strain was thus chosen
as the expression strain for LUJV NP expression and purification.
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Figure 20. Expression of SUMO-LUJV NP using IPTG induction
After establishing the most effective growth strain (R2), it was necessary to
trial batch growth media and growth in a larger volume to enable optimal
expression and stability of the required volume of protein. Cells were
transformed, incubated, and subsequently grown in LB batch cultures of 6L,
as routinely used in the laboratory. R2 cultures expressing LUJV NP were
grown at 37C until they reached OD600 of 0.6, at which point they were
induced with 100M IPTG and grown for 16 hours at 18C. Cells were then
pelleted and lysed as described. Initial expression attempts generated good
yields of soluble LUJV NP, although following stringent washing a significant
amount of protein was lost, as seen the protein eluted using relatively low
Coomassie stain of SDS PAGE gel showing the purification profile of his-SUMO-LUJV
NP in two E. coli strains – BL21 Rosetta 2 and BL21 Codon+ via IMAC. The image
shows a slice corresponding to a kDa range of approximately 90-50 kDa, with his-
SUMO-LUJV NP evident in the centre of the sliced fractions at approximately 80 kDa.
‘In’ correlates to the input fractions; ‘NB’ to the non-bound fraction; ‘BB’ to the initial
binding buffer wash.
Coomassie stain of SDS PAGE gel showing the purification profile following IPTG
induction of his-SUMO-LUJV NP via IMAC, with each imidazole concentration
corresponding to the elution fraction. The image shows a slice corresponding to a
kDa range of approximately 90-50 kDa, with his-SUMO-LUJV NP evident in the
centre of the sliced fractions at approximately 80 kDa. “BB’ indicates the initial
binding buffer wash, with numerals indicating increasing concentration (mM) of
imidazole in washes.
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concentrations of imidazole, between 2 and 20mM (figure 20). These low
concentration imidazole washes were performed to gradually remove protein
contaminants, with the hope of minimizing the loss of his-SUMO-LUJV NP.
However, experimental conditions that allowed the generation of a high yield
of highly pure protein were not identified, and so alternative expression and
purification strategies were investigated.
3.2.3.2. Auto-induction
Figure 21. Expression of SUMO-LUJV NP using auto-induction
Expression of LUJV NP using the IPTG induction protocol resulted in a
significant proportion of the expressed protein being unable to bind to the resin
– suggestive of poor solubility or improper folding. In order to remedy this, an
auto-induction protocol was adopted, involving 56 hours of bacterial growth at
a set temperature after inoculation; in this case – after much optimisation –
18C. In switching from IPTG-based induction to auto-induction based
expression, it was hoped that proteins would be expressed at a slower rate,
which may facilitate correct folding. 6L of auto induction media was inoculated
and, after 56 hours, cells were pelleted. After changing growth conditions to
auto-induction, and minor alterations to the imidazole washing stages, the
previous observations regarding poor yield due to losses during washing were
minimised. The addition of a 2M NaCl wash was adopted to remove any RNA
bound to NP, which could have influenced purification by promoting the
formation of high order RNA bound NP multimers. Taken together, these
Coomassie stain of SDS PAGE gel showing the purification profile of his-SUMO-LUJV
NP via IMAC after induction via auto-induction based growth conditions. Each
imidazole concentration (mM) corresponding to the elution fraction. The image shows
a slice corresponding to a kDa range of approximately 90-50 kDa, with his-SUMO-
LUJV NP evident in the centre of the sliced fractions at approximately 80 kDa. ‘BB’
indicates the initial binding buffer wash, with numerals indicating increasing
concentration of imidazole. 2M* indicates a 2M NaCl wash.
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protocol modifications resulted in improvements in the overall yield and purity
of the resultant his-SUMO-LUJV NP (Figure 21).
3.2.4. Purification
After establishing the basic procedures for bacterial cell growth and identifying
effective initial washing steps, it was necessary to improve the yield and
enhance purity of the expressed his-SUMO-LUJV NP such that it would be
suitable for further purification by size exclusion chromatography, and
ultimately generate a soluble folded protein suitable for antibody production.
3.2.4.1. Purification conditions
The initial NP expression conditions were based on those used by Tanner et
al. 2014 and Ariza et al. 2013 as described in 2.2.2.3. These experimental
conditions were refined throughout the study, with changes implemented
where required, as indicated in 2.2.2.3. Lysis was performed as described in
2.2.2.2 throughout. In order to effectively purify LUJV NP from its his-SUMO-
fusion, it was necessary to establish the isoelectric point (pI) of both his-
SUMO-LUJV NP and LUJV NP. Proteins held at pH conditions near their pI
values are susceptible to precipitation, due to the lack of charge to aid with
solubility. The predicted pI of LUJV NP was found to be 8.72 – using the
ExPASY Compute pI/Mw software – with the predicted pI of the his-SUMO-
LUJV NP fusion protein found to be 8.58. On the basis of these findings, the
use of buffers at a pH of 7.5 was chosen.
3.2.4.2. Ni affinity purification of his-SUMO-LUJV NP
In the previous sections, a bacterial growth strain, growth media and induction
procedure were selected for his-SUMO-LUJV NP expression. Enhancement
of the IMAC purification procedure was then necessary to allow for greater
final yield of purified LUJV NP. In order to achieve this, changes to the
washing conditions were made, with differing concentrations of imidazole
used in washing buffer preparations. In addition, larger column volumes of
washing preparations were trialled in order to remove a higher proportion of
contaminants. Proteins resolving via SDS PAGE electrophoresis to a similar
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size as the eluted his-SUMO-LUJV NP band were eluted from 80mM
imidazole fractions, as seen in figures 21 and 22. In order to try and minimise
this loss, an increase in the number of washes of the lower imidazole
concentration steps was trialled. Figure 22, compared to figure 21, shows
increased contaminant protein levels eluted at lower imidazole
concentrations, with minimal loss of the target protein at these stages also.
Figure 22. Purification of SUMO-LUJV NP via IMAC
Figure 23 shows the optimised IMAC purification profile of his-SUMO LUJV
NP extracted from R2 cells – method as in 2.2.2.3 – including cleavage and
dialysis, showing minimal loss of protein via dialysis into gel filtration buffer
(GFB) and efficient cleavage of LUJV NP. The incremental improvements
from initial attempts allowed for the purification of ~25mg of total protein prior
to dialysis, after which this was subsequently concentrated prior to loading
onto a SEC column. The shift in size from ~80kDa to ~63kDa after cleavage
with SUMO protease is consistent with the eluted protein being the expected
his-SUMO-LUJV NP, as the specificity of SUMO protease for the tertiary
structure of the SUMO tag is highly specific and should not cleave any
contaminating bacterial protein.
Coomassie stain of SDS PAGE gel showing the purification profile of his-SUMO-LUJV
NP via IMAC, with each imidazole concentration corresponding to the elution fraction.
The image shows a slice corresponding to a kDa range of approximately 90-50 KDa,
with his-SUMO-LUJV NP evident in the centre of the sliced fractions at approximately
80 KDa. ‘BB’ indicates the initial binding buffer wash, with numerals indicating
increasing concentration of imidazole. 2M* indicates a 2M NaCl wash.
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Figure 23. Purification of SUMO-LUJV NP via IMAC and cleavage by SUMO
protease
3.2.4.3. Purification of LUJV NP via size exclusion chromatography
After IMAC purification, SEC was chosen to separate cleaved LUJV NP from
contaminant proteins from the IMAC procedure, including the SUMO protease
and the his-SUMO tag. Dialysis of LUJV NP into GFB and subsequent
concentration to a volume of 5ml from 20ml resulted in a protein loss, such
that the total quantity of purified protein dropped from ~25mg to ~15mg prior
to SEC loading, as determined via Bradford assay. The purification
parameters are outlined in 2.2.2.4. Briefly, LUJV NP was loaded into a 5ml
injection loop prior to loading onto an S75 column. The gel filtration system
was allowed to run until completion at a flow rate of 0.3ml/min, with 3.3ml
fractions collected and a 280nm trace utilised to identify fractions containing
protein, as shown in figure 24. The 280nm trace identified a region of protein
concentration from fractions 35-45, which correspond to the first two peaks
visible. These fractions were collected and SDS PAGE electrophoresis
performed in order to identify the protein present. Coomassie staining allowed
for the identification of a band of ~ 63kDa – as expected for LUJV NP – in 10
of the 11 fractions. The final peak was identified as containing low MW bands,
corresponding to the 25kDa SUMO protease and 15kD a his-SUMO tag.
Coomassie stain of SDS PAGE gel showing the purification profile of his-SUMO-LUJV
NP via IMAC, with each imidazole concentration corresponding to the elution of that
fraction. The image shows a slice corresponding to a kDa range of approximately 90-
50 kDa, with his-SUMO-LUJV NP evident in the centre of the sliced fractions at
approximately 80 kDa. ‘BB’ indicates the initial binding buffer wash, with numerals
indicating increasing concentration of imidazole. 2M* indicates a 2M NaCl wash. The
‘cleaved’ fraction shows the eluted protein fraction from ‘500’ treated with SUMO
protease.
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Figure 24. SEC purification profile of LUJV NP after detection of 280nm
absorbance
Within fractions 36-39, a minor contaminant was detected with a molecular
weight of ~45kDa. As it was not feasible to identify the protein via WB due to
the lack of antisera, it was decided to only collect and pool fractions 40-44 that
did not contain this contaminant for immunochallenge in sheep for polyclonal
antibody generation. The total mass of purified protein was 1.5mg in a total
volume of 1.5ml for sheep immunisation.
Figure 25. SEC purification profile of LUJV NP after SDS gel electrophoresis
3.2.5. Purification of PICV NP via IMAC and SEC via a his-SUMO PICV
NP intermediary
After establishing the LUJV NP purification procedure described above, the
purification of PICV NP was attempted utilising the same established method.
SEC 280nm mAu trace showing LUJV NP detected by absorption at 260mn. Elutions were
collected in 3.3ml fractions.
Coomassie stain of 12% SDS PAGE gel, showing fractions collected from SEC column
containing LUJV NP, corresponding to the first two eluted peaks shown in figure 24.
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Protein expression was achieved using plasmid pET28a his-SUMO-PICV,
which expressed the PICV NP appended to SUMO and His tags, in a similar
design as described for LUJV NP expression (figure 23). Transformed E. coli
BL21 R2 cells were grown in 6L of auto-induction media for 56 hours at 18C,
then pelleted and lysed, with purification following the optimised method
established for LUJV NP purification. The expression of his-SUMO-PICV NP
proved successful, with IMAC purification yielding approximately 50mg of un-
cleaved total protein after elution. Subsequent cleavage and SEC purification
yielded several fractions containing PICV NP, which were analysed by SDS-
PAGE, as shown in figure 26.
Figure 26. SEC purification profile of PICV NP after SDS electrophoresis
Fractions 35 through 46 exhibited a band at ~62kDa corresponding to PICV
NP, along with a band at ~78kDa in fractions 39-43, presumably
corresponding to un-cleaved SUMO-PICV NP. In order to remove this
contaminating band, collected fractions were exposed to a secondary IMAC
purification step.
Coomassie stain of 12% SDS PAGE gel, showing fractions collected from SEC
column containing PICV NP – as shown, and un-cleaved his-SUMO-PICV NP –
“sPICV”.
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3.2.5.1. Secondary IMAC purification
Figure 27. Secondary IMAC purification of PICV NP
In order to complete the purification procedure, it was necessary to remove
contaminating, un-cleaved his-SUMO-PICV NP from collected SEC fractions,
achieved by a second IMAC step. Prior to loading the protein mixture onto a
His-Trap IMAC column, SUMO protease was added to the fractions in order
to cleave any remaining un-cleaved fusion proteins. After cleavage, fractions
were loaded onto the IMAC resin. Figure 27 shows the fractions collected,
with the majority of PICV NP eluted from the resin at 300mM imidazole, along
with a contaminating band at approximately 25kDa, corresponding to the
SUMO protease. The two eluted fractions were combined, and concentrated
to 5ml, prior to a second SEC procedure.
3.2.5.2. Secondary Size exclusion chromatography
In the previous section, PICV NP was purified via a secondary IMAC
purification procedure, resulting in a single fraction containing PICV NP
alongside a contaminant corresponding with the SUMO protease at ~25kDa.
In order to remove lower molecular weight contaminants, such as SUMO
Coomassie stain of 12% SDS PAGE gel, showing fractions collected from SEC
column containing PICV NP – as shown, and un-cleaved his-SUMO-PICV NP –
“sPICV”. ~kDa corresponds to the approximate kDa of resolved proteins; NB the non-
bound fraction; BB the binding buffer wash; 300 a 300mM imidazole elution; and 500
corresponding to a second 500mM elution
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protease, from the IMAC purification fraction it was necessary to perform SEC.
A 5ml volume of PICV NP in GFB was loaded onto an S75 column, with
fractions collected throughout. Figure 28 shows the collected fractions 41-47,
with PICV NP visible at approximately 62kDa. There was no observable un-
cleaved his-SUMO-PICV NP evident in collected fractions.
Figure 28. Secondary SEC pufrification of PICV NP
However, the presence of some lower molecular weight proteins is indicative
of protein degradation, due to their absence from the previous IMAC
purification step. Had analysis of the IMAC procedure shown in figure 28
indicated a similar profile of additional protein species, then there would be
cause to further purify the samples. However, as this was clear and only
showed PICV NP and a single, approximately 25kDa species corresponding
to SUMO Protease, the most likely cause for additional protein bands
appearing after SEC is through protein degradation.
3.2.6. Immune challenge
After successfully purifying LUJV NP and PICV NP from R2 cells, 1.5mg of
both proteins were sent to Alta Bisocience for the generation of polyclonal
antibodies by immunisation of sheep. The immunisation programme was for
an initial injection followed by boosting immunizations, which generated 3
bleeds, along with pre-immune sera for base-line comparison.
Coomassie stain of 12% SDS PAGE gel, showing fractions collected from SEC
column containing PICV NP.
89
Chapter 3 Expression and purification of LUJV NP and PICV NP in
Escherichia coli BL21 Rosetta 2.
3.2.6.1. Validation of LUJV NP antibody specificity
In order to determine the specificity of the polyclonal LUJV NP antibody, it was
necessary to confirm that the agent could detect, and was specific to the
provided immunogenic sample. This was done in two ways: first, the antibody
was used at a dilution of 1:2500 to detect the LUJV NP moiety of both his-
SUMO-LUJV NP and the post cleavage LUJV-NP product (figure 29B),
expressed and purified as described above (figure 23). The recognition of a
single band corresponding to both the un-cleaved and cleaved, native LUJV
NP showed the antibody was specific for the LUJV NP target. In addition, the
ability of this antibody to detect these targets at a relatively high dilution
suggested the titre of specific antibody was high.
Second, the LUJV NP antisera was used in immunofluorescence microscopy,
using cells expressing arenavirus NP either by transient transfection with
EGFP/LUJV NP-EGFP or infected/mock-infected with LCMV-Arm. It was
expected that the antibody would cross-react with LCMV NP due to the high
sequence similarity between LUJV NP and LCMV NP.
Figure 29. Validation of anti-LUJV NP abtibody via western blot
Cells were incubated for 36 hours after transfection/infection, fixed and
stained using the anti-LUJV NP antisera at a dilution of 1:2000, and, where
Comparison between a Coomassie stain of a 12% SDS PAGE gel in A and WB,
shown in B. Both gels show the purification profile of LUJV NP via IMAC, with B
demonstrating a WB staining by LUJV NP antisera at a dilution of 1:2500
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required, anti-LCMV antibody. Cells were subsequently stained with
appropriate secondary antisera, prior to mounting on microscope slides with
DAPI-stain. Figure 30A shows LUJV NP staining exactly mimicking that of
LUJV NP-EGFP, without any cross-reactivity with host cell proteins or EGFP
in EGFP transfected cells. 30B also shows the staining of LCMV-Arm NP by
LUJV NP antisera. In addition, the generated antibodies also show a good
degree of reactivity against LCMV NP. This reactivity at low concentrations
indicates that the immunological challenge was successful, and generated a
specific antibody that detected two different arenaviral NPs under analysis.
91
Chapter 3 Expression and purification of LUJV NP and PICV NP in
Escherichia coli BL21 Rosetta 2.
Figure 30. Validation of anti-LUJV NP antibody reactivity against LUJV NP and
LCMV NP via IF
3.3. Discussion
The purification of LUJV NP and PICV NP and subsequent generation of
specific antisera represents an important advance in the establishment of
tools to further probe the molecular and cellular biology of arenaviruses.
Immunofluorescence analysis of the specificity of LUJV NP antisera against LUJV NP-
EGFP in A; and LCMV-Arm NP in B, against and EGFP and mock-infected control
respectively. In both A and B, Vero cells were used. Cyan indicates DAPI staining of
DNA; green indicates EGFP, LUJV-NP EGFP and LCMV NP – as stated; magenta
indicates anti-LUJV NP staining. Scale bar indicates 10m in all instances.
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These specific antisera were previously either not available, non-reactive or
prohibitively expensive. As will be evident in later chapters in this thesis, the
provision of these antibodies was a critical first objective that permitted the
downstream analysis of native arenavirus NP in cells, and also in assembled
virus particles. The NP expression and purification techniques described here
could prove applicable for more arenaviral NPs, with further enhancements
potentially allowing for the generation of large quantities of highly pure LUJV
and PICV NP suitable for solving the high resolution crystal or solution
structures.
The purification of LUJV NP initially proved challenging, with multiple
incremental changes required to enable satisfactory purification and to meet
the required yield. Initial usage of IPTG – as a standard induction technique –
only generated a relatively poor yield of purified protein. The reasons for this
are unknown, but initial problems with poor solubility, and inefficient IMAC
purification as a result. Assessment of different wash buffer conditions
resulted in an improvement in the overall purity of resulting eluted protein, but
the overall yield of protein was unsatisfactory, with significant protein losses
due to precipitation during purification. To this end, a change in approach to
auto-induction allowed improvements on both yield and purity to be achieved.
The use of auto-induction medium generated culture which produced lysates
with a higher proportion of soluble proteins, which were seemingly easier to
separate from contaminants. While the evidence for this being solely as a
result of the auto-induction media is circumstantial, the results were far more
satisfactory than were observable than during IPTG based methods.
Imidazole washing steps were optimised during multiple purification attempts,
with incremental improvements each time. The introduction of a 2M NaCl
wash also aided in the likely removal of NP multimers bound to RNA, as
observed via the 280nm absorbance sensor during SEC. This addition
allowed for a greater yield of RNA-free protein. Finally, increasing the volumes
of imidazole washes, combined with the optimised fractions, generated a good
yield of both LUJV NP and subsequently with PICV NP. While the procedure
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was successful, the switch from IPTG-based induction to auto induction
contributed enormously to the advancements made. However, it is not
possible to say that IPTG would not have subsequently been a more
successful induction procedure, had the complete optimisation of the IMAC
purification procedure been applied to cultures prepared from IPTG based
induction.
SEC purification generally worked well throughout, with the only issue being
a loss of overall protein from the loaded sample. However, the clean fractions
observed (figures 25 & 28) illustrate that, overall, the procedure conferred the
production of purified LUJV NP, and PICV NP. Trialling different flow rates to
counter problems involving the Hagen-Poisuille principles of fluids flowing at
different rates through closed systems to help generate high resolution
clarification of proteins through the matrix. Setting the SEC flow rate higher
would allow several different flow rates of the liquid within the system, lowering
the accuracy with which the protein is clarified. Setting the flow rate to
0.3ml/min was chosen to balance this principle with practicalities surrounding
protein stability, optimising the resolution of proteins through the bead matrix.
The generation of specific antisera against these two proteins will also allow
for more in-depth analysis of LUJV NP, without the need for the expressed
protein to be tagged. The reactivity of the LUJV NP antibody in
immunofluorescence indicates that it is specific only for NP, with no-cross
reactivity observable in mock-transfected/infected cells. LCMV cross-
reactivity shown in figure 30 is greatly encouraging, and the ability to visualise
LCMV NP via WB will be invaluable, given the lack of readily available
appropriate antisera for this technique (Chapter 5; Figure 42). In addition,
PICV antisera was validated, with the data not shown due to the lack of
subsequent use of PICV and PICV NP throughout the study.
This chapter shows the generation of effective antisera against the NP of the
novel OW pathogen LUJV, and its activity against LCMV-Arm NP in infected
cells, conferring reactivity to both NPs in immunofluorescence and western
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blot analyses. In addition, the purification procedure appears to be adaptable
to other NP’s – such as PICV NP and potentially LCMV NP, among others.
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4. Host interacting partners of LUJV NP-EGFP
4.1. Introduction
LUJV is an Old World arenavirus that causes haemorrhagic shock in infected
humans, in an outwardly similar manner to that of LASV or EBOV (Sewlall et
al., 2014). In the single recorded LUJV outbreak in 2008, five patients were
exposed – four nosocomially – with four subsequently dying due to the
infection (Briese et al., 2009). The high lethality of LUJV makes it an important
topic of research, especially in the context of the frequent emergence of other
potentially pathogenic arenaviruses around the world. Indeed in 2015 alone
there have been six newly described arenaviruses isolated from either rodents
or snakes, all of which possess the potential to cause disease in humans
(Hellebuyck et al., 2015; Witkowski et al., 2015; Lavergne et al., 2015; Aqrawi
et al., 2015; Bisordi et al., 2015; Van Cuong et al., 2015; Gryseels et al., 2015;
Mikesch et al., 2010). Arenaviruses are known to pose a significant public
health threat, with LASV recently included on the World Health Organisation’s
Blueprint for R&D readiness (WHO, 2015). As with many recorded cases of
virus emergence, the movement of humans into previously unpopulated
regions exposes individuals to previously un-encountered arenaviruses. For
example, this phenomenon appears to be partly responsible for the increased
prevalence of GTOV disease within human populations of western Venezuela,
a region that is experiencing rapid development due to the rich oil reserves
(Salas et al., 1991; Milazzo et al., 2011; Talwani, 2002).
There is urgent need for improving our understanding of fundamental aspects
of the arenavirus replication strategy, in order to identify potential novel
therapeutic pathways. Utilising LUJV NP as a model for other newly emerging
infectious arenaviral nucleoproteins could also help identify potential
therapeutic strategies for other related arenaviruses of clinical importance.
Due to the limited coding capacity for RNA viruses, their proteins often perform
multiple discrete functions, and the arenavirus nucleoproteins are excellent
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examples of this. While the best characterised role of NP is that of a structural
protein, encapsidating the RNA genome and interacting with other viral
proteins during assembly (Pedersen & Konigshofer, 1976), the NP of several
arenaviruses have been shown to be involved in non-structural processes.
For example, viruses from both OW and NW clades have been shown to
possess exoribonuclease activity (Huang et al., 2015; Qi et al., 2010; Hastie
et al., 2012); inhibition of the IKK activation of IRF3 and NFB translocation
(Martínez-Sobrido et al., 2007; Rodrigo et al., 2012; Pythoud et al., 2012);
direct inhibition of RIG-I (Pythoud et al., 2012); and transcriptional
antitermination (Tortorici et al., 2001). Whilst some of these functions are only
evident during infection, NP can accomplish several in the absence of any
other viral proteins (Huang et al., 2015; Baird et al., 2012; Hastie et al., 2012).
Another way that viruses are able to maximize their limited coding capacity is
to subvert cellular functions for their own benefit, through interacting with
cellular proteins. We hypothesise the arenavirus NP must interact with
multiple cellular proteins in order to efficiently facilitate the infectious cycle.
The described body of research has established the role of NP in multiple
stages of the infectious cycle, yet it is prudent to acknowledge that other
undescribed functions may exist. Given the need for effective therapeutic
strategies for arenavirus infections, establishing previously unknown essential
roles for NP may offer additional targets for therapeutic intervention.
To aid in this process, the experiments described in this chapter aim to identify
novel cellular interacting partners of LUJV NP. To facilitate this investigation,
the strategy described here involved the expression of an EGFP (Enhanced
Green Fluorescent Protein) NP fusion protein, which we precipitated from
transfected cells using high affinity and specificity camelid single chain
antibodies. This antibody constitutes a so-called ‘GFP-Trap’, and the high
specificity of this immunoprecipitation (IP) protocol allows reduced non-
specific precipitation of many cellular proteins that can result in the
identification of false positive interactions. In order to quantify precipitated
cellular proteins and thus determine their abundance, we utilised ‘stable
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isotope labelling of amino acids in cell culture’ (SILAC) based mass
spectrometry (MS). Initial MS-based identification of potential interacting
partners then allowed for further investigation of related proteins using
technical replicates and independent validation techniques, in order to
establish a role of identified interactions in the virus life cycle. Our strategy
involved the expression of NP in isolation of other viral proteins or RNAs, in
order to examine cellular interactions that were mediated by NP alone.
4.1.1. Introduction to SILAC based MS utilising GFP-Trap co-
immunoprecipitation
The unbiased identification of precipitated interacting cellular proteins is
possible through the utilisation of SILAC based MS, in combination with the
GFP-Trap based IP. The method utilises a target protein – LUJV NP-EGFP –
and an EGFP control, with interacting cellular partners binding to the target
and control proteins, and thus being precipitated once exposed to the EGFP
monoclonal antibody conjugated to a bead matrix. SILAC represents a
quantitative proteomic technique that offers a means to compare multiple cell
populations; in this case one of which is expressing the LUJV-NP-EGFP
fusion protein, and another population expressing EGFP alone. Comparison
of the resulting MS data sets allows the identification of proteins precipitated
by virtue of their interaction with EGFP or irrelevant interaction surfaces on
the bead matrix; these proteins can then be eliminated as false positives.
The growth of cell populations in different stable isotopically labelled cell
culture media allows for the differentiation of proteins. After a succession of
passages, these isotopes become incorporated into proteins to levels greater
than 95% (Ong et al., 2002). Due to the nature of MS sample preparation
through in-gel trypsin digestion, precise SILAC isotope selection is important.
The most common medium recipe includes heavy isotopes of both arginine
and lysine, which ensures that at least one residue of labelled isotope will be
included in each peptide, due to trypsin cleaving polypeptide chains after
either arginine or lysine residues. These peptides can then be distinguished
from one another, as peptide length should be identical for sister cell
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populations after trypsin digestion, with the only anomaly being the presence
of differing isotopes.
In the following use of SILAC based proteomics, three media ‘weights’ were
used. The ‘light’ R0K0 media for control samples with no labelled amino acids
included; the ‘medium’ R6K4 13C labelled arginine and D (2H) labelled lysine;
and finally the ‘heavy’ R10K8 of 13C and 15N labelled arginine with 13C and 15N
labelled lysine. The use of this combination of isotopes enables the protein of
interest to be run in duplicate.
When these digested peptides are analysed via MS, pairs of differentially
labelled peptides can be identified due to a shift in the mass/charge ratio (m/z).
The intensity of these peaks provides quantification of the samples – control
versus target. All identified proteins are given a ratio, a ratio of 1 corresponds
to equal abundance of an identified peptide in control and target precipitated
proteins, with a higher ratio corresponding to increasing confidence that the
interaction is with the target alone. This is, however, not without issue. Certain
interacting partners may not be able to bind effectively with their partner once
EGFP is bound to beads, or conversely, the identified protein may be non-
specifically binding to motifs present on both the EGFP and LUJV – each
individual not enough to bind after washing, but the fusion peptide may allow
for the non-specific binding to occur.
As discussed above in 2.2.5 and shown schematically in figure 16, IPs were
performed utilising the Mix After Precipitation (MAP) method. In this case,
separate lysis and precipitation steps are carried out on cell populations, with
the precipitated proteins mixed in equal volumes after elution from beads. This
method allows greater identification of weaker or dynamic partners, as there
is a greater availability of binding sites, which may still produce a lower
abundance ratio. However, as there are more steps required for the MAP
method, there is an increase in chance of experimental error, minimising this
is essential to have confidence in the MS library of identified proteins.
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4.2. Results
4.2.1. Expression and purification of LUJV NP EGFP
The LUJV NP ORF cDNA was synthesised and subsequently inserted into a
pEGFP-N1 expression vector, such that it would direct the expression of LUJV
NP fused with EGFP at the C-terminus with the addition of two alanine
residues as linkers. In order to establish whether this plasmid directed
effective expression of LUJV NP-EGFP, HEK293T cells were transfected
using lipofectamine 2000 and harvested 24 hours post transfection. HEK293T
cells were chosen due to their human origin and their tissue type, as the
kidney is a common organ associated with arenaviral infection (Sewlall et al.,
2014; Bergeron et al., 2012; Yun & Walker, 2012). In addition, a further
important benefit of using human cells is that it allows the accurate
identification of detected peptides, due to the extensive characterisation and
annotation of the human proteome.
Figure 31. Visulaisation of SILAC IP via western blot and coomassie stain
A Western blot analysis of GFP-Trap IPs from differentially labelled HEK293Ts. To
visualise LUJV NP-EGFP (termed LUJV NP) an anti EGFP antisera was used to
detect the EGFP fusion protein. B represents a coomassie stain of A, showing GFP-
Trap IPs from differentially labelled HEK293T cells. R10K8 and R6K4 were
transfected with LUJV NP-EGFP, and R0K0 transfected with EGFP only.
Approximate kDa shown in B
100
Chapter 4 – Host interacting partners of LUJV NP-EGFP
Figure 31A shows a western blot of EGFP and LUJV NP-EGFP expression in
HEK293T cells. Differentially labelled cells were transfected with EGFP in
R0K0 control media, and LUJV NP-EGFP in both R6K4 and R10K8 media.
While figure 31B shows the expression of both LUJV NP-EGFP and EGFP,
along with other precipitated proteins via coomassie stain. The presence of
additional proteins besides exogenously expressed EGFP or LUJV NP-EGFP
within precipitated samples suggests cellular proteins were co-precipitated,
and we anticipated these would be identified though MS.
4.2.2. SILAC LC-MS/MS identification of LUJV NP-EGFP interacting
partners
In order to generate a library of cellular interacting proteins (from 4.2.1) which
immunoprecipitated (IPd) alongside EGFP control or LUJV NP-EGFP,
samples were identified and quantified by SILAC based MS, performed by Dr
Stuart Armstrong at the University of Liverpool.
As part of the analysis through the Mascot search engine during data
collection, each protein identity is assigned a score. This automatically
generated confidence score is based on the protein score, with a higher score
indicating that it is less likely that the identification took place by chance. This
‘protein score’ is algorithmically generated, based on protein coverage
through peptide identification and the combined scores of observable mass
spectra, which can be matched to known amino acid sequences within a given
protein. This can also be used to derive approximate protein quantitation but
is only a rudimentary representation of true abundance. Thus the confidence
score correlates to the likelihood that the identification of individual proteins is
not due to background contamination or experimental noise.
MS identification of IPd proteins resulted in the generation of unique SILAC
ratios, or abundance ratios, for each identified protein; in essence, this ratio
indicates the relative abundance of identified proteins within the sample (LUJV
NP-EGFP) compared to the EGFP only control EGFP. In cases where
proteins are not present within the control fraction, no ratio will be generated,
but they could still be regarded as genuine interacting partners. Total unique
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proteins identified numbered 276, with 86 generating an abundance ratio
between sample and control. A protein frequency graph was generated for
proteins which exhibited abundance ratios, shown in figure 32A. Among
these, 32B shows a selection of the identified proteins, based on the peptide
analysis described in 2.2.5 and its corresponding ratio for proteins discussed
below. A complete list of immunoprecipitated proteins can be found in
Appendix II.
Protein Abundance Ratio
HUMAN Zinc transporter SLC39A7 24.732
MYH9_HUMAN Myosin-9 9.9984
ACTB_HUMAN Actin 9.2999
RS3A_HUMAN 40S ribosomal protein S3a 2.9661
RL26_HUMAN 60S ribosomal protein L26 2.2099
RL11_HUMAN 60S ribosomal protein L11 2.1879
RS10_HUMAN 40S ribosomal protein S10 1.6716
RS19_HUMAN 40S ribosomal protein S19 1.5959
RL10_HUMAN 60S ribosomal protein L10 1.5385
HSP71_HUMAN Heat shock 70 kDa protein 1A/1B 1.3326
HSP7C_HUMAN Heat shock cognate 71 kDa protein 1.238
IF4A1_HUMAN EIF4A 0.94091
HS90B_HUMAN Heat shock protein HSP 90-beta 0.9378
DNJA1_HUMAN DnaJ homolog subfamily A 1 N/A
DNJA2_HUMAN DnaJ homolog subfamily A2 N/A
A) Graph showing a representation of abundance ratio of proteins against detection
frequency following SILAC MS analysis. B) Table showing a selection of proteins
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Figure 32. LC MS and MASCOT engine generated abundance ratios of LUJV NP-
EGFP after SILAC IP
4.3. Validation of identified interacting partners
4.3.1. Choosing interacting partners for further study
As discussed above, there are shortcomings with SILAC-based quantitative
MS. While confidence in the validity of interactions can be good with
incorporation of appropriate controls within experimental procedures, the
likelihood for experimental contamination is great due to the high sensitivity of
currently available MS equipment. MS identification alone does not confirm an
interaction, and indeed the absence of a protein from the MS dataset does not
exclude it as an interacting partner. In order to accurately establish an
identified protein as a true binding partner, resulting data sets must be tailored
using detailed knowledge of the limitations of the SILAC and GFP-Trap
methodologies, as well as a well-informed understanding of relevant cellular
biology and the virus lifecycle. In this context, the use of a single viral protein
for the interaction target may create problems, as some viral components may
only exhibit certain functions when in multi-component complexes.
Futhermore, dynamic interactions, or important partners within a complex may
not be identified due to the conditions of the IP. It would therefore be unwise
to dismiss all identified proteins corresponding to peptides quantified below
an arbitrary abundance ratio, and to assume that high abundance ratio
partners are relevant or important interacting partners.
In order to identify possible partners, it is useful to look at the particular roles
viral proteins may have within the viral replication cycle, in conjunction with
the established roles of similar proteins in different viruses. Our approach was
to treat the proteomics analysis as a means to apply an initial triage of
potential interacting proteins, a snapshot of the global interactome. Firstly,
identified cellular proteins with known roles in related virus nucleocapsid
proteins – such as other members of the Arenaviridae family or other
segmented negative sense viruses such as CCHFV. Secondly, proteins which
exhibited a high abundance ratio from the identified SILAC library are likely,
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but not certain, to be good candidates for further validation. The validation
process is essential, as it helps give confidence to the library, whilst also
opening new avenues for further validation of cellular proteins with related
functions. By applying the criteria described above, we generated a priority
listing of potential interacting partners that we sought to validate using multiple
alternative and complementary means.
Actin is a well-studied protein responsible for multiple internal cell transport
functions, muscle contractions and cell motility (Grummt, 2006; Pantaloni et
al., 2001; Huber et al., 2013). The association of viral proteins with such an
important and abundant cytoskeletal protein is not without precedent, with
Epstein-Barr virus, hepatitis B virus and adenoviruses among those known to
subvert the functions of actin for their own means. The utilisation of actin by
arenavirus NP is not unexpected; although assembly of arenaviruses and
internal transport is predominantly attributed to the small matrix protein Z
(Urata & Yasuda, 2012; Urata et al., 2006), and the roles of NP are thought to
predominantly surround the stability and facilitation of RNA replication. Viral
proteins utilising the cytoskeletal network in RNP trafficking is a well-
established function for nucleocapisd proteins from other RNA viruses,
including the closely related N of CCHFV (Andersson et al., 2004). In the case
of actin, identification of the utilisation of cytoskeletal proteins by NP could
open an avenue for further validation of other members of this group, such as
myosin-9 which generated the second highest abundance ratio.
The protein with the highest abundance ratio change between EGFP and
LUJV NP-EGFP was Zn Transporter SLC39A7, a Golgi-ER Zn transporter
protein. This protein was not investigated due to limited knowledge of the
potential role of this protein interacting with NP, in addition to the lack of readily
available antibody to the protein to characterise its relationship with NP.
However, it would remain a good candidate for further investigation regarding
the protein interactome of NP.
Eukaryotic initiation factor 4A (eIF4A) is an RNA helicase, responsible for the
unwinding of mRNA, processing it from its secondary structure and therefore
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facilitating codon scanning for the initiator codon (Rogers et al., 2002; Oberer
et al., 2005). NW members of the Arenaviridae family have been shown to
interact with components of the eIF4F complex (Linero et al., 2013) and thus
the presence of eIF4A in the LUJV NP interactome would potentially indicate
a cross-clade property of this protein.
The abundance ratio of eIF4A was 0.94, and given that this lies below the
desired cut-off, it would be possible to dismiss it as a contaminant. However,
as discussed above, dismissing potential partners based solely on the MS
abundance ratios is not prudent. As eIF4F complex proteins are known to be
involved in the replication strategies of the NW arenavirus JUNV and influenza
A virus, eIF4A was chosen as a potential partner for further investigation.
(Furic et al., 2010; Yanguez et al., 2011; Linero et al., 2013). eIF4A was
chosen to also act as a representative for translation complex proteins – such
as the ribosomal subunit proteins identified via SILAC MS, including
Ribosomal Protein (RP) L10, L26, S11 and S19. While its identification as an
interacting partner would not confirm the presence of other translation
associated proteins, it would act as marker to test for other translation
associated proteins, such as those described above. Similarly, if eIF4A was
not identified, it would not negate the possibility that other translation
associated cellular proteins do interact with LUJV NP.
Finally, HSP70 is a known chaperone protein, responsible for binding newly
synthesised polypeptides as they emerge from the elongating ribosome
(Mayer & Bukau, 2005). Host-cell chaperone proteins are of importance to
viral protein maturation, given their total requirement for cell-based
glycosylation enzymes, and potentially in order to maintain proteins in
monomeric states. Without proper folding, glycosylation is impossible, and
creates a rate limiting step in viral replication (Sayce et al., 2010; Dalziel et
al., 2014). While NP, which is fundamentally an RNA binding protein and
possesses no glycosylation sites, associating with a chaperone protein may
seem circumstantial, recruiting multiple chaperone proteins to sites of
replication could greatly increase functional viral protein expression. With a
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single protein responsible for recruiting so many factors, efficiency could be
increased, and thus infection spread also. Recent work regarding DENV
replication has shown that chaperone proteins are essential co-factors
throughout each stage of infection, with the DnaJ chaperone family essential
in maximising viral output. If HSP70 were confirmed as a valid interacting
partner of LUJV NP-EGFP, the DnaJ family proteins could then be pursued
further, given their known association with HSP70 (Cyr et al., 1994). Given
that they were identified solely within LUJV NP-EGFP transfected cells, they
would be a good target for future analysis in the event of an HSP70-NP
interaction.
4.3.2. GFP- and RFP-Trap co-immunoprecipitation of EGFP and LUJV
NP-EGFP visualised via western blot
Figure 33. Western blot analysis of interaction between cellular proteins and LUJV
NP-EGFP after GFP-Trap IP
As described above, eIF4A, actin and HSP70 were selected for initial
validation of the MS proteome analysis. EGFP and EGFP-fused proteins co-
precipitate with their interacting cellular partners, enabling the detection of
Western blot analysis of cellular proteins isolated via GFP- and RFP-Trap
immunoprecipitations. In all instances, HEK 293T cells were transfected with EGFP
or LUJV NP-EGFP expressing plasmids – as stated. ‘EGFP FT’ and ‘LUJV NP-EGFP
FT’ indicates the flow through fraction of cell lysates exposed to GFP/RFP trap beads.
‘EGFP IP’ and ‘LUJV NP-EGFP IP’ indicates the immunoprecipitated proteins
exposed to GFP/RFP-Trap beads.
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those cellular proteins by western blot. The absence of proteins of interest in
the EGFP IP fraction would indicate a lack of contamination or non-specific
interaction with EGFP, with presence of the cellular interacting protein in the
LUJV NP-EGFP fraction indicating a valid interaction between the cellular
protein and LUJV NP. Any presence of interacting proteins in the RFP-Trap
IP fractions would also indicate a false positive, with the protein interacting
with the camelid antibodies rather than NP. HEK 293T cells were differentially
transfected using lipofectamine 2000 with EGFP and LUJV NP EGFP and
incubated for 48 hours. Cells were then lysed and separated into soluble and
insoluble fractions, with soluble lysate loaded onto clarified GFP- and RFP-
Trap agarose beads. A “non-bound” or flow-through (FT) fraction was taken,
with beads then washed prior to elution of immunoprecipitated sample.
Figure 33 indicates that both actin and eIF4A show a valid interaction with
LUJV NP-EGFP alone. For eIF4A, a strong signal was produced in the LUJV
NP IP fraction, and was absent from the EGFP IP fraction. This indicates that
the IP of eIF4A was due to the presence of LUJV NP. Actin, similarly,
produced a signal in only the EGFP-LUJV NP IP fraction. For HSP70, a robust
signal was detected in the LUJV NP-EGFP IP, although some precipitation of
HSP70 bound to EGFP alone was evident. This suggests that some of this
precipitated HSP70 may be due to a weak EGFP interaction. The HSP70
antiserum used in the analysis is known to also react with HSC70, thus
producing two distinct bands, and also suggests that HSC70 is a potentially
valid interacting partner, also being identified in the MS analysis (Appendix II).
The lack of any observable protein precipitated during RFP-Trap
immunoprecipitation for all three IPd proteins indicates that the proteins are
not non-specifically binding to the conjugated antibodies. These findings
suggest that eIF4A, Actin and HSP70/C70 are valid interacting partners of
LUJV NP-EGFP.
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4.3.3. Immunofluorescence microscopy
4.3.3.1. Localisation
In order to determine whether LUJV NP-EGFP is able to re-distribute these
identified interacting partners within the cellular environment, it was necessary
to determine the normal distribution of LUJV NP-EGFP. HEK293T cells were
therefore differentially transfected with EGFP or LUJV NP-EGFP and
subsequently fixed in 4% formaldehyde after 36 hours, permeabilised and
mounted in DAPI mounting media for visualisation via confocal microscopy.
Figure 34 shows the normal distribution of EGFP and LUJV NP-EGFP. LUJV
NP-EGFP exhibits a predominantly cytoplasmic distribution, with distinct
cytoplasmic puncta visible throughout. These puncta mimic those generated
by NP and observed during JUNV infection (Baird et al., 2012) which were
described as representing the sites of viral replication, and named as
replication and transcription complexes (RTCs). The identification of a cross-
clade utilisation of distinct cytoplasmic structures for replication could help
identify potential avenues for therapy which target these pathways utilised by
the virus.
Figure 34. Localisation of LUJV NP-EGFP in HEK293T cells
4.3.4. Localisation of identified interacting partners
In the previous sections, LUJV NP-EGFP was found to be present within the
cytoplasm, but also within distinct cytoplasmic puncta. In addition, Actin,
HSP70 and eIF4A were found to immunoprecipitate with LUJV NP-EGFP. In
order to determine whether these proteins were redistributed within cells and
Diagram illustrating the localisation of LUJV NP-EGFP in HEK293T cells. Cyan
indicates DAPI staining; Green indicates EGFP or LUJV NP-EGFP – as stated. The
scale bar indicates 10m.
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co-localising with NP, HEK293Ts grown on cover slips were differentially
transfected with EGFP and LUJV NP-EGFP, and incubated for 48 hours. Cells
were then fixed, permeabilised and stained with relevant antisera prior to
mounting in a DAPI containing mounting media for nuclear staining. Figure 35
shows the distribution of eIF4A, HSP70 and Actin in HEK293T cells, with and
without the expression of LUJV NP-EGFP, against an EGFP control. The
results indicate no significant redistribution of HSP70 in 35A within LUJV NP-
EGFP expressing cells. Given the relatively strong indication of an interaction
via western blot, this is surprising. While complete redistribution of HSP70
would not be expected due to the requirement of HSP70 as a cellular protein
chaperone, but minor co-alignment might be expected. However, as
discussed above, NP is expressed in the absence other viral proteins, within
a living cell environment it may not encounter HSP70 due to the internal
compartmentalisation of the cell.
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Figure 35. Comparative localisations of LUJV NP-EGFP and HSP70, eIF4A and
actin
Immunofluorescence analysis of the alignment of LUJV NP-EGFP with specific
cellular proteins, as compared with EGFP control, in HEK293T cells. A: HSP70
distribution, compared between EGFP and LUJV NP-EGFP; B: Distribution of eIF4A;
C: Distribution of Actin; In A-C, Blue indicates DAPI stain of DNA, Green indicates
EGFP/LUJV NP-EGFP (as stated), Red indicates cellular proteins – identified as
shown.
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However, the observation of HSP70-NP interaction in Figure 34 could still be
valid, as after lysis, NP would be able to interact with HSP70 irrespective of
normal compartmentalisation. Actin shows some co-localization in 35C, into
discreet cytoplasmic puncta, suggesting that NP might interact with actin.
eIF4A also shows strong co-alignment with LUJV NP-EGFP, as shown in 35B,
exhibiting a robust signal within observed cytoplasmic puncta. The
mechanism responsible for this co-localisation is not possible to determine,
but the presence of a protein responsible for mRNA processing in SILAC IP
MS, western blot analysis and exhibiting co-localisation with LUJV NP-EGFP
points toward a functional interaction with LUJV NP.
4.4. Investigating the interaction between LUJV NP-EGFP and
multiple translation associated proteins
The results of the previous section showed LUJV NP co-localising with eIF4A,
an important component of the translation initiation complex. Next whether
LUJV NP interacted with other components of the translation initiation
complex, as well as any ribosomal subunit proteins was investigated. Other
cellular translation initiation factors and ribosomal subunit proteins were
identified in the initial SILAC MS dataset, as shown in figure 32B and
Appendix II, and these were thus selected for further interaction validation,
along with other functionally-related proteins not identified via MS.
Ribosomal subunit proteins act as constituent parts within one of two of the
major subunits of an active ribosome – the 40S and 60S subunits. The
functions of these individual subunit proteins outside of general translation as
part of a ribosomal complex is not wholly understood, with implications in
tumour development (Takagi et al., 2005). However, collectively they enable
the translation of mRNA into a polypeptide sequence (Ramakrishnan, 2002).
Ribosomal subunit proteins selected for validation as LUJV NP interacting
partners were those identified via SILAC MS; namely RPS19 and RPL10. In
addition, eIF2G was identified via MS but solely in the LUJV NP IPs, thus not
generating abundance ratios versus the EGFP control. The selection of these
ribosomal subunit proteins would indicate that components of both the 40S
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and 60S ribosomal subunits were IPd alongside LUJV NP, indicating that NP
interacts with more than simply initiation factors but potentially ribosomal
complexes. In addition, identifying the presence of an additional translation
initiation factor - eIF2G – would confirm that the interaction of eIF4A and NP
observed earlier was not the only translation associated protein to be IPd by
LUJV NP.
4.4.1. LUJV NP association with elements of translation initiation
complex proteins.
4.4.1.1. Immunoblot analysis
Figure 36. WB analysis of LUJV NP-EGFP co-IP with cellular translation
associated proteins
HEK293T cells were differentially transfect ed with EGFP and LUJV NP-EGFP
and incubated for 48 hours prior to lysis. Lysates were then separated into
soluble and insoluble fractions, with the soluble fraction added to clarified
GFP- and RFP-Trap beads and incubated at 4C for one hour, in addition. A
flow through fraction was collected, with beads then washed prior to elution of
Western blot analysis of cellular proteins isolated via GFP- and RFP-Trap
immunoprecipitations. In all instances, HEK 293T cells were transfected with EGFP
or LUJV NP-EGFP expressing plasmids – as stated. ‘EGFP FT’ and ‘LUJV NP-EGFP
FT’ indicates the flow through fraction of cell lysates exposed to GFP/RFP trap beads.
‘EGFP IP’ and ‘LUJV NP-EGFP IP’ indicates the immunoprecipitated proteins
exposed to GFP/RFP-Trap beads.
112
Chapter 4 – Host interacting partners of LUJV NP-EGFP
IPd sample. eIF4A was included as a positive control due to its previous
identification as a protein immunoprecipitated with LUJV NP-EGFP. In
addition, eIF2G, which had been previously identified via SILAC based MS,
was selected for study in order to determine whether NP interacts with
different elements of the initiation complex, indicating an involvement of NP in
complex recruitment. Figure 36 shows the presence of eIF2G, eIF4A, RPS19
and RPL10 all co-immunoprecipitated with LUJV NP-EGFP via a GFP-Trap
and absent from EGFP and RFP-Trap controls. The presence of these factors
indicates LUJV NP interacts with a number of translation-related factors,
including elements of both the 40S and 60S ribosomal subunits. These
findings point towards an association of NP with ribosomes and certain
translation initiation complex proteins.
4.4.1.2. Immunofluorescence analysis
The results of the previous section indicated that LUJV NP interacts with
multiple translation complex proteins. Next, the ability of LUJV NP to influence
the cellular distribution of these identified interacting partners into
characteristic cytoplasmic puncta was tested using immunofluorescence
microscopy. HEK293T cells grown on poly-L lysine treated cover slips were
differentially transfected with either EGFP or LUJV NP-EGFP and incubated
for 48 hours. Cells were then fixed with formaldehyde, permeabilised and
subsequently stained using appropriate antisera. In addition to the eIF4A,
eIF2G, RPL10 and RPS19, the localisation of additional translation associated
factors was observed against LUJV NP-EGFP, in order to establish whether
NP co-localises with different components of the translation initiation complex.
Thus, a factor from four of the major translation initiation factor groups was
selected; eIF1A, eIF2G, eIF3E, and eIF4A, along with the 60S ribosomal
subunit proteins RPL10 and L26, and the 40S subunit protein RPS11.
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Figure 37. Comparative localisation of LUJNV NP-EGFP and cellualar translation
associated proteins
As seen in figure 37A the initiator tRNAMET transfer protein (Chaudhuri et al.,
1997), eIF1A, was not identified via MS but did exhibit a degree of
redistribution within LUJV NP-EGFP expressing cells, into the observed
puncta, as opposed to a diffuse distribution observed in EGFP expressing
cells. Conversely, although eIF2G was identified as an LUJV NP interacting
partner via both MS and via specific WB immunostaining, no evident
difference between its distribution was observed between EGFP and LUJV
NP-EGFP expressing cells 37B. In 37C eIF3E, a component of the eIF3
complex responsible for positioning incoming mRNA by facilitating pre-
initiation complex (PIC) formation (Jackson et al., 2010), shows a degree of
re-distribution into cytoplasmic RTC-like structures. This is notably different to
the normally diffuse arrangement in EGFP expressing and un-transfected
cells. As in figure 35B, eIF4A exhibits a partial co-alignment with LUJV NP as
seen in 37D. The ribosomal subunit proteins RPL10, RPS11 and RPL26 in
37E, F and G respectively all showed a degree of co-alignment, supporting
Immunofluorescence analysis the of alignment LUJV NP-EGFP with specific cellular
proteins, as compared with EGFP control in HEK 293T cells. A-G show the
comparison of a cellular protein localisation compared between EGFP and LUJV NP-
EGFP expressing cells A: eIF1A B: eIF2G; C: eIF3E D: eIF4A; E RPL10A; F: RPS11;
G: RPL26. In A-G, Cyan (channel 1) indicates DAPI stain of DNA, Green (channel 2)
indicates EGFP/LUJV NP-EGFP (as stated), Red (channel 3) indicates host-cellular
protein staining (as stated). The channel 4 in A-G shows the merge of channels 2 and
3. Scale bar indicates 10μm.
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the identification of ribosomal subunit proteins via GFP-Trap IPs in figure 36.
The use of RPS11 in this instance, as opposed to RPS19, was due to the
unsuitability of the RPS19 antisera for IF microscopy. In addition, RPL26
antibody is not recommended for use in WB analysis, whereas visualisation
via IF produces a strong indication that RPL26 co-localises with LUJV NP-
EGFP in HEK293T cells. The presence of these three ribosomal subunit
proteins within RTC like-structures, combined with identification by IP,
indicates that whole ribosomes could be present within RTC like structures
rather than individual constituent proteins. These structures mimic those
observed by Baird et al. 2012 in process of JUNV infection.
4.4.2. The use of intercellular organelles in the formation of LUJV
generated RTC-like structures
In the previous section, LUJV NP-EGFP was shown to co-localise with
multiple components of the translation initiation complex. In order to better
understand the localization of NP within cytoplasmic puncta reminiscent of
arenavirus RTCs, the sub-cellular origin of these cytoplasmic inclusions was
investigated. A panel of antibodies that recognised a variety of organelle-
specific marker proteins was used to examine whether they localised with
LUJV-NP. Vero cells were differentially transfected with either EGFP or LUJV
NP-EGFP and incubated for 48 hours, where they were then fixed,
permeabilised and stained with the appropriate antisera and secondary
antibodies.
In addition to the antisera against organelle marker proteins, the LUJV NP
antibody produced in the previous chapter was used. Figure 38A
demonstrates the relative distribution of nuclear pore complex protein 98
(NUP98) a dynamic component of the nuclear pore complex. While overall
distribution of NUP98 remains intact, there is a degree of co-alignment with
LUJV NP-EGFP, potentially indicating that NP interacts with elements of the
nuclear pore complex. Whilst NUP98 itself was not identified via MS, the
complex protein importin-1 was identified in a single sample fraction, which
could indicate a transient or dynamic interaction. Figure 38B shows the
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relative distribution of -tubulin to identify whether LUJV NP-EGFP was
utilising elements of the microtubule network to re-distribute factors. There
was no change in the relative distribution of the network, and no apparent co-
alignment, which indicates there is no direct utilisation of these structures by
NP. However, NP may utilise these networks in the presence of other viral
proteins during an infection, through its previously identified interaction with
actin (figures 34&35). 38C shows the relative distribution of calnexin, a marker
for the endoplasmic reticulum. The lack of any distinct co-alignment with LUJV
NP-EGFP indicates that NP does not utilise ER derived membranes for the
establishment of RTC like structures.
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Figure 38. Utilisation of specific sub-cellular organelles by LUJV NP-EGFP
In 38D, an antibody specific for COX IV a mitochondrial marker indicates the
relative distribution of COX IV appears unaltered in the presence of LUJV NP-
EGFP vs untransfected or EGFP expressing cells.
Finally, in 38E, there is an apparent and distinct co-alignment of LUJV NP-
EGFP with the early endosomal marker Rab5, suggesting the corresponding
compartments are focal points for NP accumulation. With relevance to the
arenaviral life-cycle, the presence of NP within early endosomes as viral
factories – hijacked to form an RTC – is encouraging. The localisation of NP
within early endosomes is consistent with the known utilisation of early
Immunofluorescence analysis of the alignment of LUJV NP-EGFP’ with cellular organelle
markers, as compared with EGFP control in Vero cells. A: NUP98 distribution, compared
between EGFP and LUJV NP-EGFP; B: Distribution of β-Tubulin; C: Distribution of
Calnexin; D: Distribution of COX IV; E distribution of Rab5. In A-E, Cyan indicates DAPI
stain of DNA, Green indicates EGFP/LUJV NP-EGFP (as stated), Red indicates cellular
organelle marker staining (as stated), and magenta indicates LUJV NP staining. Scale
bar indicates 10μm.
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endosomes as sites of membrane fusion, with arenaviruses internalised and
fusion occurring within endosomes (York et al., 2008). The apparent ability of
NP to recruit a number of factors within early endosomes suggests that the
role of NP in factor recruitment may be crucial to replication.
4.5. Discussion
This chapter describes the identities of interacting partners of the NP of the
newly discovered pathogenic LUJV, when fused with EGFP. The
aforementioned interacting partners – including eIF4A, RPL10 and RPL26 –
can be functionally grouped as proteins involved in protein translation with
diverse roles in ribosome assembly and translation initiation. These
interactions suggest a potential role for NP in facilitating mRNA translation,
presumably of virus-specific mRNAs. As observed in cells undergoing JUNV
infection (Baird et al., 2012), LUJV NP-EGFP is able to form RTC-like,
punctate structures, while co-localising alongside multiple components of the
translation initiation complex within early endosomes. This is an observation
consistent with the known use of endosomes as the point of arenavirus
membrane fusion, resulting in exposure of the arenavirus RNPs to the cytosol
(York et al., 2008; Nunberg & York, 2012).
The combination of host-cell factors described indicates a potential role of NP
in facilitating the expression of viral proteins. Amongst these proteins
identified via IP and IF, there are those that could directly bind NP. It has been
shown that NP is able to re-localise a number of such translation-associated
proteins, with this being indicative of a protein that has an important role in
facilitating the translation of viral mRNAs, a role beyond its well established
role as an RNA-binding protein.
The use of unbiased SILAC-based MS to identify cellular interacting partners
of LUJV NP-EGFP via a GFP-Trap IP from differentially labelled and
transfected HEK293T cells generated a library of potential partners. In total,
276 unique proteins were isolated at least once, with 86 proteins generating
an abundance ratio between the control and duplicate LUJV NP sample. As
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discussed above, this process is not without issue. The required technique
may prevent certain interactions from being observable and introduce
experimental contaminants. Indeed, although the relative abundance eIF4A
was below that of the control, subsequent validations identify this interaction
as genuine. This highlights the importance in conducting validations on the
MS-generated library. Validating a number of results does increase
confidence in the MS data, but viewing the library as a snapshot in time, rather
than a true reflection of a protein’s complete interactome during the extended
period of the viral replication cycle, is prudent.
Not all proteins identified are feasible to validate in one study, due to time and
funding constraints. Identifying patterns between previous knowledge and the
identified proteins can help elucidate the nature of the interaction between
identified cellular proteins and NP. Two of the identified proteins shown in 29B
which were not validated further; DnaJA1 and A2 have recently been
implicated in DENV infection, with depletion of DnaJA2 significantly depleting
DENV production (Taguwa et al., 2015). The DnaJ protein family constitute
the largest and most diverse chaperone protein group. The comprehensive
work of Taguwa et al. identifies DnaJ members as essential in all stages of
the DENV replication cycle, with nine DnaJ proteins found to have a significant
effect on viral depletion when their expression is blocked (Taguwa et al.,
2015). DnaJA2, identified via SILAC MS in LUJV NP-EGFP fractions alone,
was found to be important in RNA synthesis during DENV infection. The
apparent binding of this protein to LUJV NP should be explored further given
the use of the cofactor HSP70 during DENV infection, a validated interacting
partner of LUJV NP-EGFP in this study, and a known partner of CCHFV N
(Surtees, 2014).
The initial screening of selected proteins – eIF4A, actin and HSP70 – from the
MS library suggested that all three could be valid interacting partners via
identification after GFP-Trap IP. However, the three proteins did not exhibit
similar sub-cellular localisations when viewed via IF in the presence of LUJV
NP-EGFP.
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HSP70 is a protein with well-established roles in viral infection including the
closely-related CCHFV N and HAZV N (Surtees, 2014), rabies virus (Lahaye
et al., 2012) and HCV NS5A (Khachatoorian et al., 2014), and was thus a
good candidate for further analysis. The interaction between actin and NP,
and degree of co-localisation, was expected. Actin is a known partner of
related RNA virus nucleocapsid proteins – notably CCHFV (Surtees, 2014;
Andersson et al., 2004). This could indicate that LUJV NP utilises the
cytoskeletal network to facilitate the recruitment of factors to the RTC-like
structures, in a manner similar to related RNA viruses. The lack of major
redistribution does not negate the importance of the interaction of NP with
actin in efficient viral replication through enabling internal transport.
It was however, the identification of eIF4A as an interacting partner that was
the most intriguing prospect for further analysis. Previously, the NP of JUNV
has been shown to exhibit a co-aligning distribution pattern with eIF4A in
infected Vero cells. This observation led to the hypothesis that sites of JUNV
NP protein density constituted replication complexes (Baird et al., 2012). The
cytosolic sites of NP density that LUJV NP-EGFP exhibited suggest that NP
is able to form such structures alone, and indicates that NP could be directly
involved in the translation of viral mRNAs. Figures 35B and 37D demonstrate
the presence of eIF4A within these LUJV NP generated structures which, in
addition to identification via IP, and this observation posed a question as to
why eIF4A and NP would interact. The recruitment of the translation initiation
factor eIF4A into sites of NP concentration suggests NP has a role in
facilitating the translation of host mRNAs. This is supported by the observation
that eIF4A showed a similar distribution pattern with JUNV NP in JUNV
infected cells.
Due to this intriguing observation, proteins similar to eIF4A were thus chosen
for further analysis, including other initiation factors, and ribosomal subunits.
Initiation factors from the other major groups - eIF1, eIF2 and eIF3 - were thus
chosen to identify whether NP recruited major elements of translation
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complexes, rather than an individual protein, such as eIF4A. In addition to this,
ribosomal subunits identified via MS were chosen for the same reason.
The findings in figures 35 and 37 support the theory that NP can redistribute
the constituent elements of translational complexes into cytosolic structures,
shown to be early endosomes (38E), in the absence of other viral factors. The
presence of any one of these proteins does not itself increase confidence that
LUJV NP might generate replication complexes. However, the identification of
multiple cellular proteins within such structures indicates a role in infection not
previously identified for the NP of OW arenaviruses, as it indicates an
involvement of NP in facilitating translation through factor recruitment. Indeed,
the ability of LUJV NP-EGFP to recruit such factors alone is evidence to
implicate NP in having a tangible role in translation. To this end, it seems
reasonable to suggest that LUJV NP-EGFP-induced structures are de facto
RTCs, mimicking those observed during JUNV infection.
The specific factors identified as potential partners are of interest also, with
implications for understanding the potential role of NP in translation. The initial
action during translation of mRNA is the formation of eIF2-GTP-tRNAMET,
which is subsequently guided into forming the 43S PIC by eIF1A. eIF1A then
catalyses the association of the initiator tRNAMET complex with the 40S subunit,
along with the 40S subunit inhibitor protein eIF3 (Chaudhuri et al., 1997;
Hinnebusch, 2006). Together, these proteins prime the 40S subunit, forming
the 43S PIC. eIF4A, bound to eIF4G, is subsequently responsible for the
unwinding of any 5’ secondary structures in order to facilitate mRNA import
into the 43S PIC. Without this, recognition of the initiator AUG is not possible
(Jackson et al., 2010). The utilisation of these factors by NP suggests that NP
modulates translation through relocalisation of multiple initiation factors in
order to facilitate the translation of viral mRNAs. The apparent interaction of
NP with these factors – direct or indirect – suggests that its ability to recruit
these proteins is a necessary step for the virus to replicate. In the absence of
these 43S PIC proteins, translation would not occur (Jackson et al., 2010).
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These identified factors, along with other eIFs, thus facilitate the translation of
mRNAs into polypeptide strands. The absence of eIF2G from sites of NP
concentration was surprising given other observations, and could indicate that
NP could substitute the function of eIF2G as a component of the pre-initiation
complex (PIC). The role of the eIF2 group is considered to be a rate-limiting
step in translation, so it is conceivable that a viral protein would have evolved
to increase the efficiency of PIC formation (Kimball, 1999). Indeed, the
absence of eIF2 in certain stages of poliovirus infection illustrates that the
presence of eIF2 is not essential for translation to occur (Welnowska et al.,
2011). Given the conflicting data observed, with eIF2G IPd via GFP-Trap and
its subsequent absence from RTC-like structures, further investigations are
warranted.
If such structures are utilised by viruses to act as RTCs, then the utilisation of
specific subcellular organelles by NP should correspond with known
components of the viral life cycle. Identifying subcellular organelles utilised by
NP to form RTCs produced two interesting findings. The presence of NUP98,
a marker for nuclear pore complexes (NPC), at the site of NP concentration
could help facilitate the entry of certain factors required for replication. The
use of components of the nuclear pore complex could help facilitate entry of
ribosomal proteins, tRNA and other translation mediating proteins into RTCs
(Christie et al., 2015). This was unexpected, given the lack of NPC proteins
identified via the SILAC-based MS, but could reveal a novel role of NP through
further investigation.
The localisation of NP within early endosomes was also encouraging.
Arenavirus paerticles are known to fuse with cellular membranes within
endosomes indicates that NP can independently recruit multiple factors to a
specific organelle, which has already been implicated in the virus life cycle
(Tani et al., 2014; York et al., 2008). The utilisation of endosomes by LUJV
NP to form what could prove to be RTCs in a similar manner as those
observed by Baird et al. (2012) is evidence that NP is able to modulate the
internal cellular environment to facilitate replication. Specifically, the ability of
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NP to recruit a number of proteins related to translation cannot be viewed as
circumstantial, and indicates direct involvement in facilitating translation.
Utilising endosomes as a replication centre would isolate viral replication
strategies from several internal surveillance mechanisms. Further
investigation, as discussed below in chapters 5 and 6, is required to establish
whether NP facilitation of translation is direct, or indirect, or indeed both.
In conclusion, LUJV NP-EGFP is able to recruit multiple members of the
translation initiation and subsequent elongation complexes into early
endosomes, forming RTCs independently of other viral proteins. Given the
lack of therapeutics for these viruses, if such a role could be identified in
multiple Arenaviridae family members, novel therapeutic strategies could be
identified.
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5. LCMV infection, purification and analysis of viral
proteome
5.1. Introduction
LCMV is an Old World arenavirus, with a host reservoir organism of the
common house mouse, Mus musculus (Childs et al., 1992; Knust et al., 2014).
The presence of LCMV within this host and the frequent co-habitation of
humans and M. musculus means the likelihood of LCMV transmission to
humans is relatively high. Even though LCMV does not induce clinical signs
in otherwise healthy adults, LCMV is an important global health concern,
especially among the immunocompromised where it can cause cerebral
complications and is often fatal (Wright & Fishman, 2014). In rare cases of
LCMV transmission through solid organ or tissue transplantation, mortality
rates can be 100%, depending on the donated tissue and stage of infection
within the donor (Macneil et al., 2012; Jamieson et al., 2006; Fischer et al.,
2006). LCMV also poses a significant risk to expectant mothers due to the
mild immunosuppression associated with pregnancy, their unborn child, and
during post-natal infections. (Barton et al., 2002; Jamieson et al., 2006;
Noonan et al., 1979; Attar, 2016). Infection in these developmental stages has
been indicated in substantial developmental abnormalities in infants
(Jamieson et al., 2006; Barton et al., 2002). As with all other arenaviruses,
therapeutic options are limited, with therapy restricted to supportive therapy
to combat symptoms as they develop (CDC, 2015). Unlike instances of LASV
infection, ribavirin is not routinely used clinically to treat LCMV infection; partly
due to the rarity of cases and its contraindication during pregnancy and in
children. A campaign for greater awareness of LCMV in paediatric healthcare
centres is growing, with calls for it to be included in the ‘TORCHS’ group of
routinely tested infections in infants and expectant mothers (Bonthius, 2012).
LCMV is of significant research interest in itself, and also holds additional
research value in that it represents an effective model for studying immune
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responses to viral infection in general, with historical implications in the
discovery of the major histocompatibility complex restriction and T-cell
memory (Doherty & Zinkernagel, 1975; Zinkernagel & Doherty, 1974; Lau et
al., 1994). It is also a model for studying the molecular and cellular biology of
arenaviruses, often being described as the prototypic arenavirus (de la Torre,
2009). The OW LCMV is particularly valuable in its role as a surrogate of the
HF-causing viruses LASV and LUJV, due to its ability to be propagated under
less restrictive biological containment conditions. However, the unique
cerebral tropism of LCMV compared to HF arenaviral infections mean that
findings regarding the pathogenesis of LCMV and disease progression may
not be wholly representative of other arenaviral diseases. It is therefore crucial
that studies utilising LCMV in this manner focus on common features between
LCMV and the HF-causing virus in question, in order to ensure LCMV can act
as an effective model of these diseases.
Wild-type LCMV is classified as an ACDP hazard level 3 pathogen, and as
such, its propagation requires containment level 3 (CL3) facilities, this
presents a significant barrier to research progress. However, an attenuated
strain of LCMV known as Armstrong is routinely used in research laboratories
due to its classification as an ACDP CL2 pathogen, allowing fewer
containment restrictions. The Armstrong strain is originally a splenic clone
from an infected mouse; it causes an acute infection which can normally be
cleared within a few days in healthy mice (Chiller & Oldstone, 1984). A
subtype of this strain, termed Armstrong Clone 13, was again a splenic isolate,
but was isolated from a persistently infected mouse (Chiller & Oldstone, 1984;
Wherry et al., 2003). Two single nucleotide changes were identified as being
responsible for chronic vs acute infection outcome in mice; with a mutation in
GP, F260L, and the polymerase L K1079Q responsible for the persistent form
(Matloubian et al., 1990).
In terms of arenavirus molecular biology, one long-standing observation that
remains unexplained is the presence of ribosome-like structures within the
virions of multiple arenavirus species (Pedersen & Konigshofer,
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1976)(Murphy & Whitfield, 1975). The reason for their inclusion and/or their
role in the arenavirus life cycle is poorly understood. There is evidence for NW
arenaviral NPs interacting with components of the translation initiation
complex as well as ribosomal proteins (Baird et al., 2012), consistent with the
presence of ribosome-like structures within the corresponding infectious
virions. In addition, our findings presented in the previous chapter suggest that
the recently discovered OW LUJV NP-EGFP is able to interact with a variety
of cellular translation-associated proteins, and re-distribute them within cells.
Taken together, these data suggest that robust and important interactions
may exist between arenaviral components and the cellular translational
machinery at multiple stages of the arenavirus life cycle. We reasoned that
the identification of translation-associated proteins within infectious LCMV-
Arm particles may help to both better characterise the large ribosome-like
complexes observable by EM and also provide insight as to why they might
be incorporated within virions. In addition, the availability of LCMV-Arm
presented us with an opportunity to examine whether the association between
NP and the translational machinery occurred during a productive virus
infection of living cells.
It was necessary to assess whether LCMV-Arm NP was functionally
analogous to LUJV NP-EGFP in terms of its ability to associate with translation
machinery components. The association of LCMV-Arm NP with the identified
interacting partners of LUJV NP (chapter 4), during both the intracellular and
extracellular phases of the viral life cycle. The abundant presence of specific
cellular proteins within particles, or their association with NP would be
suggestive of a potential role in LCMV infection. In addition to this, the
knowledge that differing members of the OW clade of arenaviral infections
exhibit similar and essential intracellular interactions could provide avenues
for pan-species therapeutic targeting.
Finally, experiments described in this chapter aimed to identify whether
LCMV-Arm NP played a crucial role in the selective translation of viral mRNAs
over those of the host. If LCMV NP appears to mimic the function of LUJV NP,
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it may be possible to infer that certain elements of their fundamental
interactions remain conserved.
5.2. Results
5.2.1. Infection of cells
5.2.1.1. Virus quantification via plaque assay
Prior to performing comparative studies between LCMV-Arm NP and LUJV
NP-EGFP, it was necessary to establish a means to quantify infectious LCMV-
Arm, which would allow quantitative measurement of both virus stocks as well
as provide a quantitative assessment of virus growth and viability. This was
achieved by performing a plaque assay in which Vero cells were infected with
LCMV-Arm, overlaid with CMC-DMEM and incubated for 6 days, after which
plaques were visualised via crystal violet staining. Figure 39 shows plaques
identified, and subsequently used to quantify virus.
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Figure 39. Quantification of LCMV titre via plaque assay
Based on the number of accurately countable plaques in the 10-3 dilution, the
virus titre could be quantified, with the titre found to be 1.3x105 PFU/ml, shown
in the calculation below. This titre can then be used to infect cells at an
appropriate MOI in subsequent analysis.
5.2.2. Purification of virus
After determining viral stock concentration, it was necessary to amplify and
purify LCMV-Arm in order to analyse the LCMV-Arm virion proteome. BHK21
cells were infected at an MOI of 0.001 and 6 days post infection the growth
media was collected, with the LCMV-Arm purification protocol followed as in
2.2.6. Briefly, released virus was PEG precipitated overnight from clarified
media, and then applied to the top of a 5-30% iodixanol gradient prior to
ultracentrifugation at 200,000xg. Following centrifugation, a total of 25
fractions were collected and analysed via silver staining. As shown in figure
40, fraction 24 exhibited the highest concentration of protein - corresponding
to LCMV particles. In addition, the distinct band within fraction 24 corresponds
in approximate size to the 11 kDa Z protein, observable towards the bottom
of the gel, corresponding to the arrow, in figure 40. This fraction was thus
selected for analysis by LC-MS/MS, to determine viral proteome from the
collected fraction. Prior to analysis, infectivity was confirmed via
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Figure 40. Iodixanol gradient purification of LCMV-Arm
5.2.3. Confirmation of infectivity of iodixanol purified LCMV-Arm
As described in the previous section, LCMV-Arm was collected from BHK21
cell supernatant and purified by iodixanol gradient centrifugation. In order to
determine whether the purification procedure yielded infectious LCMV-Arm,
we determined whether these collected fractions contained any infectious
particles by indirect immunofluorescence confocal microscopy using a
monoclonal anti-LCMV antibody specific for the NP of LCMV. Aliquots of 2l
were taken from fractions 21-24, diluted in DMEM, and used to infect BHK21
cells seeded on cover slips. Control samples were mock-infected with fraction
1 from the gradient, in order to show that no viral particles were spread
throughout the gradient. At 24 hrs post infection, cells were fixed,
permeabilised and stained for the presence of LCMV NP. As shown in figure
41 the detection of abundant NP in cells showed all fractions analysed by IF
contained infectious particles, with the fraction 24 showing the most abundant
staining. The lack of NP staining in the mock infected sample indicated that
Silver stain of collected 5-30% iodixanol gradient fractions separated by SDS-PAGE
after LCMV purification. Numbers above lanes indicate the numbered fraction
collected after ultracentrifugation, with 25 being the densest fraction collected.
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viral particles were not spread throughout the gradient. In addition to
confirming infectivity of the purified gradient samples, LCMV-Arm was also
found to generate cytosolic structures similar to those observed under LUJV
NP expression and JUNV infection, with NP staining showing discreet
cytosolic puncta throughout the cytosol.
Figure 41. Immunofluorescence analysis of purified LCMV-Arm infectivity
5.2.4. LC-MS/MS analysis of viral proteome
In the previous sections, infectious LCMV-Arm was purified from BHK21 cells,
via an iodixanol gradient. In order to identify cellular proteins within infectious
LCMV-Arm particles, MS analysis of fraction 24, which contained the highest
level of infectious virus, was performed by Dr Stuart Armstrong at the
University of Liverpool. This analysis was intended to provide an initial library
of virion-associated protein identities, which would guide further examination
of the LCMV-Arm proteome through immunological validation. The fraction
containing LCMV-Arm was inactivated, denatured and processed for MS
analysis. After Mascot analysis (as discussed in 4.1.1), a total of 44 unique
proteins were identified within LCMV particles, and a selection of these and
Immunofluorescence images of BHK21 cells infected with LCMV isolated from a 5-
30% iodixanol gradient. In all images series, cyan indicates DAPI stain, green
indicates LCMV-Arm NP, stained with LCMV NP antibody; scale bar indicates 10μm. 
The identifying number for each image series corresponds with the collected
gradient fraction. Mock infected utilised fraction 1 in order to confirm infectious
particles were not present throughout the gradient.
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their confidence values are shown in table 5, with the complete list available
in Appendix III.
Table 5 Identification of proteins within LCMV particles
The MS analysis detected three of the four viral proteins, namely NP, GP and
Z, which is consistent with their known structural roles in assembled virions
and the known infectivity of the virus-containing fraction 24. The confidence
levels of these three structural proteins is high, with that for NP being the
highest of all detected proteins. The L protein was not identified and this may
be due to the known low abundance of this protein, possibly with only one
copy of L associated with each of the two RNA segments. Of the cellular
proteins detected, it was noticeable that the majority could be grouped into
one of three functional classes – cytoskeletal proteins, cellular chaperones,
and proteins associated with translation machinery. Of those identified, some
were also described in the previous chapter as interacting with LUJV NP-
EGFP, such as HSP70 and Actin.
Nevertheless, it was noteworthy that some of these previously identified LUJV
NP-EGFP interacting partners – such as eIF4A, RPL10 and RPS19 – were
not detected by the LCMV MS analysis. However, the absence of proteins –
as discussed – does not preclude their presence within particles, as
evidenced by the lack of L from the MS dataset. The lack of certain proteins
from the data is most likely due to abundance, with there being only two copies
Table showing the MS identification of selected proteins from an iodixanol gradient
fraction known to contain infectious LCMV particles. Analysis was performed by Dr
Stuart Armstrong at the University of Liverpool. A complete list is available in
Appendix III
Accession
Number Confidence Identifed Protein
P09992 1271.66 LCMV Arm NP
Q711N9 556.35 Actin
P09991 200.2 LCMV Arm GP
P86221 185.54 beta-Tubulin
P86204 152.6 HSP70 2
E2GMU8 72.23 eEF1a
P86237 49.05 HSP70 1
P18541 36.44 LCMV Arm Z
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of L per particle. In addition, the annotation of the Mesocricetus auratus
genome is also limited, therefore certain peptide sequences may not be
characterised, leading to the poor annotation of identified peptides obtained
from LCMV particles generated in BHK21 cells.
5.2.5. Validation of viral proteome
The results presented in the previous section revealed a listing of viral and
cellular proteins that were identified by MS analysis within purified LCMV
particles. In order to independently validate the presence and identities of
these proteins, LCMV-Arm was again purified by iodixanol gradient
centrifugation, and was then probed for the presence of cellular proteins using
specific antibodies. In order to achieve better LCMV purification, the LCMV
purification strategy was modified by the use of a 15-40% iodixanol gradient
in place of the 5-30% used previously. The rationale behind this change was
to position the LCMV-Arm containing fraction nearer to the middle of the
gradient, rather than at its base – as had been achieved previously. It was
reasoned this approach may better separate LCMV from cellular components,
that sediment rapidly towards the bottom of the gradient.
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5.2.5.1. Immunoblotting
Figure 42. WB analysis of purified LCMV-Arm proteome
As described above, the presence of infectious virus could be tracked by
identification of NP by western blotting within aspirated fractions taken from
the gradient following centrifugation, with LCMV NP visualised through the
use of anti-LUJV NP antibodies, as described in 3.2.6.1. After loading onto
the 15-40% iodixanol gradient, the LCMV NP was predominantly concentrated
into fractions 9, 10 and 11 (figure 42), and associated LCMV infectivity of
fraction 11 was confirmed by IF using the anti-LUJV NP antibody, described
in section 3.2.4.
Next, further western blot analysis of fractions was performed using antibodies
specific for a variety of cellular proteins identified by the MS analysis. The
cellular proteins chosen for immunological validation satisfied at least one of
three criteria: firstly, that they were identified by MS analysis with high
Western blot analysis of LCMV-Arm particles, separated on a 15-40% iodixanol gradient.
Lane numbers correspond with collected gradient fractions. In all cases, relevant
antiseruk was used. In the case of LCMV-Arm NP, LUJV NP antiserum was used.
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confidence; secondly, they were known to be associated with, or comprise
components of the cellular translation machinery; or thirdly, they had
previously been identified as interacting partners with related viruses, and
thus had a plausible functional role in the context of the LCMV life cycle. The
cellular chaperone HSP70 satisfied two of these criteria, and thus HSP70-
specific antisera was used to probe fractions. The identification of a 70kDa
band in these peak fractions confirmed the presence of HSP70 in infectious
LCMV particles, with the characteristic double band expected, given the
antibody specificity to not only HSP70, but also HSC70 – as described in
section 4.3.2. Cellular proteins eIF4A and eEF1A were also prime candidates
for immunological validation due to their association with the cellular
translation machinery as well as being previously reported to associate with
LUJV NP, and other arenaviruses. The presence of these proteins within
fractions 8 through 13 was assessed by western blotting using specific
antisera, which again showed the consistent presence of both eIF4A and
eEF1A in all virus-containing gradient fractions. Finally, the presence of
ribosomal proteins RPL10, L26 and S19 was also tested, and western blotting
using specific antisera identified bands of the corresponding molecular weight.
It is noteworthy that RPL26 is present within peak virus fraction 11 in lower
abundance that either RPL10 or RPS19, which may raise doubt over the
specificity of its incorporation into virions. However, the distribution of RPL26
solely within peak fractions 10 and 11, rather than in other fractions that do
not possess any LCMV-Arm NP, provides evidence that it is not a non-specific
contaminant.
Taken together, these validations confirm the presence of multiple cellular
proteins within LCMV virions. These data demonstrate that LCMV-Arm
proteins interact with similar proteins that were previously identified via LUJV
NP-EGFP, indicating that the effect is not limited to only LUJV.
5.2.5.2. Immunofluorescence imaging
In the previous section, cellular factors associated with translational initiation
and elongation complexes, as well as ribosome subunit proteins, were
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identified within LCMV particles. Based on these observations suggested that
LCMV requires components of the cellular translation machinery for its
efficient multiplication inside cells. This hypothesis would predict that during
infection with LCMV, these cellular components would be recruited to sites
where virus multiplication and gene expression were on-going and thus virus
encoded proteins were abundant. One such location is the RTCs that are
proposed to constitute the sites for arenaviral RNA synthesis. In order to test
this prediction, the cellular location of multiple components of the cellular
translation machinery was examined in LCMV-infected cells compared to
mock-infected cells to determine whether redistribution to RTCs had occurred.
Based on the findings of the MS analysis of LCMV virions, the subsequent
immunological validation, as well as the interactome analysis of LUJV NP, a
panel of antibodies specific for cellular translation components was
assembled comprising; eIF1A, eIF4E-PHOS (S209), RPL10a, RPL26 and
RPS11. In addition, cells were counterstained with the generated LUJV NP
antibody (from section 3.2.4), this was due to the poor and expensive
commercial LCMV antibody. eIF4E-PHOS has been implicated in enhanced
5’ cap binding and tumour development (Furic et al., 2010). The potential use
of eIF4E-PHOS in viral infection would allow for increased translational
efficiency and therefore increased copies of viral proteins within an infected
cell.
5.2.5.3. Re-localisation of identified partners to RTC-like structures
during LCMV-Arm infection
In order to establish whether localisation patterns of specific cellular proteins
were altered in response to LCMV-Arm infection, it was necessary to
determine the relative distribution of these cellular proteins against the
distribution of LCMV-Arm NP, visualised by both LCMV antibody and anti-
LCMV NP antibody (3.2.6.1). A549 cells were infected with fraction 11 from
the above (5.2.5.1) purification of LCMV-Arm with mock-infected cells using
the non-infectious fraction 1 as above in figure 41. Figure 43 shows the
relative distribution of a number of cellular factors known to interact with LUJV
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NP-EGFP – with some identified within LCMV particles. The colocalisation
observed between LCMV NP and eIF4E-PHOS in 43B indicates an interaction
with the translation enhancing isoform of the cap binding protein. In addition,
several other translation-associated proteins and ribosomal subunits such as
eIF1A in 43A; RPL10 in 43C; RPL26 in 43D, and RPS11 in 43E were identified
to co-localise alongside LCMV NP in cytoplasmic puncta. As shown for LUJV
NP, ribosomal proteins RPS11, RPL10 and RPL26 all appear to show a
degree of co-localisation with LCMV NP. This observation increases
confidence in the proposal that LCMV NP might interact with these host-cell
factors and subvert their usual function during virus multiplication and relocate
them to sites of viral replication, as well as direct the packaging of these
factors into the virion. As shown in figure 38, puncta of RTC-like structures are
prominent in LCMV-Arm infected cells (figure 41), consistent with the
identified use of early endosomes by LUJV NP-EGFP. In addition, these
LCMV-Arm induced punctate structures resemble those observed with LUJV
NP-EGFP expression and also detected in the course of JUNV infection of
Vero cells (Baird et al., 2012).
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Figure 43. Comparative localisation of LCMV-Arm alongside identified interacting
partners of LUJV NP-EGFP
This section shows the relocalisation of a number cellular translation factors
into punctate structures, closely resembling those theorised to constitute
replication complexes – as observed during JUNV infection and LUJV NP-
EGFP expression.
5.3. Discussion
The data discussed above provide evidence that multiple cellular translation-
associated proteins are packaged within infections viral particles, including
Immunofluorescence analysis of the localisation of cellular proteins against mock-
infected control Vero cells and LCMV NP Infected Vero cells. A shows the localisation
of EIF1A against LCMV NP staining and LUJV NP co-stain – reactive to LCMV NP; B
shows the localisation of EIF4E PHOSPHO; C shows the localisation of RPL10; D
shows the localisation of RPL26; E shows the localisation of RPS11; In A-E, cyan
indicates DAPI staining of DNA; green indicates LCMV NP staining; red indicates the
indicated cellular protein; magenta indicates LUJV NP antisera staining of LCMV NP
and the final image in each series indicates the merge of red and green channels – in
E the merge is between red and magenta (false coloured green), due to the poor
LCMV NP staining.
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eIF4A, eEF1A and constituent protein components of both the 40S and 60S
ribosomal subunits. In addition, a subset of these proteins, as well as other
translation machinery previously identified as being associated with the LUJV
NP-EGFP, were identified as localising with LCMV-Arm NP within infected
cells. In addition, the IP of LUJV NP alongside eIF2G, eIF4A and ribosomal
subunit proteins shown in chapter 4 suggested an interaction between NP and
translation complex proteins. Taken together, these observations provide
compelling evidence for an interaction between arenavirus NPs and
components of the cellular translation machinery in both intra- and
extracellular phases of the virus life cycle.
Evidence of translation associated proteins being sequestered into proposed
sites of RNA replication and viral mRNA translation is not unexpected, given
the need for viral RNA species to be protected from PRRs within the cell in
order to prevent detection from surveillance mechanisms. The knowledge that
LUJV NP alone can re-localise factors into de-facto RTCs suggests that the
NP of both LUJV and LCMV-Arm, besides being involved in RNA binding, to
form an RNP to increase RNA stability, might play a crucial role in viral
replication through a direct involvement in translation.
The number of translation-associated proteins identified within the LCMV-Arm
virions is suggestive of an important role during the initial stages of virus
multiplication, shortly following virus entry. Once RNPs are exposed to the
cytosol after membrane fusion, the rapid transcription and subsequent
translation of viral mRNAs could be achieved through the delivery of host-cell
proteins within the virion. This would then allow for these components to
perform a critical function immediately upon virus entry, without the need for
their recruitment in the initial stages of infection. It does not seem reasonable
to suggest that such a multitude of functionally-related cellular proteins would
be included within viral particles by chance, especially given previous EM-
based evidence that ribosome like-structures are present within arenavirus
particles (Murphy & Whitfield, 1975).
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The presence of eEF1A within the virion (figure 42), in addition to the
previously discussed initiation factor eIF4A, is intriguing. The eEF1 complex
is responsible for the delivery of aminoacylated-tRNAs (aa-tRNAs) into the A
site of a ribosome during the elongation phase of polypeptide synthesis
(Mateyak & Kinzy, 2010). If eEF1A is present within LCMV particles is
associated with ribosomes, these are likely to be assembled in a
translationally ready state, and may be competent to initiate translation
immediately following entry of the virion contents into the infected host cell
through membrane fusion within the maturing endosome. It is possible that
there is a requirement of coupled transcription and translation, whereby an
active ribosome allows for the continual strand elongation of nascent RNA
from the viral polymerase; this coupling has been demonstrated for the
transcription of Bunyamweravirus (BUNV) RNAs (Barr, 2007).
As discussed above, the roles of the eIF4F complex proteins are well
established (Oberer et al., 2005; Linero et al., 2013; Furic et al., 2010;
Lefebvre et al., 2006). The presence of the eIF4A RNA helicase within the
viral particle (figure 42) is also intriguing. If as above for eEF1A, the eIF4A
within virions is associated with ribosomes, these are also likely to be in a
functional state that can perform translation immediately upon entry into a host
cell. Indeed, it is the presence of not just one of these proteins (eIF4A, eEF1A,
RPL10, RPL26 and RPS19), but the combination, which appears to suggest
that translation complexes are packaged within LCMV particles.
The presence of translation initiation and elongation factors, along with
ribosomal subunit proteins within virions leads to the question as to why they
are packaged. The general mechanism of arenaviral mRNA synthesis is
known, with primary mRNA transcription requiring cap-snatching of 5’ mRNA
caps from host mRNAs in order to prime nascent mRNA synthesis. Critically,
this initial transcription occurs on the packaged vRNA templates, however, it
is difficult to see how a ribosome would be beneficial in this context. One
possibility is that transcription and translation is coupled, in a manner similar
to that of BUNV, where the translocation of the 40S ribosome complex
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alongside the active polymerase is required to assist in the elongation of
mRNA transcripts (Barr, 2007). If 40S translocation is blocked, transcription is
prematurely terminated, leading to a loss of viral protein synthesis. This would
explain the presence of ribosomes, seemingly packaged with their associated
translation factors such as eIF4A and eEF1A.
This hypothesis would require that the transcription of mRNA from the
arenaviral genomes is not possible without the presence of an elongating
ribosome. The presence of eEF1A within the virion particle, alongside the
initiation factor eIF4A, is evidence of a potential functional complex. However,
the observations of Leung and Rawls (1977) indicated that ribosomes
packaged within virions were not required for productive arenavirus infection.
These findings were recorded over a 48-hour period, recording plaques
formed after inactivation of temperature sensitive ribosomes (Leung & Rawls,
1977). These findings do not preclude the possibility that infection is still
possible without packaged ribosomes, but that their presence results in initial
enhancement of translation.
A second possible reason for the packaging of ribosomes within virions is that
it represents an efficient mechanism to deliver ribosome complexes into cells
simply to enhance initial translation. The distinct co-alignment of NP with
eIF4E-PHOS within RTC-like structures in infected BHK21 cells is most
interesting, given that phosphorylated eIF4E is known to increase the
efficiency of cap-binding – and thus mRNA expression, and is known to have
a role in tumour development (Furic et al., 2010; Yanagiya et al., 2012;
Scheper & Proud, 2002). The presence of eIF4E-PHOS within RTCs during
LCMV infection could be in part due to the known sequestration of eIF4E by
Z, and its subsequent suppression of cellular translation (Campbell Dwyer et
al., 2000; Kentsis et al., 2001). Z and NP could work in conjunction in order to
establish complete RTCs, however, as LUJV NP-EGFP also exhibited co-
localisation with eIF4E, it is likely that NP in some way utilises eIF4E for
translational enhancement, prior to Z stimulating a shut-off of protein
expression in a manner to stimulate viral replication (Volpon et al., 2010). The
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documented enhancement of mRNA expression in the presence of eIF4E-
PHOS, known to increase protein expression in rapidly multiplying tumour
cells, could similarly play a crucial role in enhancing viral replication. If mRNAs
can be expressed more rapidly, the innate cellular defence mechanisms may
be overwhelmed before they can become fully active.
The lack of ‘free’ NP immediately after infection within cells should prevent the
effective recruitment of translation complexes due to the known association of
NP within RNPs - an association which is still required within cells (Iwasaki et
al., 2015). To this end, for NP to be able to effectively recruit factors in order
to facilitate an exponential increase in translation, to coincide with increases
in mRNA availability, there must be an abundance of free NP. Therefore, there
should be a virally encoded mechanism in order to allow for NP to recruit
cellular factors to the sites of replication.
If virions are able to deliver ribosomes which can immediately initiate
translation upon entry, the availability of NP within the cell would quickly rise,
given the transcription of both NP and L mRNAs from their respective S and
L genome segments. The role of NP in NF-B modulation would be of greater
effect if there was an abundance of free protein available within the cell quickly
(Martínez-Sobrido et al., 2007; Rodrigo et al., 2012).
In conjunction with the delivery of translation associated proteins, the
presence of the chaperone HSP70 within LCMV-Arm particles could indicate
infectious virus particles contain multiple host-cell proteins to aid in different
aspects of protein expression, not simply limited to translation. The delivery of
chaperone proteins alongside other factors could facilitate faster protein
folding – again mitigating potential rate-limiting steps (Dalziel et al., 2014).
HSP70 could also allow for NP to remain in a monomeric state, preventing it
from multimerising and therefore facilitate NP in performing its roles beyond
RNP formation.
The delivery of translation complex proteins and chaperone proteins into cells
along with the genome would allow for fast, efficient translation and
expression upon cell entry. Without the delivery of such factors, it is
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reasonable to assume infection would still be possible, but, the presence of
such factors could increase the rate at which the infection is established within
the cell. Figure 44 shows a working hypothesis for how these factors might be
arranged within an infectious viral particle. The 5’ cap pre-loaded in the L
protein could extend, with the translation initiation complex closely associated,
or potentially coupled, with the primed polymerase.
Figure 44. Diagram depicting cellular proteins included within LCMV-Arm
particles
The arrangement shown in Figure 44 illustrates the complete 40S ribosomal
sub-unit, rather than simply the identified proteins. As the individual roles of
such proteins are not fully understood, the significance of their individual
presence within particles is not possible to determine. Given that
morphological analysis of LCMV and LASV has shown that there are
ribosomal-like structures within particles, the presence of these sub-unit
proteins points towards a full ribosome-like structure within infectious
particles. This would coincide with the hypothesis that such factors are pre-
Diagram illustrating the proposed role of cellular proteins within LCMV particles.
The presence of translation-associated proteins within LCMV particles indicates
a role in infection. This proposed model indicates a ‘pre-loading’ of the viral
particle in order to quickly facilitate infection. The purple, coated with NP (red) line
indicates the viral genome associated in an RNP with NP.
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loaded within infectious particles in order to facilitate rapid translation upon
cell entry. The apparent lower abundance of RPL26 within LCMV particles
compared to the other subunits identified, namely RPS19 and RPL10, could
be explained by a number of means. Most likely, specificity of the antiserum
for RPL26 could be lower than that of RPS19 or RPL10 in the context of
western blots.
Figure 45. Predicted 3’ hairpin of LCMV NP mRNA
Another question remains regarding how arenaviral mRNAs are translated
efficiently. Arenaviral mRNAs are known not to contain a 3’ poly(A) tail but
instead contain a substantial, approximately 46 nucleotide, hairpin loop at the
Diagram showing RNA hairpin structure, predicted to form from the 3’ end of LCMV
NP mRNAs (Meyer & Southern, 1994) using the mfold web server prediction software
(Zuker, 2003).
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3’ end (figure 45) (Meyer and Southern 1993, Meyer and Southern 1994).
Given its 21 base pair length, this could act as a PAMP for Mda5, RIG-I or
PKR, thus triggering NF-κB signalling and a type I interferon 
response(Alexopoulou et al., 2001; Manche et al., 1992; Peisley et al., 2012).
The identified roles of NP as an inhibitor of NF-κB signalling (Martinez-Sobrido
et al. 2006, Pythoud et al. 2012, Rodrigo et al. 2012), it appears incongruous
to expect a virus to trigger an innate immune response, merely to
subsequently subvert it. The 3’ hairpin structure, shown in figure 45, given its
conservation, is likely to play a crucial role in a stage of the virus life cycle. NP
has an already established role in transcription (Tortorici et al., 2001;
Pinschewer et al., 2003), and the data shown in this, and the previous, chapter
suggests that NP also plays an important role in mRNA translation through
the recruitment and sequestration of translation initiation and elongation
factors.
Certain components of mRNA translation complexes are essential, while
others confer efficient translation. As discussed previously, efficient cap-
binding and 43S PIC formation is an essential step in the initiation of
translation (Jackson et al., 2010). The interaction of NP with multiple elements
of this complex is already indicative that the NP of multiple arenaviruses is
important in facilitating the formation of this complex around arenaviral
mRNAs. A separate step that confers efficient translation is that of the
circularisation of mRNA prior to initiation. This circularisation allows for
efficient, stable complexes to form, and therefore can facilitate an increase in
protein expression from any given mRNA molecule (Wells et al., 2012).
Circularisation is aided by the mRNA poly(A) tail present on host transcripts,
and the subsequent binding of this feature by PABP and its ensuing
association with the eIF4F complex scaffold protein eIF4G (Prévôt et al.,
2003). Given that there is no poly(A) tail on the viral mRNAs, the circularisation
of mRNAs via PABP1 interaction with the poly(A) tail would not be possible.
Arenaviruses likely have developed an alternative strategy to enable efficient
translation, and to preserve mRNA stability (Wells et al., 2012; Kahvejian et
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al., 2012; Weill et al., 2012). Given the presence of multiple cellular factors
within viral particles, and the interaction of LUJV NP-EGFP with multiple
translation associated proteins shown above, the evidence suggests NP could
facilitate efficient translation of mRNA.
Figure 46. Diagram depicting possible orientations of arenavirus mRNA
circularisation via NP
Detailed in figure 46 are two proposed models for how NP might facilitate
circularisation and therefore efficient translation of viral mRNAs, through the
identified interacting partners described above in addition to eIF4G. Figure
46A illustrates that NP might substitute the function of PABP, binding to the
dsRNA hairpin and then binding with eIF4G. The affinity of NP for dsRNA is
well established, with LASV NP known to have a strong affinity for dsRNA
(Hastie et al., 2012; Jiang et al., 2013). While the exoribonuclease activity of
multiple arenaviral NPs is well known (Huang et al., 2015; Jiang et al., 2013;
Hastie et al., 2012), it seems evolutionarily illogical for a virus to encode, and
constitutively express, a distinct PAMP with a major role of an encoded protein
simply to remove it. To this end, there may be a second role for such a hairpin
structure, and indeed the affinity of NP for it. The second hypothesis shown in
46B, is fundamentally similar, however rather than NP simply substituting the
function of PABP, NP could bind to the hairpin structure and then
subsequently PABP itself. PABP could then complete the circularisation
through its interaction with eIF4G (Kahvejian et al., 2012).
Diagram indicating two proposals for NP modulation of translation. A: Illustrates NP
substituting PABP to bind eIF4G, facilitating the circularisation of mRNA. B: Illustrates
NP binding to the 3’ hairpin structure of arenaviral mRNAs, with mRNA circularisation
facilitated by binding with PABP. Green colour shows the viral mRNA strand; red NP;
teal cellular initiation factors; and purple showing ribosomal subunits.
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As for the unknown function of particle-associated ribosomes, the exact
mechanism of mRNA translation is unknown, with findings in this chapter and
chapter 4 implicating NP in the efficient translation of mRNA though
generation of replication complexes and the recruitment of translation factors.
In the following chapter, the implications of th direct involvement of NP in
mRNA translation is explored.
In conclusion, this chapter shows the purification of LCMV-Arm via iodixanol
gradient purification, with such a procedure yielding infectious particles.
Subsequent analysis identified multiple cellular proteins that are packaged
within these viral particles – notably eIF4A, eEF1A and 40S and 60S
ribosomal subunit proteins. This chapter also demonstrates that, just as for
LUJV NP-EGFP, BHK21 cells infected with LCMV-Arm exhibit redistributed
cellular proteins into RTCs, indicating that the observations seen for LUJV NP
in chapter 4 are not limited to one OW arenaviral infection, but are more likely
to be a common trait for this clade of infections. Finally, given the conclusions
from this chapter, and chapter 4, two potential models for the role of NP in the
translation of viral mRNAs are proposed. The identified interactions of LUJV
NP-EGFP and LCMV-Arm NP point toward NP facilitating translation and
directly enhancing the expression of viral proteins in order to allow for rapid
infection establishment.
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Functional investigation of the role of LCMV NP in
translation of viral proteins
6.1 Introduction
The conclusions of the previous chapter led us to propose two potential
models that describe the involvement of arenavirus NP in the process of
arenaviral mRNA translation. These models have been constructed on the
basis of four supporting pieces of evidence from ourselves and others: first,
we have shown that arenavirus NP co-precipitates and co-localises in cells
with several functionally-diverse components of the cellular translation
machinery; second, the lack of 3’ poly(A) tails on arenavirus mRNAs suggests
that the canonical interaction between poly(A) binding protein (PABP) and the
3’ poly(A) tail is likely replaced by an alternative protein-RNA interaction.
Thirdly, the arenavirus NP has been previously shown to bind long RNA
hairpin structures such as those found at the arenaviral mRNA 3’ end; and
finally, previous reports from others have identified interactions between other
arenavirus NPs and components of the eIF4F cap binding complex, at the
exclusion of PABP (Linero et al., 2013; Baird et al., 2012). These models,
shown schematically in Figure 46A&B, suggest how arenavirus mRNA
translation might proceed despite the lack of a poly(A) tail, through NP-
mediated mRNA circularisation. According to these models, the arenavirus
NP would facilitate the efficiency of mRNA translation, and consequently
increase the yield of translated protein from viral mRNAs. In the context of a
virus infection, both these models might reasonably be expected to result in
preferential translation of viral mRNAs over those encoded by the host, thus
mediating shutdown of host cell-specific protein synthesis.
As alluded to above, previous studies have suggested that arenavirus mRNA
translation requires interplay between the virus-encoded NP, the 3’
sequences of mRNAs, and components of the host cell translation machinery.
JUNV NP has been shown to interact and exhibit colocalisation with the
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proposed replication centres – RTCs – of eIF4G and eIF4A but not the cap
binding protein eIF4E. It was proposed that NP acted as the cap-binding
protein, substituting eIF4E within the eIF4F complex (Linero et al., 2013).
Previous observations of arenavirus 5’ cap binding also supported NP’s role
as a cap binding protein (Qi et al., 2010). Hantavirus NP has been implicated
in the substitution of the entire eIF4F complex, and thus it is not without
precedent that NP could substitute at least one of the eIF4 complex proteins
(Mir & Panganiban, 2008). However, observations in chapter 5 suggested that
the more efficient cap binding eIF4E-PHOS was present within RTCs during
LCMV-Arm infection at greater levels than the unphosphorylated eIF4E. This
indicates that NP could recruit the more efficient form into RTCs in order to
increase translational efficiency – a divergent mechanism of eIF4F complex
interaction to that proposed previously.
In addition, the work of others has identified mRNA 3’ UTR structures in
several other viruses, such as flaviviruses, bunyaviruses and rotaviruses.
DENV translation initiation appears to revolve around the interaction between
the 3’ and 5’ UTRs, whereby the conformation can bypass cap-dependent
translation when eIF4E is depleted (Edgil et al., 2006). The strategy of
rotavirus mRNA circularisation is similar to our arenavirus proposal (46A) in
that an interaction between a virus-encoded protein and 3’ RNA replaces the
canonical interaction between PABP and the 3’ poly (A) tail. For rotaviruses,
this protein is NSP3, and it is able to interact directly with eIF4G (Vende et al.,
2000) thus mediating mRNA circularization. Bunyamwera virus (BUNV)
similarly generates mRNAs without poly(A) tails; instead they terminate with
a conserved sequence that has the potential to form a strong stem loop
structure, although no cellular or virus-encoded protein binding partner for this
element has yet been identified. Interestingly, during BUNV infection, PABP
is actively removed from the cytoplasm and imported into the nucleus likely
providing or contributing towards an effective mechanism of host-cell
translation shut-off by the protein NSs (Blakqori et al., 2009). In this scenario,
the now abundant cytosolic translation factors are available for sequestration
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by viral factors to enhance viral mRNA translation of poly(A) tail-less mRNAs.
However, how BUNV mRNAs are circularised is still unknown.
A predicted consequence of these viral 3’ mRNA secondary structures, unless
disguised, is that they likely stimulate innate immune activation via cellular
PAMP surveillance mechanisms, and would thus be an undesirable feature
for a virus to generate during infection. However, the paradoxical conservation
of structured 3’ mRNA sequence elements in all known arenaviruses and
many other RNA viruses as described above suggests these structures play
important roles within the respective replication cycles. The benefit of virus
fitness bestowed by these structures likely outweighs their inherent
drawbacks, and contributing to this, it is likely that the ability of viral proteins
to bind these structures in some way masks their dsRNA signatures,
preventing their detection as a PAMP. In this chapter we examine the
possibility that the viral component is NP.
In addition to the 3’ secondary structure, and NP, a third viral component that
could conceivably be involved in translational enhancement is the 5’ mRNA
un-translated region. While not containing any obvious secondary structural
motifs, arenavirus mRNA 5’ UTRs do possess conserved sequences, and
their role in translation has not been established.
In order to test the roles of these three components – NP, 5’ UTR and 3’ UTR
– in the enhancement of arenavirus mRNA translation, a system was
developed that allowed the generation of an arenavirus mRNA that could be
site-specifically modified, and its ability to be translated measured by
detection and quantification of a reporter protein expressed from this mRNA.
Previous findings by others have defined the precise 5’ and 3’ terminal
sequences of arenaviral mRNAs, as well as confirmed the presence of a 5’
cap structure that is used to prime translation (Fechter & Brownlee, 2005) and
propose the formation of the 3’ hairpin loop (Meyer and Southern, 1993). To
this end, using this system it would be possible to see whether deletion of
mRNA sequences or the presence of NP influenced reporter gene expression.
In this experimental design, the reporter protein gene expressed by the
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synthetic arenavirus mRNA was Gaussia luciferase, and the mRNA was
transcribed and co-transcriptionally capped in vitro.
Another central tenet of the models we propose is that the interaction between
the mRNA 5’ and 3’ ends does not require PABP, but does require eIF4G in
order to provide a scaffold for assembly of other eIF4F components, and thus
promote mRNA circularisation. This complete complex could then allow for
the complex to associate efficiently with eIF3E and other elements of the 43S
PIC, and confer efficient translation initiation. Having confirmed the
requirement of the 3’ secondary structure for efficient mRNA translation, it was
necessary to assess whether these cellular components were localised to the
RTCs during an arenavirus infection, which are proposed to be the sites of
viral gene expression and protein synthesis. This was achieved by using IF,
which supported previous work described in chapter 5, which showed
localization of eIF4G within RTCs. These sites of NP are thought to be derived
from early endosomes – as shown by the findings in chapter 4 – and to
constitute replication centres and the sites of arenaviral mRNA translation
(Baird et al., 2012).
The results presented in this chapter suggest that both the 3’ RNA secondary
structural element, as well as a virus protein, likely NP, enhances viral mRNA
translation. In addition, the localisations of cellular proteins involved in
translation are consistent with our proposed models of arenavirus mRNA
circularisation.
6.2 Results
6.2.1 Functional analysis of arenaviral-like mRNA translation
In order to examine the role of RNA sequences in promoting arenavirus mRNA
translation, it was necessary to develop a system in which the characteristics
of a model arenavirus mRNA could be site-specifically modified, and its ability
to be translated measured by detecting expression of a reporter gene. To
establish such a system, a plasmid was designed that would express an RNA
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possessing the 5’ and 3’ un-translated regions of the LCMV-Arm NP mRNA,
surrounding the gene encoding Gaussia luciferase, shown in figure 47.
Figure 47. Diagram depicting constructed arenavirus-like reporter mRNA
This reporter gene was chosen as the corresponding reporter protein is
secreted from cells, enabling a simple and rapid comparison of reporter
expression at multiple time-points.
Figure 48. pMK NPEG plasmid map
Diagram illustrating the synthesised arenaviral-like mRNA, descriptions proceed from
left to right. The green circle illustrates the 5’ ARCA cap (Promega); the first 61
nucleotides of LCMV NP mRNAs preceding the start codon shown in green; Gaussia
Luciferase sequence (genbank AY015993.1) from the start codon until the final codon
before stop codon – shown in gold, with the final 63 nucleotides, including the stop
codon, of LCMV NP mRNA shown in green.
The synthesised NPEG gene was constructed by GeneArt, and inserted into a pMK-
RQ vector. Full NPEG sequence can be found in Appendix I.
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Figure 48 illustrates the constructed plasmid, with the gene – termed
NPEndsGaussia (NPEG) under control of the bacteriophage T7 RNA
polymerase. The plasmid DNA was linearised with SfiI and transcribed in vitro
to generate a run-off RNA transcript, which was co-transcriptionally capped
using an ambion mMessage mMachine kit. RNA was subsequently purified
via a Qiagen RNeasy purification kit, with mRNAs quantified via a
NanoDrop1000 via spectrophometry. To ensure that the 3’ hairpin structure of
arenaviral mRNAs was unadulterated, a hepatitis delta virus (HDV) ribozyme
sequence was incorporated after the final nucleotide of the hairpin loop. The
presence of this HDV ribozyme sequence enabled the self-removal of the
downstream RNA sequence, immediately after the hairpin, such that no
additional non-viral 3’ nucleotides were present (Chadalavada et al., 2007).
6.2.2 Effect of LCMV infection, and presence of NP, on Gaussia
luciferase expression
To establish whether viral proteins, likely NP, were able to enhance the
expression of arenavirus-specific mRNAs, A549 cells were subjected to
lipofectamine-mediated mRNA transfection, and the levels of luciferase
reporter activity secreted into the supernatant was assessed at various time
points post transfection using the chemiluminescent coelenterazine
compound, detected by a fluorescent plate reader. Figure 49 shows that for
cells treated with mRNA transfection alone, the zero hour time point showed
low secreted luciferase, at the same level as the un-transfected negative
controls, and thus was considered to represent background signal. At 2 hours
post transfection, cells transfected with NPEG mRNA showed increased
luciferase secretion, and these levels increased up to a maximum at 6 hours
post transfection. After this time point, secreted luciferase declined, such that
after 12 hours, the luciferase signal was again approaching background
levels. These findings show that the NPEG mRNA acts as a functional mRNA
that can be translated in the absence of any viral proteins. As expected, for
cells mock transfected with mRNA, the levels of secreted luciferase levels did
not increase over the same time period.
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We next assessed whether pre-infection with LCMV had any influence on the
ability of arenaviral-like mRNA to be translated. The models presented in
figure 47 would predict that pre-infection would stimulate luciferase
expression due to the presence of abundant LCMV NP within the infected
cells. In order to provide a sufficient cytosolic pool of NP, cells were pre-
infected for 24 hrs with an MOI of 0.1 prior to mRNA transfection. The results
shown in figure 49 indicate that at early time points of 2 and 4 hours post
transfection, cells treated with both LCMV and NPEG mRNA generated
increased levels of luciferase reporter compared to cells treated with NPEG
alone. Student T-test analysis showed the level of increase at these time
points was significant, although at later time points the differences were either
negligible (Appendix IV, table 5) or insignificant. In addition, the signal
remained at peak levels between 4 and 6 hours. When compared to the
noticeable decline from the peak fraction immediately after the peak fraction
for NPEG alone samples, it would appear that arenavirus like mRNA
degradation within LCMV-infected cells was lower than uninfected cells. As
expected, cells treated with LCMV alone secreted no luciferase. These results
show that LCMV infection stimulates enhanced translation of the NPEG
mRNA, and this finding is consistent with the proposed role of NP, although
further work will need to be done to determine whether the supply of NP alone
is responsible.
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Figure 49. Enhancement of Gaussia luciferase reporter mRNA in presence of NP
6.2.3 Effect on Gaussia Luciferase expression under hRSV infection.
In the above section, LCMV-Arm infection enhanced the expression of a
Gaussia luciferase reporter that was transfected into cells as an arenaviral-
like mRNA, and it was proposed this was due to the expression of a LCMV
protein, likely NP. In order to determine whether the observed translational
enhancement effect was not simply induced as a general cellular response to
a viral infection, hRSV was used to infect A549 cells at MOI 1 for 24 hours
prior to mRNA transfection, with the comparative expression of Gaussia
luciferase (LUC) assessed as described in 6.2.2.1. Figure 50 shows the RLU
detected following NPEG mRNA transfection (green bars), with the trend in
LUC expression showing a steady increase before peaking at 6-8 hours, and
was performed by Hayley Pearson. NPEG transfected cells infected with
HRSV showed decreased NPEG expression compared to cells treated with
NPEG alone. This indicates that the translational enhancement of the NPEG
mRNA is specific to LCMV, and not to virus infection in general.
Graph showing Relative Luciferase Units (RLU) against time post-transfection of
Gaussia expression, from A549 cells. NPEG (green) shows the RLU with only NPEG
mRNA transfected into cells; LCMV-Arm (blue) shows RLU upon only LCMV-Arm
infection; NPEG & LCMV-Arm (red) shows the RLU with NPEG transfection and
LCMV-Arm infection; Control (black) shows the RLU of mock infected/transfected.
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Figure 50. NPEG expression in presence of HRSV
6.2.4 LCMV mRNA 3’ hairpin structure is responsible for efficient
translation through association with NP
In the previous sections, LCMV-Arm was shown to enhance and HRSV shown
to decrease arenaviral-like mRNA translation in A549 cells. In order to
determine whether NP interacts with the 3’ hairpin as proposed, a change was
made to the NPEG plasmid, constructed by Hayley Pearson, generating a 3’
deletion mutant (3’) – the exact sequence alteration is shown in Appendix I,
and demonstrated diagrammatically in figure 51.
Graph showing Relative Luciferase Units (RLU) against time post-transfection of
Gaussia expression, from A549 cells. NPEG (green) shows the RLU with only NPEG
mRNA transfected into cells; HRSV (pink) shows RLU upon only HRSV infection;
NPEG & HRSV (orange) shows the RLU with NPEG transfection and HRSV infection;
Control (black) shows the RLU of mock infected/transfected.
Diagram illustrating the synthesised arenaviral-like mRNA, descriptions proceed from
left to right. The green circle illustrates the 5’ ARCA cap (Promega). Gold indicates
the Gaussia luciferase ORF followed by a stop codon.
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Figure 51. Diagram depicting truncated 3’ reporter mRNA
Figure 52 shows the expression of Gaussia luciferase represented by RLU
from differentially transfected/mock transfected and infected/mock infected
A549 cells, as performed in 6.2.2.1. Cells transfected with NPEG and not
LCMV infected presented a similar expression profile to the NPEG RLU
detection in figure 49. After reaching a peak detection at 6 hours, the signal
declines towards the background at 10 hours post transfection. As observed
previously, LCMV infected and negative samples exhibited background levels
of RLU throughout. The RLU detection of the 3’ and 3’&LCMV samples
behaved identically to the negative samples, with no increase from the
background signal throughout the 10 hours of sample collection. This
indicates that the observed enhancements NP exhibited above are not
observed when the 3’ hairpin structure is absent. The lack of RLU detection
for 3’ samples indicates that the 3’ hairpin structure is essential for the
translation of arenaviral mRNAs, irrespective of the presence of NP or other
viral factors.
Graph showing Relative Luciferase Units (RLU) against time post-transfection of
Gaussia expression, from A549 cells. NPEG (green) shows the RLU with only NPEG
mRNA transfected into cells; 3’  NPEG (purple) shows RLU upon 3’  NPEG
transfection; LCMV-Arm (blue) shows RLU upon only LCMV-Arm infection; 3’  NPEG
& LCMV-Arm (yellow) shows the RLU with 3’  NPEG transfection and LCMV-Arm
infection; Control (black) shows the RLU of mock infected/transfected.
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Figure 52. Lack of enhancement of 3’ NPEG reporter mRNA in presence of NP
6.2.5 Presence of eIF4G and absence of PABP1 in RTCs and RTC-like
structures
After establishing that the translation of arenaviral-like mRNA is enhanced
during infection by LCMV-Arm through a mechanism proposed to be driven
by 3’ hairpin structures and the facilitation of circularisation by NP, it was
necessary to determine whether either of the previously proposed models (fig
42) of circularisation could be correct. The recruitment of the circularisation
components PABP or eIF4G within early endosome-derived sites of viral
translation and replication – RTCs – would provide evidence that a viral factor
aids in the circularisation of mRNA, and therefore contributes to the efficient
expression of viral proteins.
6.2.5.1 Relative localisation of eIF4G and PAPB during LCMV infection
of A549 cells
In order to provide further support for a functional role for NP in translation of
arenavirus-specific mRNAs, it was necessary to establish whether eIF4G, or
eIF4G and PABP1, were present within the theorised sites of viral translation,
RTCs. The relative locations of eIF4G and PABP1 were thus determined
during LCMV infection by IF microscopy, and compared against a mock-
infected control. A549 cells were infected at MOI 0.01 or mock-infected, then
fixed and permeabilised after 36 hours. Cells were then stained with relevant
combinations of primary and secondary antibodies in order to visualise NP
and the corresponding cellular markers. Figure 53 shows the diffuse
localisation of both eIF4G and PABP1 under mock-infected conditions. Under
LCMV-Arm infection, the distribution pattern of eIF4G (53B) shifts, appearing
to co-localise with LCMV RTCs. As other elements of the eIF4F complex were
previously identified as interacting partners of LUJV NP-EGFP and present
within LCMV-Arm induced RTCs and particles, the role of eIF4G as the major
scaffold protein of the eIF4F complex is indicative of organised and regulated
amalgamation of translation factors. The presence of eIF4G in RTCs suggests
that all the components of the eIF4F complex are present within RTCs, when
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taken with the findings shown in chapters 4 and 5. Conversely, the relative
localisation of PABP1 in LCMV-Arm infected A549 cells (53A) compared to
mock-infected cells is unaltered, indicating its absence from RTCs, with no
major evidence of PABP1 protein staining corresponding with that of NP. This
suggests that PABP1 does not have a direct role in the circularisation of
arenavirus mRNAs, and is thus not involved in viral mRNA translation, or a
major role in LCMV-Arm translational enhancement.
Figure 53. Comparative localisation of LCMV-Arm NP against eIF4G and PABP
Immunofluorescence analysis of the relative distribution of PABP1 and eIF4G, against
LCMV-Arm infected and mock infected A549 cells. A indicates the distribution of
PABP1 against mock-infected and LCMV-Arm infected cells. B indicates the
distribution of eIF4G against mock-infected and LCMV-Arm infected cells. In all image
series, cyan indicates DAPI staining of DNA; green indicates LCMV-Arm antisera
staining of LCMV-Arm NP; red indicates cellular protein of interest staining (as stated);
magenta indicates LUJV NP antisera staining of LCMV-Arm NP. In all cases, the
merged image is a composite of green and red channels.
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6.2.5.2 Relative localisation of eIF4G with LUJV NP-EGFP
After establishing the presence of eIF4G within RTCs during LCMV infection,
it was necessary to determine whether this effect was observed when NP was
expressed in isolation from other viral components, or in other words whether
LUJV NP-EGFP specifically could relocalise eIF4G on its own. Identifying a
general effect in more than one OW virus would indicate a potential key role
for NP in the arenaviral translation in general, rather than limited to solely
LCMV-Arm. A549 cells were differentially transfected with LUJV NP-EFP or
EGFP. These cells were then fixed, permeabilised and differentially stained
with anti-eIF4G and PABP1 antibodies, with the relative localisation of eIF4G
and PABP1 subsequently determined via IF microscopy. Figure 54 shows the
localisation of eIF4G within RTC-like structures comprising LUJV NP-EGFP
protein density, a shift from its normal localisation in un-transfected and mock
transfected cells. The presence of eIF4G in these structures suggests that
LUJV NP is responsible for the recruitment of several elements of the
translation initiation complex into RTCs. The localisation of PAPB1 in LUJV
NP-EGFP expressing cells showed a limited degree of co-alignment with
LUJV NP-EGFP compared to the EGFP control, evidence of a potentially
different strategy to that of LCMV-Arm, although the similarities between LUJV
NP and LCMV-Arm NP observed previously indicate that the association of
PAPB1 with LUJV NP-EGFP should be explored further.
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Figure 54. Comparative localistation of LUJV NP-EGFP against eIG4G and PABP
6.3 Discussion
This chapter aimed to explore the role of NP in the translation of viral mRNAs,
and to test a proposed model for how NP might achieve this. Previously
identified interactions of LUJV NP-EGFP, and the subsequent localisation of
such factors within RTCs in LCMV-Arm infected cells, suggested NP had a
role in facilitating translation. This the experiments performed in this chapter
demonstrated that, after infection by LCMV-Arm, the translation of arenavirus-
like mRNAs is enhanced. The identification of these interacting partners within
LCMV infectious particles also supported a model of ‘pre-loading’ of viral
particles in order to facilitate rapid infection establishment within cells, as
illustrated in figure 44.
Figure 46 illustrated our two proposals for efficient viral mRNA expression.
The evidence discussed in chapters 4 and 5 indicated NP facilitates the
formation of potentially functional RTCs. To this end, it is likely that this role is
not limited to the recruitment of translation-associated proteins into RTCs –
as described in chapters 4 and 5. The proposed models present the known
interacting partners of LUJV NP and LCMV-Arm NP – eIF4F complex proteins
and ribosomal subunit proteins – arranged in their orientations corresponding
to how they are thought to operate during eukaryotic mRNA translation. As
Immunofluorescence images showing the relative localisation of LUJV NP-EGFP with A
eIF4G and B PABP1. Cyan shows DAPI staining of DNA; Green shows LUJV NP-EGFP;
Red shows cellular protein staining (as indicated); Magenta shows LUJV NP antibody
staining with the merge images showing both green and red channels. Scale bar indicates
10m.
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discussed previously, PABP1 is required for circularisation of cellular mRNAs,
and thus efficient translation, through association with the major scaffolding
element of the eIF4F complex – eIF4G (Kahvejian et al., 2012; Prévôt et al.,
2003; Jackson et al., 2010). In order for one of these models of viral mRNA
circularisation to be justifiable, the presence of eIF4G or both eIF4G and
PABP1 within RTCs would be necessary. Figure 53 indicates that eIF4G and
not PABP1 is present within RTCs, during LCMV-Arm infection. The absence
of PABP1 suggests that it plays no role in the circularisation of arenaviral
mRNA, whereas the presence of eIF4G mimics that observed under infection
by the NW arenavirus JUNV (Linero et al., 2013). These findings support our
proposal that viral mRNA circularisation is facilitated by the binding of NP to
the 3’ hairpin structure, followed by eIF4G association – as shown in figure
55A, with the non-circularised from in the absence of NP shown in 55B.
Figure 55. Proposed role of NP in circularisation of arenaviral mRNAs
If the proposed role of NP in translation enhancement is correct, then in the
presence of NP there would be an increase in translational efficiency. In order
to test this hypothesis, an arenaviral-like mRNA was synthesised, with 5’ and
3’ elements identical to that of LCMV with an internal reporter, Gaussia
luciferase, enabling quantitative comparison between Gaussia expression in
NP-containing cells and non-NP containing cells. Figure 49 shows the
enhancement of mRNA translation in the presence of NP, through LCMV-Arm
A Diagram illustrating the proposed model for viral mRNA circularisation in the
presence of NP, with all elements of the eIF4F complex present, prior to the release of
associated factors through GTP hydrolysis of eIF5B. B Diagram illustrating the
proposal in the absence of NP. For diagrammatical purposes, not all elements of
initiation complex are shown.
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infection. This observation supports the previous assertions that NP plays an
effective role in translational enhancement, through its interactions with a wide
array of cellular translation factors. While it cannot be included from this
particular observation that NP is solely responsible for this enhancement, the
presence of viral proteins enables increased translational enhancement of
mRNAs lacking a poly(A) tail; possessing a 3’ hairpin structure, identical in
sequence to those found on WT LCMV mRNAs.
In order to assess whether this enhanced translation following virus infection
was specific to infection by an arenavirus, the structurally unrelated HRSV
was also used to co-infect the NPEG transfected cells. HRSV infection did not
provide translational enhancement, suggesting arenaviral mRNA expression
is not simply up-regulated through a non-specific virus infection-related effect.
The lack of any enhancement suggests that the increase in reporter
expression observed under LCMV-Arm infection is due to a specific LCMV
driven event.
In addition, mutation of the NPEG plasmid, generating a 3’ deletion mutant as
shown in figure 51, indicated the importance of the 3’ hairpin in facilitating the
translational enhancement observed previously. The lack of RLU observed
under 3’ transfection not only supports the theory that the 3’ hairpin is a
structure required for efficient translation, but that it is a necessity for the
translation of arenaviral mRNA. The total lack of Gaussia luciferase signal
upon the removal of the 3’ mRNA hairpin structure strongly suggests that
cellular components interact with the 3’ hairpin structure of arenaviral
transcripts, with viral components enhancing this relationship in some
manner.
This chapter has demonstrated that the NP of both LUJV-Arm and LCMV
colocalises with eIF4G and not PABP1 inside RTCs, indicating that arenaviral
mRNAs are circularised via a novel mechanism. Due to the presence of
dsRNA sequences at the 3’ end of viral mRNAs, NP is the most likely viral
protein to interact with dsRNA sequences on mRNAs (Meyer & Southern,
1994; Hastie et al., 2012). Translational enhancement of mRNAs possessing
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3’ hairpins during LCMV-Arm infection indicates that a viral factor does indeed
facilitate efficient mRNA expression – most likely through circularisation by
NP. This novel mechanism of arenaviral protein expression should be
explored in related arenaviruses, with the potential to be exploited by
therapeutics.
As ribosomes have been previously identified as not essential for replication
(Leung & Rawls, 1977), their presence within arenaviral particles has been
largely ignored. The identification of ribosomal subunits within viral particles
in this study alongside a wide array of translation factors, indicated an
involvement in the viral life cycle. As illustrated in figure 44, corresponding
with the findings shown in figure 42, that multiple cellular proteins are
incorporated into LCMV-Arm particles, our proposition is that translation-
associated cellular components are ‘pre-loaded’ within LCMV-Arm particles.
Virally transported ribosomes could then immediately transcribe newly
translated mRNAs after membrane fusion and initial transcription has
occurred. This immediate availability could then confer increased initial protein
expression in order to increase the intracellular levels of viral proteins quickly.
In order to test the activity of these ribosomes, it would be preferable to
inactivate them irreversibly prior to infection in order to compare the protein
expression of WT vs the inactivated state. Temporarily inactivating ribosomes
through treatment with cyclohexamide or similar compounds would not
achieve the desired result, as the effect would subside immediately upon
removal of the inhibitor compound (Schneider-Poetsch et al. 2010). The use
of an irreversible ribosomal inactivating protein (RIP) such as saporin could
establish the required inactivation (Iglesias et al. 1993); however, the
introduction of such an agent into an infectious viral particle would create a
delivery vector for the RIP. Thus it was determined that it would not be
possible establish whether virally-delivered ribosomes have any effect on
establishing infection under the containment facilities available.
The previous findings discussed above enabled the generation of a number
of functional models. Figure 44 proposed the presence of multiple cellular
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translation factors, arranged within infectious LCMV particles to allow for
immediate, potentially coupled, transcription and translation upon cell entry,
within early endosomes – as shown in figure 38 – a proposition not without
precedent given the coupled nature of bunyavirus transcription and translation
(York et al., 2008; Barr, 2007). The presence of such an array of factors within
infectious particles suggests they are unlikely be included by chance, and
were theorised to therefore be important in the context of viral infection.
As discussed above, other viruses possessing 3’ UTR structures within their
mRNAs possess strategies for increasing their translational efficiency through
the 3’UTR and a viral protein co-factor. The NSP3 or rotaviruses is a distinct
example, whereby the interaction of the protein with the 3’ UTR and eIF4G
confers efficient translation of viral mRNAs. Arenaviruses, with their known
and prominent 3’ UTR hairpin, would require a similar strategy, and the
combined findings of chapter 4, 5 and 6 indicate that NP of two OW
arenaviruses aid in the generation of RTCs and the recruitment of translation
associated proteins to them; LCMV-Arm infected cells exhibit an enhanced
translation of arenaviral-like mRNAs and that 3’ hairpin structure of mRNA is
essential for the translation of mRNAs.
This experiments described in this chapter show that LCMV-Arm NP and
LUJV NP co-localising with eIF4G within RTCs and RTC-like structures in
A549 cells, with PABP1 absent from LCMV-Arm RTCs, indicating NP plays a
significant role in mRNA translational efficiency, through mRNA
circularisation. In assessing the proposed model of arenaviral mRNA
translation, A549 cells expressing an arenaviral-like mRNA exhibited a
translational enhancement in cells containing NP. The results presented here
indicate a novel mechanism in arenaviral mRNA translation, through the
interaction of a viral factor, theorised to be NP, circularising arenaviral-like
mRNA through binding with the 3’ hairpin displayed on arenaviral mRNAs.
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The Arenaviridae family are a group of viruses of increasing global
importance. Collectively they are by far the largest cause of haemorrhagic
infections per year, with LASV infection the most prominent, causing in excess
of the 20-50,000 reported deaths per annum. These neglected pathogens
have the potential to cause major outbreaks on a scale similar to the 2013-16
West African Ebola virus outbreak, due to their similar transmission route,
morbidity and symptom profile. Indeed, many presenting cases of severe
febrile illness admitted to Ebola Treatment Units in Sierra Leone were in fact
due to LASV, rather than EBOV (Personal Experience, 2015). The 2014/15
outbreak has highlighted the frailties in healthcare provision within developing
states, and their reliance on overseas aid to manage severe public-health
events. The incidence of emergence of new pathogens is still high, with
several arenaviruses emerging in 2015 alone (Bisordi et al., 2015; Aqrawi et
al., 2015; Lavergne et al., 2015; Witkowski et al., 2015; Gryseels et al., 2015);
this trend highlights the danger that potentially devastating infections could
emerge from isolated population centres.
The need to gain further understanding of highly pathogenic arenaviruses,
along with other neglected tropical diseases, is apparent. There is potential
for a novel pathogenic outbreak in a naïve population with poor healthcare
surveillance leading to more large-scale outbreaks. Lessons learned from the
West African Ebola virus outbreak have highlighted the necessity to have
effective healthcare surveillance in rural communities (Crowe et al., 2015;
Richards et al., 2015; Olugasa & Dogba, 2015), but without effective treatment
strategies there will always be the risk for novel infections to cause more
widespread outbreaks, outside of isolation.
Arenaviral replication strategies are incompletely understood. Identifying the
roles of proteins such as NP in the replication cycle could unlock potential
strategies for therapy. Establishing NP as a protein important in translation
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suggests a novel role for a protein already known to be multi-functional. The
roles of NP in encapsidation, transcription and immune modulation are well
established, but its role in mRNA translation is less so (Tortorici et al., 2001;
Pedersen & Konigshofer, 1976; Martinez-Sobrido et al., 2009).
LUJV NP and LCMV-Arm NP interact with, and redistribute, several
components of translation complexes
The interaction of LUJV NP with translation-associated proteins presented
here illustrates a new insight regarding OW arenaviral replication strategies.
Facilitating translation through factor recruitment alone is of distinct interest.
The ability of LUJV NP to seemingly recruit a number of translation factors
and ribosomes to de-facto RTCs is evidence of NP redistributing cellular
proteins and disrupting the cellular environment beyond previously described
functions. Baird et. al. (2012) reported the establishment of cytosolic
structures in cells during JUNV infection, and the localisation of numerous
cellular factors to these structures suggested their role in replication. In this
study, these so called RTCs have been identified as being derived from early
endosomes (figure 35). The knowledge that LUJV NP generates cytosolic
structures containing a collection of proteins involved in translation - as
observed during JUNV infection - indicates that RTC generation is not limited
to NW pathogens. The ability of NP to hi-jack early endosomes to gather
cellular proteins is interesting, given the lack of other viral proteins to assist in
subverting the cell’s natural defences against such re-organisation. As early
endosomes are the site of viral membrane fusion (York et al., 2008), the
utilisation of these structures by NP is consistent with previous knowledge
regarding the arenaviral life cycle.
LUJV NP-EGFP appears to be able to stimulate re-distribution of a multitude
of cellular translation factors, even with an EGFP tag. Figures 35, 37 & 54,
indicated the redistribution of multiple cellular proteins into distinct cytosolic
puncta. The SILAC MS dataset used primarily to identify potential interacting
partners initially identified three potential avenues – HSP70, actin (along with
other cytoskeletal elements) and eIF4A. All three were identified via GFP-Trap
IPs as valid interacting partners, but the redistribution and co-alignment of
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eIF4A, allied with similar observations for the NW virus JUNV, indicated LUJV
NP may act in a manner similar to its South American cousins (Baird et al.,
2012). Further investigations established that LUJV NP-EGFP could
redistribute a number of cellular proteins into distinct cytosolic structures. The
alignment with several ribosomal proteins, including their immunoprecipitation
via GFP-Trap, also supported these observations.
The subsequent application of these findings to LCMV-Arm NP and the re-
distribution of similar translation factors indicates that this strategy is of
importance to multiple members of the Arenaviridae family. Three separate
viruses exhibit such features – shown in figures 35, 37, 43, 53 & 54, and Baird
et al. 2012 – which suggests that recruitment by NP of translation factors
straddles both NW and OW clades. This evidence led us to propose a model
for NP in translational modulation that conflicts with that proposed by Linero
et al. in 2013. The findings that JUNV NP interacted with eIF4G and eIF4A,
but not eIF4E conflict with the strong correlation of LCMV-Arm NP with eIF4E-
PHOS, as seen in figure 43. The findings presented here suggest a novel
mechanism regarding the role of the arenavirus NP in viral mRNA translation.
Presence of NP enhances viral mRNA translation
Observations presented here also reveal that NP, in conjunction with its
known recruitment of translation-associated complexes, enhances mRNA
translation; most likely in order to enhance virus replication. The proposed
mechanism shown in figure 46 was assessed by establishing whether the
presence of NP generated an enhancement of translation. The increase in
translational efficiency observed demonstrated that the involvement of NP is
not incidental and that this highly multi-functional protein plays crucial roles in
several parts of the viral life cycle. The mechanism underlying this
enhancement is not fully understood, but the findings in figures 49 & 52
support the proposal in figure 55 that NP interacts with the 3’ mRNA hairpin
structure, facilitating circularisation.
The 3’ end of LCMV NP mRNAs has been known for some time to generate
hairpin structures (Meyer & Southern, 1994), with the corresponding
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sequences at the 3’ end of LUJV NP mRNA also predicted to generate a large
27bp hairpin structure, shown in figure 56, with this LUJV NP predicted hairpin
exhibiting 96% canonical base pairing.
Figure 56. Predicted 3’ hairpin on LUJV NP mRNAs
This hairpin structure – as for LCMV – is of great interest. As discussed
previously, it would seem incongruous for a virus to specifically encode and
mFold predicted secondary RNA structure of 3’ LUJV NP (Zuker, 2003). LUJV NP
sequence obtained from GenBank – accession number NC_012776.1.
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display such a significant hairpin structure on mRNA sequences. Double
stranded RNA is a known PAMP for immune surveillance proteins, with
multiple viruses exhibiting strategies to avoid the detection of dsRNA
replication intermediaries (Hastie et al., 2012; Oshiumi et al., 2013; Hale et
al., 2008). The conspicuous presence of the 3’ hairpin within mRNA
sequences poses an intriguing question as to what its function is (Meyer &
Southern, 1994).
The findings of this work indicate a role for NP in translation, and it is thus
proposed that the role of NP could be to enhance mRNA expression, rather
than merely limited to factor recruitment. This proposal was based on NP
interacting with 3’ mRNA hairpins to facilitate mRNA circularisation. In order
to test this hypothesis, an arenaviral-like mRNA was generated, with LCMV
NP sequences at both the 5’ and 3’ ends – shown in figure 47. Translational
efficiency of this arenaviral-like mRNA was increased in the presence of
LCMV-Arm NP against the -NP transfection control. The identification of a
significant enhancement of reporter expression in cells expressing NP
indicated that NP enhances translational efficiency. The model proposed in
Chapter 6, figure 55, was supported by these findings. These findings indicate
a novel role of NP in arenaviral mRNA translation.
Arenaviruses package ribosomal proteins alongside translation
initiation and elongation factors within infectious viral particles.
The enhancement of mRNA translation shown here alone would be of interest,
however, the identification of a multitude of translation factors – all of which
appear to be involved in viral mRNA translation, facilitated by NP – within
infectious viral particles is most intriguing.
As discussed above, the combination of a wide array of proteins identified
within LCMV-Arm particles indicated a role for NP in translation. Pre-loading
of viral particles with translation-associated machinery could potentially
expedite initial infection establishment, as viral proteins could be rapidly
expressed, without the rate-limiting step of recruiting factors in order to allow
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translation to occur. If translation-associated machinery could be deployed
alongside transcribing L, synthesised mRNAs could be translated rapidly.
This coupling could be similar to the closely related Bunyaviridae, whereby
transcription of the genome to form mRNA requires the simultaneous
translocation of ribosomes along nascent mRNA (Barr, 2007). Whilst there is
no evidence to suggest that mRNA synthesis requires the presence of
ribosomes at this time, the presence of multiple cellular proteins within viral
particles, including ribosomal subunits, does indicate an involvement in
replication strategies. The model proposes that the delivery of ribosomes and
their associated initiation and elongation factors (figure 42) will contribute to
efficient and rapid mRNA translation. In all likelihood, given the apparent
interaction of NP with 3’ hairpin structures and the likely mRNA circularisation
as a result, the pre-loading and delivery of translational machinery is likely not
directly coupled to transcription, but a situational efficiency step.
By delivering factors and removing the need for cellular proteins to be
recruited immediately, rapid translation of mRNA could occur, facilitating the
synthesis of increasing copies of viral proteins. This would, in turn allow more
cellular factors to be recruited in order to keep up with the growing
translational demands.
The enhancement of mRNA translation seen in figure 49 supports this theory,
given that, in the presence of NP, overall signal induction is greater, and drops
at a lower rate than the control sample. This might be due to NP being able to
gather all the necessary components in one subcellular location, increasing
efficiency. eIF4E-Phospho has for some time been known to exhibit increased
5’ cap binding efficiency vs un-phosphorylated eIF4E, increasing translational
efficiency as a result, and is contraindicated in tumour development (Furic et
al., 2010). The distinct co-alignment of LCMV-Arm NP with eIF4E-phospho in
RTCs acts as further evidence that NP facilitates translational enhancement.
Arenaviral nucleoproteins exhibit a novel role in establishing an
environment conducive to replication and enhancing translation.
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These findings overall have shown that arenaviral NPs are capable of
orchestrating a significant re-organisation of cellular translation factors, in a
relationship that ultimately increases mRNA translational efficiency. Figures
35, 37, 38, 43, 53 & 54 demonstrate the partial re-distribution of multiple
components of translational machinery was demonstrated, most notably all
subunits in the eIF4F complex. Translational machinery is also demonstrated
to be packaged within viral particles, an observation which suggests that
machinery could be ‘delivered’ to target cells, in order to facilitate rapid
infection establishment, thus removing the need to recruit a huge array of
host-cell factors prior to mRNA translation. Finally, an arenaviral factor
proposed to be NP has also been demonstrated to directly enhance mRNA
translation, potentially through the interaction with large dsRNA hairpin
structures present on the 3’ ends of viral mRNAs – as shown in figures 45 &
56. These observations suggest that NP has a greater role in replication than
previously proposed, through the direct recruitment of translational machinery,
and a proposed enhancement of viral mRNA translation through 3’ interaction
and mRNA circularisation.
Implications of findings
This study has shown that the NP of LUJV and of LCMV-Arm appears to
expedite rapid viral replication through a novel mechanism of circularising the
viral mRNA during the translational process, having first facilitated the
recruitment and redistribution of several translational-associated complexes.
Disruption of these processes may thus be a potential avenue of therapeutic
attack during infection.
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Sequences of LUJV NP-EGFP, his-SUMO-LUJV NP; his-SUMO-










































CTG: Final LUJV NP residue.
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GTG: Initial EGFP residue.
LUJV NP sequence corresponds to accession number NC_012776. EGFP sequence





































TCC: Final SUMO residue.






































TCC: Final SUMO residue.
PICV NP sequence corresponds to accession number AF081555.1


















Yellow – T7 Promoter; GG non viral; Blue – LCMV S seg NP 5’ UTR (; Pink –
Gaussia Lucif; Green – LCMV S seg NP genome 3’ UTR; Grey – HDV
ribozyme; no colour – junk; Sag Paneer – T7 term
LCMV 5’ and 3’ sequences based on sequence corresponding with accession
number AY847350.1, with 3’ sequences corresponding to those observed by
Meyer et. al (Meyer & Southern, 1994). Gaussia luciferase sequence
















Yellow – T7 Promoter; GG non viral; Blue – LCMV S seg NP 5’ UTR (; Pink –
Gaussia Lucif;; Grey – HDV ribozyme; no colour – junk; Sag Paneer – T7 term
3’ NPEG
GenBank accession numbers for sequences used in neiugbour joining
phylogenetic analysis of arenaviruses shown in figure 4:
ALLV CLHP2472 (AY216502, AY012687); AMAV BeAn70563 (AF512834);
BCNV AVA0070039 (AY924390, AY922491), A0060209 (AY216503); CATV
AVA0400135 (DQ865244), AVA0400212 (DQ865245); CHPV 810419 (EU,
260464, EU260463); CPXV BeAn119303 (AY216519, AF512832); DANV
0710-2678 (EU136039, EU136038); FLEV BeAn293022 (EU627611,
AF512831); GTOV INH-95551 (AY358024, AF485258), CVH-960101
(AY497548); IPPYV DakAnB188d (DQ328878, DQ328877); JUNV MC2
(AY216507, D10072), XJ13 (AY358022, AY358023), CbalV4454
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(DQ272266); LASV LP (AF181853), 803213 (AF181854), Weller (AY628206),
AV (AY179171, AF246121), Z148 (AY628204, AY628205), Josiah (U73034,
J043204), NL (AY179172, AY179173); LATV MARU10924 (EU627612,
AF485259); LCMV Armstrong (AY847351), ARM53b (M20869), WE
(AF004519, M22138), Marseille12 (DQ286932, DQ286931), M1 (AB261991);
MACV Carvallo (AY619642, AY619643), Chicava (AY624354, AY624355),
Mallele (AY619644, AY619645), MARU222688 (AY922407), 9530537
(AY571959); MOBV ACAR3080MRC5P2 (DQ328876, AY342390); MOPV
AN20410 (AY772169, AY772170), Mozambique (DQ328875, DQ328874);
NAAV AVD1240007 (EU123329); OLVV 3229-1 (AY216514, U34248); PARV
12056 (EU627613, AF485261); PICV (K02734), MunchiqueCoAn4763
(EF529745, EF529744), AN3739 (AF427517); PIRV VAV-488 (AY216505,
AF277659); SABV SPH114202 (AY358026, U41071); SKTV AVD1000090
(EU123328); TAMV W10777 (EU627614, AF512828); TCRV (J04340,





SILAC MS IP interactome analysis of EGFP and LUJV NP-EGFP
Protein













[Lujo virus] 12 1.95E-43 NaN NaN 0 1385400 14801000
A6NFI3 Zinc finger protein 316 1 0.0071437 2.5558 0.69218 50811 322060 230000
O00148
ATP-dependent RNA
helicase DDX39A 2 2.99E-05 NaN NaN 0 0 930870
O00159 Unconventional myosin-Ic 10 4.09E-26 NaN NaN 0 0 2953100
O15116
U6 snRNA-associated Sm-
like protein LSm1 1 0.037709 NaN NaN 5368400 0 0
O15144
Actin-related protein 2/3
complex subunit 2 1 0.014107 NaN NaN 0 0 0
O15260 Surfeit locus protein 4 1 0.030274 NaN NaN 0 0 212770
O15523
ATP-dependent RNA
helicase DDX3Y 3 4.49E-06 NaN NaN 0 0 570670
O43175
D-3-phosphoglycerate
dehydrogenase 4 6.70E-33 1.2142 1.0342 204290 171100 2382900
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O43707 Alpha-actinin-4 2 0.00058141 NaN NaN 0 0 163280
O43795 Unconventional myosin-Ib 3 6.76E-07 NaN NaN 0 0 1659000
O43813 LanC-like protein 1 1 0.0013375 NaN NaN 0 0 356150
O60361
Putative nucleoside
diphosphate kinase 2 3.58E-05 0.62651 0.59043 52348 35229 424140
O60506
Heterogeneous nuclear
ribonucleoprotein Q 1 0.00044816 NaN NaN 0 0 163170
O60884
DnaJ homolog subfamily A
member 2 1 0.011885 NaN NaN 0 0 109910
O75323
Protein NipSnap homolog
2 1 0.01752 NaN NaN 0 439250 0
O94832 Unconventional myosin-Id 18 2.36E-54 NaN NaN 0 0 8499000
O94905 Erlin-2 2 2.78E-06 NaN NaN 0 666610 0
O95831
Apoptosis-inducing factor
1, mitochondrial 4 3.26E-11 NaN NaN 0 0 604610
P00330 Alcohol dehydrogenase 1 9 4.89E-25 NaN NaN 9163300 0 0
P00338
L-lactate dehydrogenase A




mitochondrial 1 0.00079264 NaN NaN 0 0 258170
P00558
Phosphoglycerate kinase





aldolase A 8 4.89E-26 1.0899 0.99837 181280 245480 3525000
P04406
lyceraldehyde-3-










subunit alpha-1 2 4.81E-09 1.246 0.73396 49358 75710 404490
P05109 Protein S100-A8 2 5.60E-05 NaN NaN 479430 0 0
P05141 ADP/ATP translocase 2 4 1.42E-13 0.38364 0.27351 961580 702380 1816200
P05388
60S acidic ribosomal
protein P0 4 6.52E-12 1.2319 1.6088 100010 201850 3003700
P05455 pus La protein 3 1.39E-18 0.90389 1.1375 79991 133230 780200
P06576
ATP synthase subunit
beta, mitochondrial 5 5.36E-15 0.18097 0.071425 10289000 319070 1276400
P06733 Alpha-enolase 9 6.94E-55 0.78425 0.74893 1120500 1134600 7081400
P06748 ucleophosmin 2 1.88E-07 1.5289 1.796 128560 238470 2945600
P07195
L-lactate dehydrogenase B
chain 9 6.26E-28 0.68318 0.90323 847710 531260 5948600
P07355 Annexin A2 4 2.33E-13 1.8488 0.37351 138030 766610 1095400




Heat shock protein HSP
90-alpha 16 6.38E-75 1.095 1.0118 778150 958780 7292100
P07910
Heterogeneous nuclear
ribonucleoproteins C1/C2 2 1.37E-06 NaN NaN 0 0 329710
P08107
Heat shock 70 kDa protein
1A/1B 14 2.68E-94 2.1893 1.3326 2323600 6790300 22955000
P08133 Annexin A6 6 5.75E-14 NaN NaN 0 1549800 482830
P08195
F2 cell-surface antigen
heavy chain 1 0.00055029 NaN NaN 0 0 185580
P08238
Heat shock protein HSP
90-beta 17 2.49E-104 1.0009 0.9378 2760000 3860400 18920000




subunit alpha 1 0.018091 NaN NaN 0 0 182380
P08758 Annexin A5 1 0.0059068 NaN NaN 0 0 347870
P08865 40S ribosomal protein SA 2 2.05E-08 NaN NaN 0 0 802460
P09651
Heterogeneous nuclear
ribonucleoprotein A1 3 1.80E-16 2.1637 1.1898 22142 109280 806980
P09661
U2 small nuclear
ribonucleoprotein A 2 5.55E-07 0.36891 0.3364 81347 109240 481330
P09874
Poly [ADP-ribose]
polymerase 1 1 1.69E-05 NaN NaN 0 0 408210




60 kDa heat shock protein,
mitochondrial 6 3.49E-36 1.3638 0.71148 1298100 2377200 4906500
P11021
78 kDa glucose-regulated
protein 8 4.04E-40 0.92944 0.43071 2036300 493400 1771500
P11142
Heat shock cognate 71
kDa protein 19 1.82E-140 1.9749 1.238 6556500 12155000 35096000
P11532 ystrophin 1 0.0025418 NaN NaN 6057600 0 0
P11586
C-1-tetrahydrofolate
synthase, cytoplasmic 1 0.0077035 NaN NaN 0 0 96828
P11940
Polyadenylate-binding
protein 1 4 3.82E-12 NaN NaN 0 0 1326500
P12268
Inosine-5-monophosphate
dehydrogenase 2 1 0.00089879 NaN NaN 0 0 463590
P12277 Creatine kinase B-type 3 2.92E-08 0.67959 1.0187 137720 190930 1642500
P12956
X-ray repair cross-
complementing protein 6 2 3.95E-05 NaN NaN 0 0 210210
P13010
X-ray repair cross-
complementing protein 5 1 0.033143 NaN NaN 0 0 0
P13639 longation factor 2 14 3.34E-42 0.8134 0.93243 744160 819830 8101300
P13797 Plastin-3 1 0.015139 NaN NaN 0 0 149880
P14174
acrophage migration
inhibitory factor 2 5.86E-06 NaN NaN 331570 0 211640
P14618
Pyruvate kinase isozymes
M1/M2 6 4.55E-16 0.75999 0.7908 202230 166320 2099800
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P14625 Endoplasmin 3 2.22E-11 NaN NaN 0 0 536950
P14868
Aspartate--tRNA ligase,
cytoplasmic 2 0.00010136 NaN NaN 0 0 355250
P14923 Junction plakoglobin 2 0.00014268 NaN NaN 398360 0 0
P15880 0S ribosomal protein S2 3 1.68E-10 NaN NaN 0 0 728490
P17066
Heat shock 70 kDa protein
6 6 5.32E-48 NaN NaN 0 0 1621000
P17844
Probable ATP-dependent
RNA helicase DDX5 5 1.24E-12 1.1928 1.3813 115180 228750 1687100
P17987
T-complex protein 1
subunit alpha 19 5.07E-73 7.2754 3.029 84553 1821400 14344000
P18077
60S ribosomal protein
L35a 1 0.015747 NaN NaN 0 0 109660
P18124 0S ribosomal protein L7 2 2.12E-05 NaN NaN 0 0 797210
P18621 60S ribosomal protein L17 1 0.0066318 NaN NaN 0 0 86397
P19105
Myosin regulatory light
chain 12A 1 0.0036507 NaN NaN 0 0 1021800
P19338 Nucleolin 6 1.41E-22 0.51881 0.49505 627790 377260 3410800
P20929 Nebulin 1 0.0047187 NaN NaN 3074600 0 0
P21796
Voltage-dependent anion-
selective channel protein 1 2 5.58E-06 NaN NaN 0 1153300 0
P22626
Heterogeneous nuclear





and glutamine-rich 14 1.73E-54 NaN NaN 0 0 30277000
P23396 0S ribosomal protein S3 8 1.65E-33 0.74082 1 627100 267880 3761300
P23528 Cofilin-1 3 2.52E-09 NaN NaN 0 0 1921000
P25705
ATP synthase subunit
alpha, mitochondrial 9 6.01E-87 0.7528 0.34238 3221900 1116600 2379600
P26373 60S ribosomal protein L13 3 4.27E-08 NaN NaN 0 0 1535200
P26599
Polypyrimidine tract-
binding protein 1 2 4.51E-05 NaN NaN 0 0 237230
P26641
Elongation factor 1-
gamma 2 2.34E-10 0.90816 1.1409 180960 268430 1308600
P27348 14-3-3 protein theta 3 2.69E-06 NaN NaN 0 0 0
P27635 60S ribosomal protein L10 2 1.87E-05 1.4225 1.5385 18562 30080 383390
P27824 Calnexin 4 1.83E-22 1.141 0.60868 271400 453780 1592700
P28288
ATP-binding cassette sub-
family D member 3 1 0.036281 NaN NaN 0 0 0
P28289 Tropomodulin-1 1 0.032546 NaN NaN 0 0 65091
P30041 Peroxiredoxin-6 1 0.011617 NaN NaN 0 0 194410
P30049
ATP synthase subunit
delta, mitochondrial 1 0.00023439 NaN NaN 244690 0 0





phosphatase 2A 65 kDa
regulatory subunit A alpha
isoform 1 0.0014952 NaN NaN 0 0 99268
P31689
DnaJ homolog subfamily A
member 1 1 0.00030598 NaN NaN 0 0 194700
P31944 Caspase-14 1 0.00017719 NaN NaN 0 0 0
P31947 14-3-3 protein sigma 3 2.70E-06 0.74038 0.89705 73372 71496 369530
P31948
Stress-induced-
phosphoprotein 1 3 1.20E-07 0.33873 0.33194 59710 17269 354250




mitochondrial 4 1.34E-10 2.0119 1.6623 55332 153090 1314000
P34932
Heat shock 70 kDa protein
4 1 0.00035539 NaN NaN 0 0 313400
P35232 rohibitin 1 0.0028581 NaN NaN 0 0 190550
P35268 60S ribosomal protein L22 3 2.89E-13 0.28814 0.25022 144210 75081 543420
P35520 ystathionine beta-synthase 1 0.0041126 NaN NaN 0 0 57129
P35579 Myosin-9 70 0 3.2353 9.9984 167240 542150 78072000
P35580 Myosin-10 52 2.57E-246 NaN NaN 0 0 30107000






catalytic subunit 2 0.0001022 NaN NaN 0 0 356940
P38646
Stress-70 protein,
mitochondrial 4 6.36E-12 NaN NaN 449510 0 974000
P38919
Eukaryotic initiation factor
4A-III 2 6.45E-07 NaN NaN 0 0 152090
P39019 40S ribosomal protein S19 3 3.00E-07 1.3208 1.5959 51723 81103 1013700






kDa subunit 1 0.0049495 NaN NaN 0 0 287330
P40227
T-complex protein 1
subunit zeta 14 3.22E-49 6.4889 2.8557 535080 4870400 19104000
P40926
Malate dehydrogenase,
mitochondrial 2 0.00037261 NaN NaN 0 0 510030
P45880
Voltage-dependent anion-
selective channel protein 2 2 4.37E-09 4.9879 0.41194 53620 530850 141800
P46777 0S ribosomal protein L5 6 3.08E-13 NaN NaN 0 0 1624100
P46778 60S ribosomal protein L21 1 0.0049021 NaN NaN 0 0 875630
P46779 60S ribosomal protein L28 1 0.0073929 NaN NaN 263170 0 0
P46782 0S ribosomal protein S5 1 1.29E-10 NaN NaN 0 0 1726200
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P46783 40S ribosomal protein S10 2 9.60E-05 1.2633 1.6716 56898 84267 983380
P47914 60S ribosomal protein L29 1 1.01E-10 0.39905 0.86743 88133 44291 446790
P48643
T-complex protein 1
subunit epsilon 13 4.59E-39 NaN NaN 0 2422000 12966000
P49368
T-complex protein 1
subunit gamma 14 3.78E-45 6.9248 2.7664 413180 4783400 10439000
P49411
Elongation factor Tu,




10 1 0.0031442 NaN NaN 0 0 0
P50914 60S ribosomal protein L14 1 0.00011154 NaN NaN 0 0 765350
P50990
T-complex protein 1
subunit theta 26 2.02E-99 7.044 2.7919 496550 5909800 26036000
P50991
T-complex protein 1
subunit delta 16 8.28E-74 6.2234 2.5249 1117300 9851800 18270000
P51572
B-cell receptor-associated
protein 31 4 1.35E-07 1.2351 0.4969 496130 156880 691600
P52179 Myomesin-1 1 0.0042913 NaN NaN 0 0 5696300
P52272
Heterogeneous nuclear
ribonucleoprotein M 7 8.08E-25 0.84575 0.87184 129620 122690 1884000
P52907
F-actin-capping protein





transporter 1 3 2.71E-08 NaN NaN 0 0 1714600
P54577
Tyrosine--tRNA ligase,
cytoplasmic 1 0.0098503 NaN NaN 0 0 0
P55060 Exportin-2 1 0.013963 NaN NaN 0 0 188930
P55072
Transitional endoplasmic
reticulum ATPase 2 1.38E-05 0.91366 1.2746 28152 54409 377210
P55084
Trifunctional enzyme
subunit beta, mitochondrial 1 0.037102 NaN NaN 0 0 0
P55795
Heterogeneous nuclear
ribonucleoprotein H2 1 8.16E-06 NaN NaN 0 0 565120
P59998
Actin-related protein 2/3
complex subunit 4 1 0.0012306 NaN NaN 0 0 0
P60174
Triosephosphate
isomerase 2 1.18E-13 NaN NaN 0 0 499880
P60660 Myosin light polypeptide 6 7 2.55E-19 NaN NaN 0 0 5742600
P60842
Eukaryotic initiation factor
4A-I 5 1.46E-16 0.75834 0.94091 176150 214840 1758100
P60953
Cell division control protein
42 homolog 1 0.016719 NaN NaN 0 0 112870
P61158 Actin-related protein 3 3 7.51E-07 NaN NaN 0 0 582160
P61247 40S ribosomal protein S3a 3 3.81E-10 1.4965 2.9661 12220 32449 860630
P61254 60S ribosomal protein L26 4 1.18E-10 1.5074 2.2099 32424 58285 1914900





L37a 1 1.69E-05 NaN NaN 152280 0 0
P61604
10 kDa heat shock protein,
mitochondrial 1 6.90E-07 NaN NaN 465970 0 0
P61978
Heterogeneous nuclear
ribonucleoprotein K 2 1.22E-07 NaN NaN 0 0 1408100
P61981 14-3-3 protein gamma 3 2.64E-06 NaN NaN 0 0 47379
P62195
26S protease regulatory
subunit 8 1 0.017487 NaN NaN 0 0 187760
P62249 40S ribosomal protein S16 3 4.81E-08 0.8428 1.1157 44867 46831 758760
P62258 14-3-3 protein epsilon 3 3.13E-06 NaN NaN 0 0 274930
P62277 40S ribosomal protein S13 2 1.28E-11 0.88541 1.0779 242540 285250 1511200
P62280 40S ribosomal protein S11 2 0.00025699 NaN NaN 0 0 490190
P62424 60S ribosomal protein L7a 1 0.0020585 NaN NaN 0 0 665860
P62701
40S ribosomal protein S4,
X isoform 4 7.96E-11 NaN NaN 0 0 2112500
P62753 0S ribosomal protein S6 3 4.43E-07 NaN NaN 0 0 1355600
P62805 stone H4 1 0.0022684 NaN NaN 147460 0 0
P62826
TP-binding nuclear protein
Ran 2 2.85E-07 1.2363 0.57936 124360 209820 391840
P62829 60S ribosomal protein L23 2 0.00026706 1.3332 0.91427 54660 94805 773160
P62851 40S ribosomal protein S25 2 1.02E-05 NaN NaN 0 0 902610





L10a 1 0.0019691 NaN NaN 0 0 404960
P62913 60S ribosomal protein L11 3 2.97E-56 2.7353 2.1879 142330 438650 1819300
P62917 0S ribosomal protein L8 2 3.58E-05 NaN NaN 0 0 2003300
P62937
Peptidyl-prolyl cis-trans
isomerase A 2 0.00010342 NaN NaN 0 0 956050
P62987
Ubiquitin-60S ribosomal
protein L40 3 8.91E-28 0.58509 0.78138 947290 2180700 4241000
P63104 14-3-3 protein zeta/delta 4 1.61E-08 NaN NaN 0 0 1599000
P67809
Nuclease-sensitive
element-binding protein 1 1 1.63E-05 NaN NaN 0 0 219170
P68133
Actin, alpha skeletal
muscle 13 3.23E-107 2.8824 7.6779 543620 1498500 20792000
P68371 Tubulin beta-4B chain 8 5.32E-40 0.98747 0.99468 293370 325730 1199100
P78371
T-complex protein 1
subunit beta 20 5.42E-105 5.6687 2.2561 842360 6889700 21806000
P78426 Homeobox protein Nkx-6.1 1 0.0096283 NaN NaN 482520 0 0
P81605 ermcidin 1 0.0012778 NaN NaN 948600 0 0
P83731 60S ribosomal protein L24 2 7.32E-06 NaN NaN 0 0 781700
P84085 ADP-ribosylation factor 5 1 0.0039433 NaN NaN 0 0 203080
Q00839
Heterogeneous nuclear
ribonucleoprotein U 2 2.57E-05 2.6264 1.1759 41749 224340 304260
Q01469
Fatty acid-binding protein,
epidermal 1 0.005731 NaN NaN 160840 0 0
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Q02413 Desmoglein-1 2 5.85E-05 NaN NaN 530590 0 0
Q02543
60S ribosomal protein
L18a 1 0.00050872 NaN NaN 0 0 348750
Q02790
Peptidyl-prolyl cis-trans
isomerase FKBP4 1 0.03161 NaN NaN 0 0 101890
Q02878 0S ribosomal protein L6 1 0.00027608 NaN NaN 0 0 0
Q06830 Peroxiredoxin-1 3 2.19E-11 0.47735 0.54294 350050 266860 1798400




protein, mitochondrial 1 1.89E-08 NaN NaN 263950 0 0
Q08188
Protein-glutamine gamma-
glutamyltransferase E 2 0.00058225 NaN NaN 183820 0 0
Q0D2K2 Kelch-like protein 30 1 0.024261 NaN NaN 454900 0 0
Q12792 Twinfilin-1 1 0.00024424 NaN NaN 0 0 238700
Q12905
Interleukin enhancer-
binding factor 2 1 0.0023142 NaN NaN 0 0 352010
Q13162 Peroxiredoxin-4 2 1.93E-07 NaN NaN 0 0 173580
Q13283
Ras GTPase-activating
protein-binding protein 1 1 0.0074658 NaN NaN 0 0 274210
Q13310
Polyadenylate-binding





ribonucleoprotein D0 1 0.0001989 NaN NaN 0 0 492080
Q14140
SERTA domain-containing
protein 2 1 0.027867 NaN NaN 5129100 0 0
Q14697
Neutral alpha-glucosidase
AB 1 0.0016445 1.4999 0.85036 40337 64412 144770
Q14974 Importin subunit beta-1 3 5.16E-08 NaN NaN 0 0 701470
Q15084
Protein disulfide-
isomerase A6 3 3.66E-10 2.5558 0.69218 50811 322060 868310
Q15233 Non-P 12 9.44E-53 0.72151 6.4697 140930 126650 24313000




polymerase I subunit C 1 0.026831 0.33259 0.10911 4043200 2308000 2371500
Q15758
Neutral amino acid
transporter B(0) 2 1.36E-05 NaN NaN 0 0 581110
Q16563
Synaptophysin-like protein
1 1 0.0020673 NaN NaN 0 0 326310
Q16576
Histone-binding protein
RBBP7 1 0.0098765 1.352 0.94173 15801 27959 89772




2 subunit 3-like protein 1 0.01249 NaN NaN 0 0 120050
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Q3SYG4 Protein PTHB1 1 0.013167 1.8233 1.3174 331400 834590 2500800
Q562R1 Beta-actin-like protein 2 7 5.93E-50 NaN NaN 0 0 69915000
Q58FF8
Putative heat shock
protein HSP 90-beta 2 6 3.10E-17 NaN NaN 0 0 507560
Q5THK1 Protein PRR14L 1 0.016542 NaN NaN 592250 0 0
Q5VTE0
Putative elongation factor
1-alpha-like 3 7 1.08E-43 0.95943 0.91038 4274600 4205800 21289000
Q684P5
Rap1 GTPase-activating
protein 2 1 0.041051 NaN NaN 1502300 0 0
Q6NXT2 istone H3.3C 1 0.014121 NaN NaN 161710 0 0
Q86TJ2
Transcriptional adapter 2-
beta 1 0.013113 NaN NaN 2142600 0 0
Q86WA8
Lon protease homolog 2,
peroxisomal 1 0.03869 NaN NaN 0 0 996110
Q8IWC1
MAP7 domain-containing
protein 3 1 0.038695 NaN NaN 0 0 180080
Q8IZP2 Putative protein FAM10A4 1 0.012812 NaN NaN 0 0 107450
Q8N960
Centrosomal protein of




protein 3 2.31E-24 0.96584 1.7466 70836 103170 984980
Q92485
Acid sphingomyelinase-
like phosphodiesterase 3b 1 0.0091832 NaN NaN 0 94595 0
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Q92504 Zinc transporter SLC39A7 1 0.013713 5.1273 24.732 11893 64673 1402300
Q92734 rotein TFG 2 1.52E-09 NaN NaN 0 0 1279200
Q92841
Probable ATP-dependent
RNA helicase DDX17 4 5.30E-12 NaN NaN 0 0 101600
Q96KD3 Protein FAM71F1 1 0.01615 NaN NaN 938570 0 0
Q99623 Prohibitin-2 1 2.00E-05 0.67946 0.23133 291060 231880 427100
Q99832
T-complex protein 1
subunit eta 12 2.99E-48 8.0658 3.3106 561950 2619400 12316000








9 1 7.49E-08 NaN NaN 0 0 221480
Q9C0B2
Uncharacterized protein
KIAA1751 1 0.0061334 0.92596 0.91981 63021 143410 305410
Q9H489
Putative testis-specific Y-




beta-4 1 0.0039972 NaN NaN 0 0 216690
Q9NYL9 Tropomodulin-3 1 0.0015437 NaN NaN 0 0 243430
Q9NZI8
Insulin-like growth factor 2






protein] dehydratase 3 1 0.00026613 NaN NaN 0 0 186260




homolog 1B 1 0.01525 NaN NaN 0 0 82763
Q9UG63
ATP-binding cassette sub-
family F member 2 1 0.016292 NaN NaN 0 0 34830
Q9UHB6
LIM domain and actin-
binding protein 1 11 2.08E-26 NaN NaN 0 0 5240000
Q9ULV4 Coronin-1C 14 1.61E-37 3.2517 12.324 29349 117870 20424000
Q9UM54 Unconventional myosin-VI 5 2.68E-10 NaN NaN 0 0 761200
Q9UQ80
Proliferation-associated
protein 2G4 4 1.79E-10 NaN NaN 0 0 2040000
Q9Y265 RuvB-like 1 1 0.015002 NaN NaN 0 0 293060
Q9Y3I0
tRNA-splicing ligase RtcB













P09992 35 1271.66 Nucleoprotein 95913946.2
Q711N9 15 556.35 Actin, cytoplasmic 1 18381609.14
A9XDF3 14 426.14 Serine protease 5099672.694
G8IFB9 14 326.67 Clathrin heavy chain 1462694.652




P86221 5 185.54 Tubulin beta-4B chain 2522698.128
Q91Y69 6 174.58 Matrix metalloproteinase-2 26967677.16
P97279 7 156.13
Inter-alpha-trypsin inhibitor
heavy chain H2 5101193.058
P86204 5 152.6
Heat shock-related 70 kDa
protein 2 3110992.727




C0HJG9 5 115.57 Annexin A2 999802.9267
P86234 5 113.86 Tubulin alpha-3 chain 3144298.408
E2GMV3 3 104.32 Milk fat globule-EGF factor 8 8697570.245
Q925Q6 2 97.01
Tissue inhibitor of matrix
metalloproteinase-2 17757786.88
Q80Z94 3 91.98 Gap junction protein 1579046.793
D0G7D9 4 87.42
Collagen type VI alpha 3
subunit 927789.7218






heavy chain H3 2205684.314
E2GMU8 3 72.23
Eukaryotic translation
elongation factor 1 alpha 2216206.695
P86246 2 69.25





T-complex protein 1 subunit
beta 1236180.263
P02544 2 50.29 Vimentin 122132.0219
P86237 2 49.05
Heat shock 70 kDa protein 1-
like 255273.7396
B6V7E0 2 47.37 Decorin 6957576.72
P01945 2 46.58 Hemoglobin subunit alpha 12319848.96
D0G6X1 2 46.58
Collagen type VI alpha 1
subunit 872339.4204
P70110 2 41.88 Platelet glycoprotein 4 218104.4245
P86247 2 38.9 Keratin, type II cytoskeletal 8 5537907.721
P18541 2 36.44 RING finger protein Z 2520837.402
Q60546 1 31.81 Coagulation factor X 517630.2584
Q5KTJ7 1 27.72 Ras-related protein Rab-3B 108930.9741
P86208 1 26.2
T-complex protein 1 subunit
alpha 169559.7865
Q60522 1 25.18 CD44 antigen 365024.1273
K7WL83 1 25.04 Beta-globin 118395069.6
A6YF56 1 24.77 Serum albumin 4280235.095
Q8VIB7 1 23.29 Attractin 12779869.83
Q7M090 1 23.03 Annexin II 971075.2667
P97277 1 22.41 Alpha-1-antitrypsin 1187194.317
Q5KTJ6 1 22.25 Ras-related protein Rab-13 352767.1339
P13540 1 22.01 Myosin-7 327422.7109
Q7M0B0 1 21.33 Alpha-1-inhibitor III 4374146.615




Table showing the total values for RLU detection.
P value
Time (h) 1 2 3 1 2 3 1 2 3 1 2 3 NPEG : NPEG& LCMV
0 18315 20525 20885 19840 19490 18465 18480 18980 21330 19290 22100 21730 0.806417
2 31465 27030 30590 19030 18930 21245 40925 37760 33300 20085 20045 20390 0.0422957
4 57535 56020 53370 17755 18310 19900 70595 60025 69575 19700 19190 19910 0.0362849
6 69290 65855 62870 18940 20385 19010 75900 62945 62355 20295 19075 19975 0.835561
8 49900 47210 46710 17895 19460 20220 39895 40405 50140 18345 18945 20500 0.268915
10 32715 33850 38745 20940 19660 20150 35670 29250 30830 20525 20065 20420 0.299313
12 35120 29095 31555 18885 21605 18515 27365 29870 33790 19695 19875 20610 0.570151
NPEG LCMV NPEG & LCMV Negative
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The end.
